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Advanced Signal Processing and Control in Anaesthesia
Catarina Sofia da Costa Nunes
This thesis comprises three major stages: classification of depth of anaesthesia (DOA);
modelling a typical patient’s behaviour during a surgical procedure; and control of DOA
with simultaneous administration of propofol and remifentanil. Clinical data gathered in the
operating theatre was used in this project.
Multiresolution wavelet analysis was used to extract meaningful features from the auditory
evoked potentials (AEP). These features were classified into different DOA levels using a
fuzzy relational classifier (FRC). The FRC uses fuzzy clustering and fuzzy relational
composition. The FRC had a good performance and was able to distinguish between the
DOA levels.
A hybrid patient model was developed for the induction and maintenance phase of
anaesthesia. An adaptive network-based fuzzy inference system was used to adapt
Takagi-Sugeno-Kang (TSK) fuzzy models relating systolic arterial pressure (SAP), heart
rate (HR), and the wavelet extracted AEP features with the effect concentrations of
propofol and remifentanil. The effect of surgical stimuli on SAP and HR, and the analgesic
properties of remifentanil were described by Mamdani fuzzy models, constructed with
anaesthetist cooperation. The model proved to be adequate, reflecting the effect of drugs
and surgical stimuli.
A multivariable fuzzy controller was developed for the simultaneous administration of
propofol and remifentanil. The controller is based on linguistic rules that interact with three
decision tables, one of which represents a fuzzy PI controller. The infusion rates of the two
drugs are determined according to the DOA level and surgical stimulus. Remifentanil is
titrated according to the required analgesia level and its synergistic interaction with
propofol. The controller was able to adequately achieve and maintain the target DOA level,
under different conditions.
Overall, it was possible to model the interaction between propofol and remifentanil, and to
successfully use this model to develop a closed-loop system in anaesthesia.
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Chapter 1
Introduction
‘Anaesthesia’ and ‘depth of anaesthesia’ are two different entities that are frequently
confused because they share a common word: anaesthesia. However, anaesthesia comprises
muscle relaxation, analgesia and unconsciousness (i.e. depth of anaesthesia). In other
words, depth of anaesthesia (DOA) is one of the components of anaesthesia. These
concepts are still a matter of debate in the medical area, leading to the lack of a global
standard definition.
Initially, a single drug was used and signs such as movement, lacrimation and sweating,
helped to determine DOA. The introduction of balanced anaesthesia (the use of three drugs,
i.e. a muscle relaxant, an analgesic and an anaesthetic) improved the safety and comfort of
the patient facilitating the surgical procedure, but the clinical signs were obscured by the
effects of the different drugs. The anaesthetist started to use the measurable cardiovascular
parameters such as blood pressure and heart rate, to base his/her decision about DOA.
However, these parameters are influenced by drugs such as
 
-blockers. In addition,
different patients respond in different ways, increasing the variability of the clinical signs.
Therefore, the search for an adequate DOA monitor turned to signals from within the
central nervous system (CNS) (Stanski, 1994; Thornton and Jones, 1993).
The electroencephalogram (EEG) was one of the first signals studied. However, the EEG
was found to respond differently to different anaesthetic agents (Iselin-Chaves et al., 1998;
Simanski et al., 2001; Singh, 1999). An appropriate signal should show similar graded
changes with anaesthetic concentrations for different agents, it should show appropriate
changes with surgical stimulus, and indicate awareness and light anaesthesia. The auditory
evoked potentials (AEP), which are the responses on the EEG to an auditory stimulus, have
been the focus of many researches and have led to some very useful results in monitoring
DOA (Backory, 1999; Elkfafi, 1995; Kenny, 2000; Kumar et al., 2000; Nayak and Roy,
1998; Thornton and Sharpe, 1998; Thornton et al., 1989a).
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Unconsciousness (DOA) is very hard to define and to measure adequately, since no direct
measurements exist. In addition, to distinguish between stages that could lead to implicit or
explicit memory, with or without pain and the adequate stage of unconsciousness without
memory or recall, is not a trivial task (Jones, 1994).
Methods need to be developed to extract relevant features from the AEP and to classify
these features into different levels of DOA. This information could be used to construct a
control system for DOA, considering the adequate infusion rate of the anaesthetic drug. In
recent years, several researchers have developed different control structures for inhalational
and intravenous agents, using the AEP and other monitoring techniques. Due to the
complexity and importance of DOA, this is an area still open to improvement.
Balanced anaesthesia introduced the problem of drug interactions. The anaesthetic and
analgesic drugs may have different types of interactions, increasing or decreasing the
effects of each drug, potentiating the different side effects or even introducing new side
effects (Berenbaum, 1989; Minto et al., 2000). The anaesthetist needs to be aware of the
interactions between drugs for the safety of patients. When considering drug interactions,
several aspects need to be considered, such as the properties of the two drugs, the presence
of surgical stimulus and the level of DOA. In addition, there are pharmacokinetic and
pharmacodynamic interactions, the first relating to the distribution and clearance of the
drugs in the body, the second concerned mainly with the effects of the drugs. The study and
quantification of the effects inherent to the simultaneous administration of the two drugs is
a new and challenging area of great importance.
Propofol is the most used intravenous anaesthetic agent for its hypnotic properties and
almost lack of side effects compared to inhalational agents. In general, propofol is
combined with one of the synthetic opioids so as to provide analgesia. However, the
optimal propofol infusion rate and concentration are largely affected by the choice of
opioid and, in some cases, by the duration of the infusion (Vuyk, 1999, 2000). Therefore, it
is important to analyse the effects of opioids so as to decrease the amount of drug infused
and the recovery time. One of the advantages of propofol and many of the opioids is that
they can be infused automatically using infusion pumps and titrated according to patient’s
needs.
Target controlled infusion (TCI) systems are widely implemented in the operating theatre,
determining the infusion rate of propofol based on a target plasma concentration which is
set by the anaesthetist. This may insert a delay in the patient’s response, since the drug
effect is governed by the effect concentration and not the plasma concentration (Bovill,
2
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2000; Morita et al., 2000; Shafer and Varvel, 1991). In addition, the opioids are
administered in bolus doses or constant continuous infusions by the anaesthetist.
The introduction of the new and ultra-short acting opioid remifentanil, improved the
operating conditions, increased the ability to rapidly control the level of analgesia and
reduced the recovery time (Camu and Royston, 1999). However, remifentanil has strong
interactions with propofol, which could be used to an advantage in reducing the overall
amount of drug infused.
Analgesia, i.e. pain relief, is difficult to establish since there in no measure of pain. There is
the risk of implicit memory with pain, which has a severe effect on the patient and could
lead to traumatic experiences and post-operative disorders. Therefore, the analgesic drug
should be adequately combined with the anaesthetic drug to be of efficiency in general
anaesthesia. In general, the analgesic drug is titrated according to the type of surgical
procedure, the amount of surgical stimulus and the effects of the stimulus on the
haemodynamic responses. An opioid with a rapid onset of action (such as remifentanil)
allows for a rapid response to the stimulus effects. The analysis of the brain signals would
improve the quality of analgesia, since there would be information about the arousal caused
by the stimulus in the CNS and subsequent effects on the level of unconsciousness.
A simulation system would help to train the anaesthetist in different circumstances,
reflecting the drug interactions. A monitoring and control system is of great value to
process the information from the CNS, advising the anaesthetist about the DOA level and
required infusion rate. The analysis of the signals from the CNS is crucial, since it can be
done on-line in the operating theatre. Without this the anaesthetist has no information about
the brain signals. In addition, such a structure would also work as an alarm system, alerting
the anaesthetist to any event that could interfere with the infusion profiles and/or the patient
safety, and any fault(s) in the equipment.
This project searches for a solution to the problems presented above and for a
robust/reliable control system that could determine the optimal infusion rate of both drugs
(anaesthetic and analgesic) simultaneously, and titrate each drug in accordance to its effects
and interactions. Such a system would be a valuable assistant to the anaesthetist in the
operating theatre.
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1.1 Thesis Overview
This thesis is divided into seven chapters, references and bibliography, and five appendices.
A brief explanation of the contents of each part is presented next.
Chapter 2 explains the concepts of anaesthesia and depth of anaesthesia (DOA). The
methods of DOA assessment from clinical signals to evoked potentials, are presented. The
chapter finishes with a review of the control and monitoring techniques used for DOA.
Chapter 3 deals with the classification of DOA using the auditory evoked potentials (AEP)
and the haemodynamic parameters systolic arterial pressure (SAP) and heart rate (HR).
Multiresolution analysis with wavelet transforms is used to extract meaningful features
from the AEP relating to the classification of DOA. A fuzzy relational classifier (FRC) is
developed and implemented using clinical data. The FRC uses fuzzy clustering and
relational matrices to establish the link between the natural data clusters and the DOA
levels. The results of the FRC are presented and compared with the results of a neural
network and a neuro-fuzzy system.
Chapter 4 presents the clinical data gathered and used during this research, and the
characteristics of the anaesthetic propofol and analgesic remifentanil, i.e. the two drugs
focused upon in this project. The pharmacokinetic models of both drugs are presented with
the concept and mathematical derivation of the effect concentration. In addition, a review
of the effects of interactions of drugs relating to the simultaneous administration of
anaesthetic and analgesic drugs, is presented. Special attention is given to the synergistic
interaction of propofol and remifentanil.
In Chapter 5, a hybrid patient model is constructed using fuzzy logic techniques and
nonlinear optimization. The data gathered in the operating theatre are used to construct and
train the models. The cardiovascular parameters and wavelet extracted AEP features are
modelled considering two different phases of general anaesthesia, i.e. induction and
maintenance. The synergism between propofol and remifentanil is modelled using an
Adaptive Network-Based Fuzzy Inference System (ANFIS). The effects of surgical
stimulus on SAP and HR are modelled using the anaesthetist’s opinion translated into fuzzy
rules.
Chapter 6 is the development of a multivariable control structure for DOA, with
4
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simultaneous administration of propofol and remifentanil. The patient model is tested in
open-loop simulations with different drug profiles. The closed-loop simulation system is
presented in this chapter, linking the patient model, the FRC of DOA and the control
structure. First, a single-output controller is developed, determining the infusion rate of the
hypnotic drug and using the analgesic in a constant infusion rate. Second, a multivariable
controller is constructed so as to determine the infusion rates of both drugs. The controllers
are constructed using fuzzy logic techniques, and tested via a series of simulations with the
developed patient model.
Finally, Chapter 7 presents the conclusions and recommendations for future work.
5
Chapter 2
Depth of Anaesthesia
2.1 Introduction
The word anaesthesia is derived from the Greek and means ‘without feeling’. It was first
used by the Greek philosopher Dioscorides in the first century AD to describe the narcotic
effect of the plant mandragora. In 1771 Encyclopedia Britannica defined anaesthesia as a
‘privation of the senses’. However, modern anaesthesia is considered to date from 1846,
when W. Morton introduced ether anaesthesia for dental surgery (Stanski, 1994).
Anaesthesia can be defined as the lack of response or recall to noxious stimuli. General
anaesthesia includes paralysis (muscle relaxation), unconsciousness (depth of anaesthesia)
and analgesia (pain relief). The first two are concentrated in the operating theatre, whereas
the third is also related to post-operative conditions. In addition, different surgical
procedures require different proportions of the three components.
The assessment of depth of anaesthesia (DOA) during surgery under general anaesthesia
has become a very difficult process since the introduction of balanced anaesthesia. In the
early days of anaesthesia, when a single agent (e.g. ether) was used to control all the three
components of anaesthesia, signs of inadequate anaesthesia could be obtained relatively
easily from clinical measurements and from patient movement. The main concern was that
muscular relaxation could only be provided at deep levels of anaesthesia. Therefore, the
hypnotic and analgesic components were in excess of those required, resulting in long
recoveries and other side effects. Postoperative respiratory and venous thrombotic
complications were frequent (Carrie et al., 1996; Newton, 1993). The point requiring most
skill and care in the administration of anaesthetics was to determine when it has been
6
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carried far enough, so as to avoid a too-deep stage of anaesthesia (Thornton and Jones,
1993).
The introduction of intravenous drugs as part of a balanced anaesthesia, (i.e. the use of a
muscle relaxant, an analgesic, and an anaesthetic) made anaesthesia safer for the patient.
The three components of anaesthesia could be more easily adjusted to individual
requirements improving the patient’s operative and post-operative well-being. However,
this also meant that the measures of anaesthetic depth became obscured or even completely
ablated, making the task of measuring DOA more difficult.
Several questions arise from balanced anaesthesia: the introduction of muscle relaxants
meant that excellent relaxation could be obtained while the patient was only lightly
anaesthetised. The degree of neuromuscular block can be monitored by observing the
muscle response to nerve stimulation, commonly the ulnar nerve. Asbury and Linkens
(1986) and Mahfouf (1994) are some of the researchers who designed automatic control
systems of neuromuscular blockade. However, analgesia and unconsciousness are not so
easy to measure. When a patient is unconscious it is not always clear how much analgesia
is an agent providing or what is the patient’s level of unconsciousness.
Jones (1994) reported several cases of conscious awareness occurring in apparently
anaesthetised patients. Explicit memory of conscious awareness with pain during
anaesthesia is different from the situation where there is explicit memory of intraoperative
events but no pain (i.e. adequate analgesia but inadequate hypnosis). Conscious awareness
with pain perception is the most worrying complication for patients and anaesthetists alike.
This may cause post-traumatic stress disorder resulting in nightmares, anxiety, a
preoccupation with dead and even bereavement conflict. Therefore, it is very important to
establish an adequate method for measuring DOA.
Anaesthesiologists use a variety of observations, such as blood pressure, heart rate,
lacrimation, movement, sweating, and pupil response, to make a judgement on the DOA
(Shieh, 1994). However, agents such as neuromuscular blockers,   -blockers,
anticholinergics or opioids obscure these signs of anaesthetic depth making them
unreliable. This has prompted the search for methods for detecting awareness during
anaesthesia and the graded changes that occur within the central nervous system (CNS)
related to DOA.
Depth of anaesthesia can be considered as a balance between the depression of the CNS by
the anaesthetic drug and the stimulation of surgery. A reliable monitor of DOA is of great
7
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importance to establish effective control in the operating theatre.
2.2 Assessing Depth of Anaesthesia
Depth of anaesthesia is difficult to define and to measure accurately. ”Anaesthesia
monitoring”, to assure that the level of anaesthesia is adequate, is of major importance for
the anaesthetist, so that accidental conscious awareness during general anaesthesia can be
avoided. If the event of conscious awareness occurs, it could lead to extreme psychological
consequences for the patient and to a malpractice litigation against the anaesthetist.
The different monitoring methods that have been investigated for DOA can be divided into
two groups: those that directly detect awareness and those that indirectly detect the level of
consciousness by bioassays of anaesthetic depth (Doyle and Tong, 1996). The majority of
monitoring methods used at present are indirect, meaning that the anaesthetist has to
deduce the patient anaesthetic state based on the patient’s response.
The Tunstall’s isolated forearm technique is an example of the direct monitoring methods.
One forearm is protected from neuromuscular block with a tourniquet and, at intervals, the
patient is asked to squeeze the anaesthesiologist’s hand in a specified way (Doyle and
Tong, 1996). However, if the patient is unconscious he will not able to respond to the
anaesthetist’s command. It is worth noting that this technique may be suitable for surgical
interventions where only analgesia and muscle relaxation is needed but not for general
anaesthesia.
The isolated forearm technique has also been used in unconscious patients, but instead of
the patient squeezing the anesthesiologist’s hand the response is analysed by the movement
of the arm as a reaction to noxious stimuli. Thornton and Jones (1993) report that patients
responding with the isolated arm during anaesthesia rarely recall this experience
postoperatively, and they do not appear to experience pain at the time. These results raise
the probability that very light anaesthesia is sufficient to abolish the sensation of pain to a
range of surgical stimuli without any significant effect on conscious awareness but
inhibiting explicit recall. Consequently, the patient is unconscious but the brain may be
able to register information as shown by implicit memory of intraoperative events. This
monitoring technique cannot be used during long periods of time, otherwise the patient may
suffer from the effects of ischaemia. In addition, the tourniquet is an extra cause of pain for
8
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the patient, making it an unsuitable technique altogether.
A review of the indirect monitoring methods is given here. These bioassays of anaesthetic
depth include clinical signs, electroencephalogram, evoked potentials, and others.
2.2.1 Clinical Signs
Clinical signs of DOA derive directly from the patient. Haemodynamic responses such as
heart rate (HR), systolic arterial pressure (SAP), mean arterial pressure (MAP), and
diastolic arterial pressure (DAP) are widely used in current anaesthetic practice for DOA
assessment, it is therefore likely that they carry useful information. However, the usefulness
of clinical signs is reduced by drugs such as  -blockers or opioids, and conditions such as
surgical haemorrhage, i.e. bleeding.
Anaesthetists use a variety of clinical signs, such as pupil response, sweating, lacrimation
and haemodynamic responses. The relevance of these clinical signs has been widely
discussed.
Thornton and Jones (1993) report that after the introduction of curare (Second World War),
clinical signs such as pupil size, respiratory and peripheral movement were eliminated. In
addition, it was very difficult to categorize the clinical signs of anaesthesia for one
inhalational anaesthetic agent, let alone for agents in general.
Patient movement as an indicator of DOA is useless when the patient is paralysed via a
muscle relaxant. Respiration cannot be used if a patient is under artificial ventilation. Pupil
diameter is reduced artificially with the application of opioids. Nevertheless, the use of
clinical signs is well spread in anaesthesia.
Greenhow et al. (1992) describe an expert system that provides decision-support for control
of DOA by merging a number of qualitative clinical signs and quantitative on-line
measurements. They use a measure of relevance and certainty to reflect the usefulness of
clinical signs in different situations.
Linkens and Rehman (1992) use artificial neural networks to determine DOA, with
isoflurane as the inhalational anaesthetic. Target values for HR, SAP and respiration rate
are derived by the anaesthetist for individual patients undergoing surgery, and used as input
to the system. They conclude that anaesthetic agents affect the respiratory system,
9
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cardiovascular system, central nervous system and muscle.
The objective of Robb et al. (1993) was to determine if a clinically acceptable anaesthetic
state could be achieved by altering isoflurane dosage to maintain SAP at a predetermined
value. They suggest that SAP is a major component in the clinical assessment of DOA.
Shieh (1994) uses a hierarchical structure to monitor DOA, based on measurable data such
as SAP and HR, and on non-numerical clinical signs such as sweating, lacrimation, and
pupil response which are observed by the anaesthetist and input manually to the system.
Vefghi and Linkens (1999) use SAP, HR, respiration rate, age, weight, and sex to classify
the anaesthetic state. Frei et al. (2000) used MAP regulation to maintain the patient in an
adequate level of DOA. The overall control objective of Rao et al. (2000) was to maintain
the haemodynamic variables MAP, cardiac output, and mean pulmonary arterial pressure at
desired setpoints.
Haemodynamic responses are also used as a comparison when other measures of DOA are
being investigated (Crabb et al., 1996; de Beer et al., 1996). Mortier et al. (1998) report on
the complex nature of DOA when simple measures of the EEG correlate poorly with
clinical parameters. In particular, haemodynamic parameters are used to determine the
efficacy of opioids and evaluate total intravenous anaesthesia (TIVA) (Alexander et al.,
1999a; Hogue et al., 1996; McAtamney et al., 1998). Opioids are used to control
haemodynamic changes in response to noxious stimulus (Casati et al., 2001; Hall et al.,
2000; Joo et al., 2001; Litman, 2000; O’Hare et al.,1999; Song et al., 1999; Thompson et
al., 1998).
Wuesten et al. (2001) titrated the opioids to maintain HR and MAP within 20% of baseline,
and defined inadequate analgesia as responses to surgical stimulus by hypertension and
tachycardia. However, inadequate hypnosis was defined as the EEG bispectral index
greater than 60 and was treated with propofol.
Satisfactory anaesthesia requires adequate cardiovascular and respiratory stability, no or
minimal patient movement, and no awareness or recall of events during the procedure
(Kenny, 2000). Therefore, it is acceptable that haemodynamic parameters should be used as
an extra information to assess DOA. However, to rely only upon them will not reflect DOA
in general anaesthesia.
10
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2.2.2 Anaesthetic Concentration
Monitoring DOA using the concentration of the anaesthetic agent has been widely used in
the case of inhalational drugs. The minimum alveolar concentration (MAC) of inhaled
anaesthetic required to prevent 50% of patients from responding to painful stimulus has
been used as a monitor of DOA (Stanski, 1994). MAC is measured by end-tidal
concentration. The end-tidal concentration of anaesthetic in the alveoli is used as an
indicator of the anaesthetic concentration in the brain. The MAC concept describes a
concentration-versus-response relationship.
Chilcoat et al. (1984) used a control system to bring the tension of anaesthetic in the brain
to any value specified in MAC units. One of the many researches in control of MAC of
inhalational agents is by Nayak and Roy (1998) who use MAC and evoked potentials to
estimate DOA.
The introduction of intravenous agents reduced the toxic effect of inhalational agents
specially in the liver and kidneys but also in the operating room environment (Morgan,
1983; Zbinden and Luginbuhl; 1996). However, there is not an equivalent of MAC for
intravenous agents.
The steady-state plasma concentration of intravenous anaesthetic required to prevent 50%
of patients from responding, does not correspond to MAC for inhalational agents because it
cannot be measured on-line. In addition, the relationship between infusion-rate and blood
level concentration of intravenous drugs varies widely between patients.
The variability of pharmacokinetics for intravenous agents has been reported by several
researchers (Glass, 1998; Vuyk, 1998). Similar infusion rates produce significantly
different blood concentrations. For instance, the pharmacokinetics of propofol are affected
by age, gender and weight (Hirota et al., 1999; McFarlan et al., 1999; Schuttler and Ihmsen,
1993; Vuyk et al., 2001).
Davidson et al. (1993) reported that a 67% nitrous oxide dosage reduced the EC50
(effective concentration of propofol at which 50% of patients do not respond to a painful
stimulus) by 30%. Furthermore, Vuyk (2000) analysed the reduction in the required
concentration of propofol via opioids.
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2.2.3 Electroencephalogram
The electroencephalogram (EEG) has been used to monitor the effects of general
anaesthetics on the CNS, and is known to show graded changes with increasing
concentrations of anaesthetics (Doyle and Tong, 1996; Thornton and Sharpe, 1998).
Generated from within the CNS, the EEG is not affected by neuromuscular blocking agents
and it has been used to monitor DOA.
The EEG represents cortical electrical activity derived from summated excitory and
inhibitory postsynaptic activity, which are controlled and paced by subcortical thalamic
nuclei. The EEG is a non-invasive indicator of cerebral function when the patient is
unconscious and unresponsive (Stanski, 1994).
The unprocessed EEG is difficult to interpret, such a complex signal is of limited value
(Mortier et al., 1998). Therefore, several techniques involving frequency analysis of the
EEG have been developed so that a reduced number of numerical parameters could be used
on-line by the anaesthetist, and still reflect the descriptive properties of the EEG with
respect to DOA.
Bispectral analysis is one of the techniques used to compress the information on the EEG.
This is a method of signal processing that accommodates quadratic interactions between
wave components making up the EEG trace, by quantifying phase coupling. Therefore, it
determines the harmonic and phase relations among the various EEG frequencies (Jones,
1996; Kissin, 2000).
Mortier et al. (1998) use the bispectral index (BIS) as the control variable for the
administration of propofol in 10 patients during spinal anaesthesia. The BIS describes the
complex EEG pattern as a single variable, and similarly to the EEG the BIS behaves
differently with different anaesthetics. For this reason, they developed BIS using a database
of EEG data recorded with different anaesthetics. BIS was also used by Absalom and
Kenny (1999) to control propofol infusion for anaesthesia in patient undergoing
orthopaedic surgery.
Kissin (2000) states that BIS is promising as a monitor of unconsciousness. However, BIS
should be derived statistically from a database which includes many types of anaesthetics
and their combinations. If BIS is used with a new drug or new patient population that was
not in the original database, it must be re-evaluated. In the same study, it is reported that the
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accuracy of BIS is altered with the addition of opioids or nitrous oxide. The accuracy of
BIS monitoring to prevent awareness is higher when a single anaesthetic is used.
Gajraj et al. (1999) compared the bispectral EEG analysis with auditory evoked potentials
(AEP) for monitoring DOA during propofol anaesthesia. They reported that the BIS was
unable to detect the transaction from unconscious to consciousness. Nevertheless, BIS
appeared to measure the effect of the hypnotic at the time of unconsciousness.
Muthuswamy and Roy (1999) used fuzzy integrals and bispectral analysis of the EEG to
predict movement under anaesthesia. They designed a methodology for estimating DOA in
a canine model that integrates EEG derived parameters, haemodynamic parameters, and
MAC of inhalational agents (isoflurane, halothane, and nitrous oxide). The EEG
characteristics changed with the anaesthetic level and various other physiological
parameters. As a result, they concluded that a single model may not be accurate at all times.
Singh (1999) reported that the utility of BIS depends on the anaesthetic technique being
used. When isoflurane or propofol are used as the primary anaesthetic agents, changes in
BIS correlate with the probability of response to skin incision. If opioids are used, the
correlation of BIS values with movement response to skin incision becomes less
significant. They conclude, that BIS is a monitor of sedation or hypnosis and cannot
provide pre-emptive warning about inadequacy of all the components of anaesthesia.
Gentilini et al. (2001a, 2001b) are part of a research group that has been studying the use of
BIS in closed-loop control of anaesthesia. They use BIS for modelling and closed-loop
control of hypnosis with the volatile anaesthetic isoflurane. The controller is based on a
model identified from experiments on 20 volunteers (Gentilini et al., 2001b). The model is
used to predict BIS from the measured endtidal isoflurane concentrations. The complex
systems include artifact tolerance, respiratory system model, and a smooth transfer between
manual and automatic control. The closed-loop system was tested on one patient and
presented an acceptable performance. This study confirmed the usefulness of the BIS
monitor for the titration of the drug. The authors state that this closed-loop system can be
used with other volatile anaesthetics, as long as the appropriate pharmacokinetic and
pharmacodynamic model is used. If intravenous anaesthetics are used the approach has to
be completely changed, since the respiratory system will not be used and the concentrations
cannot be measured online. This is a ongoing study which involves several researchers,
such as Luginbuhl and Schinder (2002). They reported two case studies using BIS to detect
awareness, when using the anaesthetic drug propofol and the analgesic remifentanil. The
BIS monitoring proved to be a useful tool for early detection of an unintended decrease of
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hypnotic drug effect. BIS correlates with both the incidence of explicit and implicit
awareness. The use of DOA monitors is useful in prevention of awareness together with
practice guidelines and continuous education of the anaesthetist.
Simanski et al. (2001) considered the control of neuromuscular blockade and control of
DOA using BIS and the cardiac output as inputs to the system. They concluded that the
main disadvantage of the EEG measurement is the variation with different anaesthetic
agents.
Spectral edge frequency (SEF) (95% of the power) and the median frequency (MF) (50% of
the power) of the EEG have also been investigated for the possibility of detecting
awareness. Gajraj et al. (1998) showed that there was almost no separation between the MF
and SEF values obtained in the awake and unconscious subjects, raising doubts about the
adequacy of these measurements. The same study showed that BIS correlates well with
predicted blood concentration of propofol during recovery of anaesthesia, but the auditory
evoked potentials were better at distinguishing consciousness from unconsciousness.
Asteroth et al. (1997) used the MF as the control variable to adjust the vaporizer setting.
They reported that MF alone does not include enough information to enable proper
classification.
Graaf et al. (1997) use neural networks to extract features from the raw EEG. They use
these features to design a decision support system in anaesthesia.
Kuizenga et al. (1998) studied the effects of propofol on the EEG in 10 healthy surgical
patients under extradural analgesia. The EEG amplitude in six frequency bands was related
to arterial blood propofol concentration and responsiveness to verbal commands. They
observed a biphasic EEG amplitude response to an increasing blood concentration of
propofol in all frequency bands. In the same research, it was reported that the study of EEG
changes caused by hypnosis in the anaesthetised surgical patient are hindered by the effects
of currently administered sedative and analgesic drugs.
Zhang and Roy (2001) use EEG derived parameters such as complexity, regularity, and
spectral entropy to estimate DOA.
The EEG changes vary from different combinations of anaesthetic agents used, because
different agents have different effects on the EEG (Thornton and Jones, 1993). In addition,
Iselin-Chaves et al. (1998) report that each anaesthetic alters the EEG differently, making
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precise correlation between EEG changes and DOA problematic.
2.2.4 Evoked Potentials
Evoked potentials (EP) are derived from the EEG in response to auditory, somatosensory,
nociceptive and visual stimuli. They reflect the functional integrity of specific peripheral
and CNS regions in humans (Thornton and Sharpe, 1998).
The EP are described in terms of the post-stimulation latency in ms (time between
application of a stimulus and the occurrence of a peak in the EP waveform) and
peak-to-peak amplitude (in mV or nV) of individual peaks in the waveform. These peaks
and troughs arise from specific neural generators.
EP are sensitive to anaesthetic drugs. As a result, they have been investigated as possible
measures of anaesthetic drug effect and DOA (Kumar et al., 2000; Stanski, 1994; Thornton
and Jones, 1993).
The change in EP is similar and uniform for potent inhalational and intravenous
anaesthetics. This contrast with the EEG, in which different parameters must be examined
depending on the anaesthetic being used.
According to the type of stimulus used, there are four main EP: auditory evoked potentials
(AEP), somatosensory evoked potentials (SEP), movement evoked potentials (MEP) and
visual evoked potentials (VEP). The advantages and disadvantages of SEP, VEP and MED
are presented here. The AEP are described in greater detail in Section 2.3. The AEP have
been greatly used to monitor DOA, the signal shows similar graded changes with different
anaesthetics and reflects the subjective clinical signs used by the anaesthetist.
2.2.4.1 Visual Evoked Potentials
Visual evoked potentials (VEP) are recorded after monocular stimulation with recording
electrodes over the occipital parietal and central scalp. The VEP are recorded in response to
visual stimuli such as flashing lights or a checker board pattern. VEP have the disadvantage
that the highly reproducible pattern of EP requires the subject to focus on the checker
board, which is not possible for anaesthetised patients. In addition, VEP with flashing lights
are variable between patients and trials, this has been described as qualitative rather than
quantitative (Thornton and Sharpe, 1998). Kumar et al. (2000) states that VEP cannot be
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reliably interpreted intra-operatively.
VEP have been used in neurology to confirm and localize sensory abnormalities, to identify
silent lesion and to monitor changes, but little research exists with respect to anaesthesia
(Nuwer, 1998).
2.2.4.2 Motor Evoked Potentials
Motor evoked potentials (MEP) are recorded by measuring compound muscle action
potentials (with the help of fine wire electrodes) within muscles innervated by the motor
nerve of surface electrodes, after direct stimulation of the nerve in the operative field. MEP
assess the function of the motor cortex and descending tracts (Kumar et al., 2000).
Pechstein et al. (1998) tested the influence of two anaesthetic techniques of general
anaesthesia (isoflurane plus nitrous oxide or propofol) in the MEP. The MEP were
monitored by transcranial and direct cortical high frequency repetitive electrical
stimulation. They concluded, that high doses of isoflurane and nitrous oxide are not
compatible with the recording of muscle activity, and that evaluation of muscular responses
after transcranial stimulation is not feasible with balanced anaesthesia with isoflurane.
Motor function testing is not feasible during some operations and neuromuscular blocking
drugs may obscure the responses completely.
2.2.4.3 Somatosensory Evoked Potentials
Somatosensory evoked potentials (SEP) are produced by stimulation of the sensory system.
They can be recorded by stimulating almost any nerve trunk at various levels. The most
frequent are those in response to median and ulnar nerve stimulation. The SEP elicited in
response to cutaneous painful stimuli have a larger latency depending on the site and type
of stimulus (Thornton and Sharpe, 1998).
Nuwer (1998) reviews the applications of SEP in neurology and in the operating room. He
states that certain inhalational anaesthetics must be avoided when using cortical SEP
monitoring, because the response can be abolished by them. However, SEP have been very
useful in monitoring the spinal cord during scoliosis procedures and other surgical
interventions in which it (the spinal cord) is at risk of damage. SEP tests are of better
quality when the patient is tested asleep, and they have been used in the intensive care unit
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(ICU) to assess prognosis for comatose patients.
Kumar et al. (2000) explain that both false-negative and false-positive results have been
reported with intraoperative SEP monitoring. However, the reliability of SEP to predict
post-operative somatic sensory function is very good. This supports the idea of SEP being
used mainly in ICU.
Cortically generated SEP waves reflect the analgesic rather than the hypnotic action of
anaesthesia. Thornton and Jones (1993) report observations that etomidate and propofol
(which are devoid of analgesic action) failed to depress the response, whereas opioids like
fentanyl, sufentanil, and morfine significantly suppress amplitudes of SEP. In contrast,
Samra et al. (2001) report that there is large variability in SEP morphology with the
introduction of opioids. They compare the effects of two opioids (remifentanil and fentanyl)
on intraoperative monitoring of SEP during isoflurane anaesthesia, but it is not clear if the
results presented are due to the analgesic action or to the interaction between the analgesic
and the anaesthetic drugs.
2.2.5 Other Methods of DOA Assessment
The lower esophageal contractibility method measures contractions of the lower esophagus.
The striated portion of the esophagus is innervated by reticular formation of the brain stem.
Stanski (1994) explains how DOA might be measured by the degree of spontaneous
contraction of the lower esophagus. Considering that increasing concentrations of potent
inhalated anaesthetics decreased lower esophageal contractibility, it was inferred that the
frequency of such contractions could predict movement in response to skin incision during
anaesthesia.
Thornton and Jones (1993) state that there is large variability between patients, with
different anaesthetic techniques. They also report that the dose response curve for provoked
esophageal contractions was shallower than that for spontaneous contractions. Therefore,
the method may be inappropriate for assessing cognitive function during anaesthesia.
Furthermore, Thornton et al. (1989b) reported that there was no consistent relationship
between esophageal contractions and evoked potentials. In addition, there was also no
relation between lower esophageal contractibility and propofol blood concentration.
Bojanic et al. (2001) place the hypothesis of ocular microtremor (OMT) as a tool for
measuring DOA. OMT is a fine high frequency tremor of the eyes caused by extra-ocular
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muscle activity stimulated by impulses emanating in the brainstem. They studied the effect
of general anaesthesia induced with propofol on the OMT in 22 patients. There were
significant differences between the last awake OMT recording and the first recording at
loss of consciousness. Further studies are needed to establish the efficacy of this method;
OMT has an obvious measurement difficulty.
2.3 Auditory Evoked Potentials
The auditory evoked potentials (AEP) waveform with its series of peaks and troughs
represents the passage of electrical activity from cochlea to cortex. The AEP are measured
via electrodes on the surface of the scalp. They are responses on the EEG to clicks applied
to both ears. Among all the EP the AEP are the most promising and most studied to
monitor DOA (Abbod et al., 1998; Backory, 1999; Elkfafi, 1995; Elkfafi et al., 1998;
Kenny, 2000; Kenny and Mantzaridis, 1999; Linkens et al., 1997a; Nayak and Roy, 1998;
Thornton and Sharpe, 1998; Thornton et al., 1989a).
The AEP consist of three waves: the brainstem waves (1-10 ms), the middle latency waves
(or early cortical, 10-100 ms), and the late latency waves (or late cortical,  100 ms). These
waves are generated from different levels of the neuraxis, which are differentially sensitive
to drugs and sensory stimuli. The AEP are not affected by neuromuscular blocking drugs.
The late cortical waves are attenuated and even abolished by general anaesthesia, sedation,
and sleep. Therefore, they are not appropriate for clinical use.
The brainstem waves latencies have dose-related increases when inhalational agents are
used. However, intravenous agents (such as propofol) have little or no effect on the
brainstem waves. As a result, they cannot be used to measure DOA when intravenous
agents are present (Thornton and Jones, 1993).
Middle latency evoked potentials (MLAEP) are able to distinguish between the aware and
anaesthetised state and subsequent CNS depression, reflecting the balance between CNS
depressions caused by anaesthetic drugs and arousal caused by surgical or other stimuli.
Changes in the latency of the MLAEP correlate with the transition from awake to
unconscious, and subsequent decreases and increases in the amplitude of these waves
reflect the interplay of general anaesthetics, surgical stimulation and obtunding of the latter
by analgesics (Thornton and Sharpe, 1998).
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Figure 2-1 and Figure 2-2 show the MLAEP signal (peaks labelled Na, Pa, Nb, Pb) when
the patient is awake and anaesthetised respectively (Backory, 1999). The difference in
amplitude and latency of the peaks is clear between the two figures, reflecting the
correlation between MLAEP and DOA.
Kumar et al. (2000) state that the change in the MLAEP reflects the hypnotic component of
anaesthesia as opposed to an analgesic effect. The MLAEP are particularly helpful in
understanding the central effects of various anaesthetic agents and in monitoring the
concept of implicit memory, awareness and DOA. The AEP reflect the subjective clinical
signs that anaesthetists use, and indicate the response of the CNS. However, AEP have the
disadvantage of being susceptible to intraoperative disturbances (Simanski et al., 2001).
Figure 2-1: The AEP from an awake patient (Backry, 1999).
Figure 2-2: The AEP from an anaesthetised patient (Backory, 1999).
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Considering the ability of the MLAEP to reflect the anaesthetic state, there are two studies
based on the possibility of the MLAEP predicting movement during general anaesthesia.
Schwender et al. (1997) reported that during intraoperative movement, amplitudes of the
MLAEP increased and latencies decreased progressively. When movement was observed,
the recorded MLAEP were similar to the awake state. This study was performed in 40
patients undergoing elective laparotomy under epidural analgesia, anaesthesia was
produced with isoflurane or propofol. In contrast, Kochs et al. (1999) reported that none of
the AEP or EEG variables were able to predict whether patients would move to surgical
incision. However, data collected after skin incision, when the patient was actually moving,
reflected significant changes in Pa and Nb amplitude from the pre-to-post incision. Of
course the information is obtained too late to be of predictive value for the
anaesthesiologist. Therefore, MLAEP may not predict movement in response to surgical
stimuli, but they indicate inadequate anaesthesia by responding to movement.
Signal processing of the AEP is divided into two steps: extracting the AEP, and obtaining
relevant features from the signal so as to assess DOA. Subsequent sections explain the
extraction of the AEP from the EEG and also the different methods used for AEP feature
extraction.
2.3.1 Signal Extraction
The AEP are responses in the EEG to auditory stimuli. Therefore, it is necessary to extract
the AEP from the random background EEG or noise. Ensemble averaging is the most used
tool in the analysis of evoked brain waves (Aunon et al., 1981; Thornton and Sharpe,
1998).
This technique requires the stimulus to be applied at a known and precise point in time, and
is straightforward for auditory, visual and electrical stimuli.
It is assumed that the measured waveform f  t  is of the form:
f  t   a  t  	 n 
 t  2-1
where a


t

is the evoked potential and n


t

is the noise (i.e. the ongoing EEG). Therefore,
if the noise n 
 t  is independent of the AEP and a 
 t  repeats itself with each stimulus
presentation, then an estimate of the AEP can be obtained by simple ensemble averaging
(Aunon et al., 1981).
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Ensemble averaging decreases the noise in a manner inversely proportional to the square
root of the number of replications, assuming that the signal component is deterministic, the
expected value of n  t  is zero, the noise in one epoch is not correlated to the noise in
another, and that the average power is the same for each epoch of noise.
2.3.2 AEP Feature Extraction
The MLAEP show graded changes with anaesthetic concentrations and show similar
changes for different agents in the time and frequency domains. Appropriate choice of
signal features for data compression with acceptable classification performance is of
primary concern in the design of automatic DOA monitors. Researchers have used a
different number of discriminatory features extracted from the MLAEP. A review of these
methods is presented next.
2.3.2.1 Pa and Nb Latencies
Several researchers reported that the Nb latency is associated with wakefulness and
conscious awareness with explicit recall. As the latency increases, amnesia occurs,
followed by loss of consciousness and ultimately loss of implicit memory (de Beer et al.,
1996; Kumar et al., 2000; Newton et al., 1989; Savoia et al., 1988; Schwender et al., 1997;
Thornton and Jones, 1993; Webb et al., 1996).
Increasing concentrations of propofol reduced amplitudes and increased latencies of waves
Pa and Nb. These changes in the early cortical variables were related linearly to
concentration. Researchers concluded that MLAEP reflect the hypnotic component of an
anaesthetic drug (Schwender et al., 1994; Thornton et al., 1989a; White et al., 1999).
Palm et al. (2001) investigated the dose-response relationship of propofol and MLAEP.
They studied 100 patients in cardiac surgery with a propofol/sufentanil regimen. The
MLAEP where evaluated using Pa/Nb amplitudes and Nb latencies. Propofol suppressed
amplitude Pa/Nb in a dose dependent manner. In the same study, it was reported that AEP
are less influenced by the application of opioids and benzodiazepines, whereas anaesthetics
like isoflurane or propofol diminish MLAEP in a dose dependent manner. As a result, the
preserved MLAEP during opioid-based anaesthesia allow the processing of auditory
information.
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2.3.2.2 AEP Index
The AEP index is a mathematical derivative which reflects the AEP waveform
morphology, and is calculated from the amplitude difference between successive segments
of the MLAEP.
Gajraj et al. (1998, 1999) used the AEP index to distinguish the transition from
unconsciousness to consciousness. They reported that the AEP index was better than BIS at
distinguishing consciousness from unconsciousness, while BIS correlated well with
predicted blood concentration of propofol. They concluded that AEP index provides a
measure of the overall balance between surgery, analgesia and hypnosis. This characteristic
of the MLAEP is also supported by Thornton et al. (1988, 1989b). They reported that the
amplitude of cortical waves in the AEP are sensitive not only to anaesthetic concentration
but also to surgical stimulation.
Doi et al. (1997) also stated that the AEP index did not correlate with blood propofol
concentration before eye opening. They observed that the AEP index reflects the level of
consciousness rather than blood concentration of propofol. Schraag et al. (1999b) proved
that the AEP index has more discriminatory power (describing the transition from
conscious to unconscious state) than BIS.
2.3.2.3 AEP Feature Extraction using the Wavelet Transform
One of the methods used for detailed feature extraction from recorded AEP during
anaesthesia, is the wavelet transform (WT) (Backory, 1999; Lee et al., 1997, 1998; Miller
et al., 1998; Qin et al., 1998; Thakor et al., 1993). The WT has also been used for feature
extraction of other biomedical signals such as the electrocardiogram (ECG) (Bahoura et al.,
1997; Li et al., 1995). The power of the WT lies in its multiscale information analysis
which can characterize a signal very well. The WT has potential for processing
time-varying biomedical signals.
Multiresolution analysis (MRA) with WT was used to decompose the signal into
approximations at different scales of resolution. The wavelet coefficients of the MLAEP
detail components were used to calculate the average energy in each of the components
(Abbod and Linkens, 1998b; Backory et al., 1998; Linkens et al., 1997a). These features
were validated by Backory (1999) using data from 14 patients under general anaesthesia.
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Stockmanns et al. (1997) investigated if the WT could be used for the quantification of the
MLAEP signal. Their analysis was based on the consecutive extraction of the details from
the original signal. The MLAEP of 7 healthy volunteers were processed by a
one-dimensional discrete wavelet-decomposition. Only one parameter was obtained by
combining significant coefficients. This wavelet parameter of the MLAEP could detect
anaesthetised and awake with similar accuracy and over-all classification comparable to the
Nb latency. This method was not used under clinical conditions, therefore no interference
from noxious stimulus is present.
Nayak and Roy (1998) used the discrete time wavelet transform (DTWT) to compact the
MLAEP. A step wise discriminant analysis was performed to obtain three features from the
MLAEP that could separate responders from nonresponders. They reported that acceptable
clinical performance was obtained in dogs.
Nayak and Roy (1995) compared the DOA prediction performance of the WT with power
spectrum and the autoregressive parameter of the MLAEP. Results showed that WT
parameters used in combination with anaesthetic concentration classified correctly all the
testing data. The better performance of the WT was attributed to good localization in the
time frequency domain and low sensitivity to signal-to-noise ratio. In this study, MLAEP
data was collected from dogs under isoflurane anaesthesia.
2.3.2.4 Other Methods of AEP Feature Extraction
Munglani et al. (1993) used coherent frequency of the AEP as a measure of consciousness
in isoflurane anaesthesia. The coherent frequency of AEP is derived using auditory clicks
presented at frequencies in the range 5-47 Hz (after Fourier transform). They concluded
that the coherent frequency reflects the likelihood of cognition during anaesthesia, as it
showed consistent changes with anaesthetic administration and stimulation.
Elkfafi et al. (1997) processed the AEP using a parametric identification technique. The
basis of this approach was a parametric model (ARX) provided for both the required signal
(AEP) and the superimposed noise (EEG). Three factors were elicited to describe the
changes in amplitudes and latencies of MLAEP. They compared the use of AEP with the
use of classical cardiovascular parameters for monitoring DOA. AEP signals gave reliable
results in all cases while sometimes SAP and HR did not represent DOA adequately for
physiological reasons (e.g. blood loss, fluid loss).
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Allen and Smith (2001) used a simple back-propagation neural network to extract pertinent
features for the AEP signal. These features are used as input to a control system for
administration of anaesthetic.
2.4 Monitoring and Control in Anaesthesia
The adequacy of a DOA monitor has been deeply discussed in the research area. Ideally,
such a monitor should distinguish between the awake and the unconscious state and should
not be affected by the haemodynamic status of the patient or by vasoactive drugs. A
reliable monitor of DOA should present similar answers with different anaesthetic drugs
administered to equal potency. Furthermore, it should have the ability to control
anaesthesia in a closed-loop system.
A closed-loop control system for anaesthesia allows more frequent and more accurate
adjustments to the DOA (i.e. automated and online measurement of DOA). As a result,
better control is possible. The anaesthetic drug is titrated according to the individual
patient, allowing for interpatient variability of pharmacokinetics and pharmacodynamics,
and responding to changes of surgical stimuli. General anaesthesia would be safer for the
patient as it helps to reduce the incidence of awareness and overdose, and optimizes the
recovery times. If automated, the system would help the anaesthetist by reducing his
workload and supplementing clinical signs (which the anaesthetist has access to) with
information from within the CNS.
Absalom and Kenny (2000) commented on the usefulness of closed-loop control systems as
a research tool in anaesthesia, for the study of the effects of drug interactions and different
anaesthetic techniques. These systems can also be used as a supplementary training tool for
anaesthetists (Schuttler and Schwilden, 1996).
A closed-loop control system in anaesthesia should be able to achieve and maintain an
adequate level of DOA. In the previous section a review was carried out of the anaesthetic
depth indicators used in anaesthesia. In this section, a general review about the control and
monitoring systems used by researchers is presented.
Greenhow et al. (1992) described an expert system called RESAC (real time expert system
for advice and control) that provides decision-support for control of anaesthetic depth by
merging a number of qualitative clinical signs and quantitative on-line measurements.
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RESAC uses fuzzy logic and Bayesian inference to cope with conflicting and uncertain
evidence of the clinical signs. The system is an advisor to the anaesthetist as to the
anaesthetic state. Linkens and Rehman (1992) demonstrated the ability of an artificial
neural network (ANN) to replicate the advice from RESAC. They used target values of HR,
SAP and respiration rate (desired by the anaesthetist for individual patients undergoing
surgery) as inputs for the training of the program.
Webb et al. (1996) describes a preliminary study of automatic control of anaesthetic drug
during surgery, in an attempt to improve the quality of control, to minimise drug usage, and
to minimise the recovery time from surgery. The technique combines a fuzzy logic
controller and a neural-based processing of the AEP.
An automatic model based control of volatile anaesthetics exploiting the MF was used by
Asteroth et al. (1997) to adjust the vaporizer settings. However, an explicit invertible model
is required to capture the dependence of control parameters and effects. Due to
mathematical restrictions, this approach cannot be generalised to more than one narcotic.
Mortier et al. (1998) used BIS to control propofol administration by a patient
individualized adaptive model-based controller incorporating target controlled infusion
(TCI) technology combined with a pharmacokinetic-pharmacodynamic model. The
closed-loop system was able to sedate patients undergoing surgery under spinal anaesthesia.
This reduced the clinical workload and the amount of drug infused. Morley et al. (2000)
also used BIS as the target of a proportional-integral-derivative (PID) controller algorithm
for drug administration, so as to free the anaesthetist from the task of adjusting anaesthetic
depth manually. No clinical utility beyond this was demonstrated. Furthermore, the
closed-loop system worked well in clinical practice but it did not perform better than the
anaesthetist manual control.
Neural networks constitute popular approaches for estimating DOA from MLAEP features.
Nayak and Roy (1998) used this approach to control inhalational anaesthetic concentration
(isoflurane) delivered to a patient, based on a fuzzy logic controller. The system had a
clinically acceptable performance in dogs.
Huang et al. (1999) used a system that determines DOA by assessing the characteristics of
the MLAEP which were extracted by WT. A four layer ANN was used to classify the
MLAEP features coupled with the effect concentration of propofol into responders and
nonresponders. The DOA as determined by the ANN is regulated by a fuzzy logic based
controller for the scheduled decrementation or incrementation of propofol. This system was
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implemented using experiments with dogs.
Kenny and Mantzaridis (1999) used the AEP index as the input of a control algorithm that
sets the blood level of propofol to be achieved by a TCI pump. The algorithm calculates the
required target concentration of propofol from the difference between the measured AEP
index and a set AEP index target values selected by the anaesthetist. There was no
incidence of intraoperative awareness and movement interfering with surgery was minimal
in the 100 patients studied. Note that the anaesthetist needs to be familiar with values of the
AEP index so as to be able to select an adequate target.
The AEP index is also used by Kenny (2000) in a closed-loop control system to administer
propofol in 100 patients breathing spontaneously and also in patients who received a
paralysing drug during surgery. The quality of anaesthesia was judged to be satisfactory as
assessed by scores of automatic activity, cardiovascular stability and minimal movement
during surgery. No occurrence of awareness was reported.
A simple back-propagation neural network can learn the AEP and provide a satisfactory
input to a fuzzy logic infusion controller for the administration of anaesthetic drugs. This
approach is used by Allen and Smith (2001). Neural networks were also used by Vefghi and
Linkens (1999) to classify SAP, HR, respiration rate, age, weight and sex into three
anaesthetic states (aware, relaxed and deep). The network accurately mapped the different
variables into the corresponding anaesthetic states and dosage for different patients.
Decision support information in anaesthesia is becoming more and more popular. Lowe et
al. (2001) developed an intelligent monitor with intuitive graphical presentation of
decision-support information for the anaesthetist. Jones et al. (2001) used fuzzy trend
templates to develop a sentinel anaesthesia monitor to lighten the cognitive load of the
anaesthetist. There is a motivation for developing an automated (and therefore vigilant)
system that would be able to detect the presence or onset of an undesirable state of health in
the anaesthetised patient, and present a possible diagnosis to the attending anaesthetist. The
fuzzy trend templates were a good representation of the anaesthetist diagnosis knowledge
(Lowe et al., 1999a, b) . Previously, Becker et al. (1997) designed an intelligent patient
monitoring and alarm system for the operating theatre. This system evaluated the patient’s
haemodynamic state using a knowledge-based approach on the basis of a vital parameter
database. This knowledge base is formed by evaluation rules expressed by the anaesthetist
in natural language. The research prototype of the whole system was implemented and
evaluated in the operating theatre. The evaluation of 684 events yielded a sensitivity and
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predictability of the alarm recognition on more than 99%.
Zhang and Roy (1999, 2001) used an adaptive network-based fuzzy inference system
(ANFIS) to integrate EEG extracted features for decision making in anaesthesia. By
eliciting fuzzy IF-THEN rules the model provides a way to address the DOA estimation
problem. This monitoring system was implemented in experiments with dogs under
propofol anaesthesia.
A multitasked closed-loop control consisting of two additional controllers is presented by
Gentilini et al. (2001a). They tried to control MAP and control hypnosis through BIS, for
isoflurane anaesthesia. This is an advisor control system used with the anaesthetist close
supervision. Another decision support system was designed by Graaf et al. (1997) and
offers data processing to alert the anaesthetist.
Linkens and colleagues (Abbod et al., 1998; Backory et al., 1998; Elkfafi et al., 1997;
Linkens and Abbod, 1998; Linkens and Mahfouf, 2001; Linkens et al., 1996b; Linkens et
al., 1998) have been engaged in research into modelling and control in biomedicine for
many years. A hierarchical fuzzy monitor for DOA was developed by Shieh (1994). This
hierarchical structure has two levels, the first level used numerical clinical signs (SAP and
HR) to interpret a primary DOA based on a rule-base derived by the anaesthetist
experience. The second level used non-numerical data, such as sweating, lacrimation and
pupil response which was merged with the primary DOA from the first level to decide with
more confidence. Linkens et al. (1996b) used a self-organizing fuzzy modelling approach to
generate the rules from the hierarchical structure on-line using input and output data. After
this approach using only clinical signs the group started to research signals from within the
CNS. A quantitative feature extraction was implemented to extract the factors describing
the changes in amplitudes and latencies of the MLAEP. As a result, three principal factors
were obtained and then merged together using qualitative fuzzy logic to create a reliable
index for monitoring depth of anaesthesia (Elkfafi, 1995; Elkfafi et al., 1997; Elkfafi et al.,
1998). Furthermore, a multi-sensor fusion system for monitoring and control of DOA was
designed (Abbod and Linkens, 1998a; Linkens and Abbod, 1998; Linkens et al., 1998).
This system used neuro-fuzzy and multiresolution wavelet analysis for monitoring the DOA
based on the MLAEP signal. Another measure of DOA was based on the cardiovascular
system status using a rule-based fuzzy logic classifier. The two measures were merged
together using rule-based fuzzy logic data fusion to decide the final DOA. Backory (1999)
used an artificial neural network to classify the MLAEP extracted features into DOA levels.
DOA was used as the input to a predictive controller that set the desired target blood
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propofol concentration.
2.4.1 Target Controlled Infusion
Target controlled infusion (TCI) is an infusion system which allows the anaesthetist to
select the target blood concentration required for a particular effect, and then control DOA
by adjusting the requested target concentration.
TCI systems are very much in use by anaesthetists, specially since infusion pumps
incorporate ‘Diprifusor’ (TCI system for propofol). These pumps can be used to induce and
maintain anaesthesia with propofol. If using such a system, the anaesthetist simply needs to
set the initial target blood concentration required for an intravenous drug in a similar way to
setting the percentage concentration of an inhalational agent with a vaporiser. The target
concentration is achieved and maintained with no further intervention required by the
anaesthetist. However, the anaesthetist can make changes to the target concentration at any
time.
The rational administration of TCI requires an appropriate pharmacokinetic data set.
Software is required to achieve and maintain a target blood concentration of an anaesthetic
by balancing the rate of infusion with the process of distribution and elimination (Jacobs,
1990). Therefore, information about the pharmacokinetic properties of the drug in
appropriate patients is required. The choice of pharmacokinetic model and infusion control
algorithm are major determinants of the performance of a TCI system
In the classical approach, TCI devices consist of an infusion pump attached to a computer.
The computer is programmed with a pharmacokinetic model as well as pharmacokinetic
data. The computer translates predictions from the model into instructions to control the
infusion pump. The required infusion rate to maintain the desired target plasma
concentration is delivered by the infusion pump. Many research groups developed their
own system (e.g. Alvis et al., 1985a, b; Chaudhri et al., 1992; Glass et al., 1990; Shafer et
al., 1990; White and Kenny, 1989). Since 1996 TCI devices have been implemented in the
infusion pumps by a number of manufacturers, such as the ‘Diprifusor’ by Zeneca.
Glass et al. (1989) reported the accuracy with which propofol was delivered using two
different sets of pharmacokinetic parameters. They concluded that by using the newer set of
parameters the accuracy of the predicted (by the TCI) and measured propofol levels would
be better. White and Kenny (1989) also compared the predicted and measured blood
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concentrations of propofol in 408 patients. They confirmed the overall validity of their TCI
system.
Russell et al. (1995) compared a manual infusion with TCI of propofol in 160 patients. The
TCI resulted in a more rapid induction of anaesthesia and allowed earlier insertion of a
laryngeal mask airway. In addition, there was less response to surgical stimulus. TCI does
not change the properties of drugs and the theoretical advantage over manually controlled
infusions is increased controllability by the anaesthetist (van den Nieuwenhuyzen et al.,
2000).
TCI has also been investigated for use in analgesia by Milne and Kenny (1998). The
synthetic opioids, such as alfentanil, remifentanil and sufentanil, all have shorter durations
of action and are more suitable for use in TCI systems than opioids such as morphine, with
a slow blood-brain equilibration. They reported a high degree of patient satisfaction when
using patient-controlled analgesia (i.e. the patient controlled the target concentration using
a push-button hand set).
Adjuvant agents such as sedative agents given for premedication, co-induction agents,
nitrous oxide or one of the synthetic opioids, affect the required target propofol
concentration during induction and maintenance of anaesthesia. The effects of these agents
on the TCI system for propofol have been investigated by Vuyk (1998). He designed an
infusion scheme so as to provide a good clinical performance of the TCI system in the
presence of an optimal manually controlled infusion of an opioid.
The TCI systems are capable of creating a stable blood concentration. However, when the
target concentration is changed the resulting effect correlates better with a theoretical effect
site concentration. The efficacy of the TCI systems that can perform effect-site steering is
still a process under investigation (Jacobs and Williams, 1993; van den Nieuwenhuyzen et
al., 2000).
2.5 Summary
Anaesthesia is a complex branch of the medical science profession. Depth of anaesthesia
(DOA) (one of the three components of anaesthesia) offers a challenge in the areas of
classification and control. In TIVA when different drugs are used to obtain hypnosis (i.e.
DOA), muscle relaxation and analgesia, a reliable method of assessing DOA is of major
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importance.
In this chapter a review of the advances in anaesthesia was presented, starting with the first
time the word “Anaesthesia” was used, including the introduction of balanced anaesthesia,
and finishing with the overall research projects dedicated to automated control systems.
With all its advantages a closed-loop control system in anaesthesia needs a reliable
numerical indicator of DOA before it can be successfully implemented in the operating
theatre.
Initially, movement was used as a monitor for DOA. However, paralysis using
neuromuscular relaxants prompted the search for other indicators. The next reasonable
candidates were the qualitative clinical signs such as pupil diameter or respiratory
movement, and the measurable haemodynamic parameters such as SAP or HR. Qualitative
clinical signs are highly subjective and easily obscured by opioids, muscle relaxants and
techniques such as artificial ventilation. Arterial pressure and HR are also affected by
adjuvant agents such as  -blockers, but these signs are still useful and very must in use by
anaesthetists. All these clinical signs are very useful in detecting inadequate anaesthesia, in
the sense that if the patient moves or has high haemodynamic responses then DOA is not
satisfactory. However, DOA may not be adequate even if the clinical signs do not present
any evidence of this.
Unconsciousness should be measured from within the CNS, where the effect of the
hypnotic drug occurs. The search for a signal from within the CNS started with the EEG.
The EEG shows graded changes with increasing concentrations of anaesthetics, and it is not
affected by neuromuscular agents. Nevertheless, EEG changes vary with different
anaesthetic agents. As a result, researchers turned to the evoked potentials (EP) as the next
candidates for investigation. Among all the EP, the AEP have been pointed out as the best
signal for assessing DOA.
A signal which is able to reflect the hypnotic component of anaesthesia is the main
objective of the AEP analysis. The MLAEP have been the focus of research in anaesthesia
over recent years. MLAEP are known to distinguish the aware and unconscious state and
the subsequent CNS depression. This signal provides a measure of the overall balance
between surgery, analgesia and hypnosis. The techniques used to extract detailed features
from the MLAEP were also discussed in this chapter. The WT appears to be the most
promising for processing time-varying biomedical signals.
Closed-loop control systems in anaesthesia were presented. Different control algorithms
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and classification techniques are used by researchers. All the above systems are used to
control the administration of the anaesthetic drug (i.e. the hypnotic), while other adjuvant
drugs such as the analgesic are administered by the anaesthetist. Most of these systems are
advisors, except the ones tested in animals.
Artificial intelligent techniques such as ANN and fuzzy logic are mostly used, since direct
measurements are unavailable, mathematical models are either unobtainable or too
complex, and there is a large uncertainty in the process parameters (i.e. the patient).
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3.1 Introduction
Fuzzy logic is no stranger to medicine. Lotfi A. Zadeh (1965) himself anticipated very early
that the fields of pattern classification and information processing would be application
domains of his theory.
Fuzzy set theory makes it possible to define inexact medical entities as fuzzy sets. It offers a
linguistic approach that represents an excellent approximation to medical texts.
Furthermore, fuzzy logic provides reasoning methods capable of making approximate
inferences, since many uncertainties are present in medical or biological data as well as in
the decision making process (Adlassing, 1986; Akay et al., 1997).
The high complexity of biological systems, and the nonexistence of accurate mathematical
models are some of the aspects that make fuzzy logic a well defined solution. The
knowledge of experienced physicians and biomedical engineers is an important source of
information for the design of intelligent machines in medicine. In Zadeh’s own words
(1994a):
“The role model of fuzzy logic is the human mind.”
Fuzzy logic has been widely used in diagnostic monitoring in anaesthesia and other areas of
medicine. Several researchers have used fuzzy logic approaches for alarm and/or
monitoring systems in anaesthesia (Becker et al., 1997; Elkfafi et al., 1998; Guez and
Nevo, 1996; Lowe et al., 1999a; Shieh, 1994). The basic concepts of fuzzy logic theory are
32
_________________________________________________________________________________________________________________________________________________________
Chapter 3: Development of a New Fuzzy Relational Classifier for Depth of Anaesthesia
presented in Appendix B.
The classification of DOA is the first step when moving towards a closed-loop control
system. As discussed in the previous chapter, different signals are used as indicators of
anaesthetic depth. However, the main relevance is given to MLAEP as an indicator of the
degree of hypnosis of a patient under anaesthesia.
Several methods have been used to classify MLAEP features into levels of DOA. Different
researchers use different techniques. However, ANN and fuzzy logic based systems are
already proving to be popular. From a simple four layer ANN (Huang et al., 1999; Nayak
and Roy, 1995, 1998) to a more complex Kohonen Self-Organizing Map (KSOM)
(Backory, 1999), and including the back-propagation ANN (Allen and Smith, 2001), there
are many examples of neural networks used in the area. Fuzzy logic has also been used in
the classification of DOA; one of the fuzzy logic-based approaches is the adaptive
network-based fuzzy inference system (ANFIS) used by Zhang and Roy (1999, 2001), and
by Linkens and colleagues (Abbod and Linkens, 1998a, b; Linkens and Abbod, 1998;
Linkens et al., 1998). These classification methods are based on soft computing techniques,
and although ANN have given fairly good results, they are still black box methods and it is
not trivial to understand all the details behind the ANN final decision. Furthermore, to
adequately train an ANN a large amount of clinical data is required, and these may in some
cases be difficult to gather. As a result, some research on ANN has been carried-out using
animals (Huang et al., 1999; Nayak and Roy, 1995, 1998). The fuzzy logic-based
classification systems appear to be more transparent as the anaesthetist’s knowledge can be
incorporated into the decision process.
In this chapter a Fuzzy Relational Classifier (FRC) for DOA is presented. This FRC uses
features extracted from the AEP by multiresolution analysis (MRA) and wavelet transforms
(WT), and cardiovascular parameters to enhance the overall decision making process. The
FRC uses a combination of fuzzy clustering and fuzzy relations to establish an inference
system. The classifier is trained by unsupervised fuzzy c-means clustering, then a fuzzy
relation between cluster membership functions and the class identifiers is computed. The
fuzzy relation specifies the existing relationship between the clusters and the classes (i.e.
the different levels of DOA).
The FRC is described in detail throughout the chapter. First, an introduction to fuzzy
clustering is presented, followed by the general structure of the classifier. Several aspects
have to be considered when implementing the FRC to classify DOA including: the set of
features used, the different levels of DOA, and how these are obtained and structured. The
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classifier is trained and tested with different sets of clinical data. The results are presented
and compared with the results of other classifiers.
3.2 Fuzzy Clustering
Cluster analysis intends to classify objects according to similarities among them, and to
organize data into groups. The objective is to differentiate between classes in a manner
which is simple and easy to visualize. As a result, solutions are restricted in an unknown
way. The use of fuzzy sets is an attempt to resolve this problem.
In a ‘hard’ clustering algorithm, each object must be assigned to a single cluster. This
restriction is not a realistic one, since many objects may have the characteristics of several
classes. It is more natural to assign to each object a set of memberships, one for each class.
This is the general idea of fuzzy clustering.
The first fuzzy clustering algorithm was presented by Ruspini (1969), as a method of
representation of data, based on the idea of fuzzy sets. The objective was to avoid some of
the problems of ‘hard’ clustering procedures and to provide a better insight into the
structure of the original data. In 1973, Dunn developed the first fuzzy extension of the
least-squared approach to clustering, and later in the year this was generalized by Bezdek to
an infinite family of algorithms (Bezdek and Pal, 1991; Dunn, 1973). This approach
conceived by Dunn is one of the most widely used algorithms within fuzzy clustering, the
fuzzy c-means algorithm. This family of algorithms is based on an interactive optimization
of a fuzzy objective function. They are popular due to their efficacy, simplicity and
computational efficiency.
Different approaches to fuzzy clustering have been developed over the years. Gustafson and
Kessel (1979) argued that the use of fuzzy covariances was a natural approach to fuzzy
clustering. In addition, Karayiannis (1996) presented a new approach based on
reformulation. He developed a new family of possibilistic c-means algorithms by selecting
the natural logarithm as a generator function. In 1999, Hathaway et al. present an extended
family of c-means type models, and attempts to empirically identify those which are least
influenced by the presence of outliers (Hathaway et al., 1999). In other study, Zahid et al.
(1999) designed a clustering validity criterion and a fuzzy clustering algorithm based on the
combination of the fuzzy c-means algorithm and the k-nearest neighbours decision rule.
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Fuzzy clustering has been used for identification, modelling and monitoring in different
areas. Tool condition monitoring in machining is one of the areas where fuzzy clustering
has been successfully implemented (Fu et al., 1998; Li and Elbestawi, 1996). Umayahara
and Nakamori (1998) developed an elliptic type fuzzy modelling and simulation method
using fuzzy clustering. The clustering algorithm is used to detect local linear varieties and
implemented for prediction of water quality. Furthermore, Pal et al. (2000) used fuzzy
clustering for extraction of rules from input-output data; this was implemented and tested in
mathematical examples and in the inverted pendulum problem. Another application of
fuzzy clustering is the medical diagnosis area, since biological systems are extremely
complex and the boundaries between distinct medical diagnosis are not shapely defined
(Steimann, 1997).
The mathematical structure of fuzzy clustering is presented next with a detailed description
of the fuzzy c-means algorithm.
Each data observation consists of n measurable variables, grouped into an n-dimensional
column vector zk  

zik, . . . , znk 
T
, zk   n. A set of N observations is denoted by
Z   zk|k  1, 2, . . . ,N  , and is represented as an n 	 N matrix:
Z 

z11 z12

z1N
z21 z22  z2N
   
zn1 zn2  znN
3-1
The columns of this matrix are called patterns (or objects), the rows are called the features
(or attributes) and Z is called the data matrix. The meaning of the columns and rows
depends on the context and will be defined when the method is applied (i.e. Section 3.4).
A cluster can be regarded as a group of objects that are more similar to one another than to
members of other clusters. The objective is to partition the data set Z into c clusters (for the
time being let’s assume that c is known). Fuzzy clustering allows the objects to belong to
several clusters simultaneously, with different degrees of membership (Bezdek and Pal,
1991; Babuska, 1998).
The next step is to define the fuzzy partition in terms of membership functions. Let us
denote the membership function of zk in the i cluster by  i  zk    ik . A c  N matrix
U
   ik  represents a fuzzy partition if and only if its elements satisfy the conditions:
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ik   0,1  1  i  c, 1  k  N 3-2
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N #
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Therefore, the fuzzy partitioning space of Z is the set:
Mfc % U & ' c ( N|) ik * + 0,1 , , - i,k; . i
/
1
c
0
ik 1 1, - k; 0 2 . k
/
1
N
0
ik 2 N, - i 3-5
The ith row of the fuzzy partition U contains values of the ith membership function of the
fuzzy subset i of Z. Equation 3-3 constrains the sum of each column to 1, and thus the total
membership of each zk in Z equals one.
Many of the fuzzy clustering algorithms are based on minimisation of the basic c-means
objective function (Dunn, 1973), presented in Equation 3-6.
J 3 Z; U,v 4
1
. i / 1
c
. k / 1
N
3
0
ik 4
m 5 zk
6
v i
7
2 3-6
where
U 8 9 : ik ; < Mfc 3-7
is a fuzzy partition matrix of Z,
V 8 9 v1,v2, . . . ,vc ; v i < = n 3-8
is a vector of centres of clusters,
Dik2 8 7 zk 6 v i 7 2 8 > zk 6 v i ? TA > zk 6 v i ? 3-9
is a squared inner-product distance norm (A 8 I is the Euclidean norm), and
m
<
9 1, @ A 3-10
is a weighting exponent, which determines the fuzziness of the resulting clusters. The value
of Equation 3-6 can be seen as a measure of the total variance of zk from v i.
The fuzzy c-means algorithm is one of the most used fuzzy clustering algorithms, the
details of this algorithm are presented in the next section.
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3.2.1 Fuzzy c-means Algorithm
The minimization of the c-means functional (Equation 3-6) represents a nonlinear
optimization problem that can be solved using a Picard iteration, for instance, through the
first-order conditions for stationary points. This can be found by adjoining the constraint in
Equation 3-7 to J using the Lagrange multipliers:
J B Z; U,v C D E i F 1
c
E k F 1
N
B G ik C
mDik2 H I k J 1
N K
k L iM 1
c N
ik O 1 3-11
and by setting the gradients of J with respect to U, V and K to zero. If Dik2 P 0, Q i, k and
m P 1, then R U,V S T Mfc U V n W c may minimize J only if:
X
ik
Y
1
Z
j
[
1
c DikA
DjkA
2
m \ 1
, 1 ] i ] c 1 ] k ] N 3-12
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v i
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N a
ik
mzk
b
k c 1
N a
ik
m
, 1 d i d c. 3-13
Equation 3-13 gives v i as the weighted mean of the data items that belong to a cluster,
where the weights are the membership degrees. This is why the algorithm is called
c-means. The general algorithm is presented next.
e First, given the data set Z, choose the number of clusters 1 f c f N, the weighting
exponent m g 1, the termination tolerance h i 0 and the norm inducing matrix A.
j Second, initialize the partititon matrix U k 0 l m Mfc, then:
n Repeat for l o 1,2, . . .
Step 1: Compute the cluster prototypes (means):
v ip
l l
o
q
k
r
1
N
s
ikt
l u 1 v mzk
w
k
x 1
N
y
ikz
l{ 1 v m
, 1 | i | c 3-14
Step 2: Compute the distances:
DikA2 } zk ~ v i

l

TA zk
~
v i

l

, 1 | i | c, 1 | k | N 3-15
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Step 3: Update the partition matrix:
if DikA  0 for 1  i  c , 1  k  N ,

ik
l   1

j 1
c DikA
DjkA
2
m  1
3-16
otherwise

ik
l 
 0 if DikA  0 , and  ik l  Ł  0,1  with

i 1
c

ik
l 
 1
until  U

l   U

l  1    
.
3.3 Structure of the Fuzzy Relational Classifier
The objective is to identify structures in data similar to known structures. A fuzzy logic
relation is used to establish the correspondence between structures in the features space and
the class identifiers.
3.3.1 Training the Classifier
The training of the fuzzy relation classifier requires two steps. First, unsupervised fuzzy
c-means clustering is performed in the feature space, then, from the obtained fuzzy partition
and the labels of the training data set, a fuzzy relation is computed. Figure 3-1 shows a
diagram explaining the training procedure.
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Figure 3-1: Training of the Fuzzy Relational Classifier.
3.3.1.1 Exploratory Data Analysis
The features space is partitioned to represent the natural structures in the data. These
structures are discovered by unsupervised cluster analysis using the fuzzy c-means
algorithm described in Section 3.2.1.
The data should be considered in the matrix form 3-1. The training data set Z is partitioned
into c fuzzy subsets (clusters). The membership of the data samples in the clusters is
described by the fuzzy partition matrix U and each cluster is characterized by its centre v i,
Equations 3-7 and 3-14 respectively.
Prior to clustering, several parameters have to be defined in the algorithm, i.e. c (number of
clusters), m (fuzzy exponent) and  (termination tolerance). The choice of c can be verified
by assessing the validity of the obtained partition. The Xie-Beni index (Xie and Beni, 1991)
is a commonly used validity criterion, of the form:
  U,V; Z  

i  1
c 
k  1
N 
ik
m  zk  vi
 2
N
i  j
min    vi
¡
vj   ¢ 2
3-17
The definition of £ ¤ U,V; Z ¥ is independent of the algorithm used to obtain ¦ ij. Therefore, it
is not internal to the clustering algorithm. The best partition is the one that minimises the
value of £ ¤ U,V; Z ¥ , since a smaller £ ¤ U,V; Z ¥ means a more compact and separate
c-partition. The cluster algorithm is run for different values of c and m, and then several
times for each of these settings with a different initialization matrix. The number of
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clusters, which minimizes the measure, is finally set.
3.3.1.2 Fuzzy Relation
A fuzzy relation encodes the logical relation between the cluster membership and the class
membership. This relation is computed from the information in the fuzzy partition matrix U
and in the target vectors containing the membership of the pattern in the classes. The k th
target vector is denoted by:
wk § ¨ w1k,w2k, . . . ,wLk ©
T 3-18
where wjk ª ¨ 0,1 © and L ª « is the number of classes. For the training data, where the
classification is exactly known, wjk
¬ ­
0,1 ® . The target vector wk is then a vector of all
zeros except for a one at the place of the known class index.
For each of the training samples zk, the vector of cluster membership degrees ¯ ik is
contained in the k th column of U.
¯ k
° ±
¯ 1k, ¯ 2k, . . . , ¯ ck
²
T 3-19
The binary fuzzy relation, R, is a mapping R :
±
0,1
²
c ³
±
0,1
²
L ´ µ 0,1 ¶ . It can be
represented as a c · L matrix:
R ¸
r11 r12
¹
r1L
r21 r22 ¹ r2L
º º º º
rc1 rc1 ¹ rcL
3-20
The relation R is obtained by aggregating the partial relations Rk, computed for the training
samples (Pedrycz, 1994).
»
rij ¼ k ¸ min
»
1,1 ½ ¾ ik ¿ wjk ¼ j ¸ 1,2, . . . ,L i ¸ 1,2, . . . ,c 3-21
The aggregation of the relations Rk is computed by means of a fuzzy conjunction operator:
R ¸
k
À
1
N
Á Rk 3-22
implemented element-wise by the minimum function:
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rij Â
kÃ 1,2,...,N
min Ä Å rij Æ k Ç 3-23
The relation matrix R is the basis of the FRC, since it is used to classify unseen patterns.
3.3.2 Classification of New Patterns
The main objective of any classifier is to determine the class of a new pattern. First, the
cluster membership function È is calculated from the distances to the cluster centres, vk, as
in the fuzzy c-means algorithm. Second, the class membership function vector w is
computed by fuzzy relation composition using the Lukasiewicz implication:
wj Â
1
É i É c
max Ê max Ë Ì i Í rij Î a, 0 Ï Ð j Ñ 1,2, . . . ,L 3-24
where a is considered to be one in the initial algorithm used by Setnes and Babuska (1999).
Finally, defuzzification is applied to obtain a crisp decision, using the maximum method,
i.e.:
y Ñ
1 É jÉ L
arg max wj 3-25
where y is the class index. Figure 3-2 illustrates this classification procedure.
Figure 3-2: Classification of a new pattern by the FRC.
Note that the FRC can classify a new pattern well, wrongly, or not classify it at all.
Unclassified cases happen when multiple j’s satisfy Equation 3-25, meaning that a pattern
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has the same membership value in more than one class. This could be due to noise in the
features, misclassifications of training samples or inappropriate feature selection. Therefore
it is necessary to select the best features so that no unclassified cases occur. Applying a
fuzzy relation for classification will in general decrease the number of misclassifications.
Furthermore, the FRC is not sensitive to the order in which training examples are presented
and the risk of overtraining is eliminated.
3.4 Classification of Depth of Anaesthesia
The FRC is used to classify a set of features into different DOA levels. The computed fuzzy
relation specifies the existing relationship between the clusters and the classes (i.e. levels of
DOA).
The classifier will use two sets of features on the classification process. The first set is
constituted from the AEP signal, and the second set is constituted from the cardiovascular
parameters. These features are described in detail in the following sections.
3.4.1 Auditory Evoked Potentials Parameters
The AEP were recorded in the operating theatre using surface electrodes. The recording
system used in this research was the one developed by the Intelligent Systems Group, in the
Department of Automatic Control and System Engineering, the University of Sheffield.
This system was used in previous researches (Abbod and Linkens, 1998a; Abbod et al.,
1998; Backory et al., 1998; Linkens et al., 1997a, b), it comprises an IBM-compatible PC
(Intel PI 150 MHz) fitted with a Digital Signal Processing (DSP) board. A pre-amplifier is
used to amplify the responses before they are transmitted to the DSP board where the signal
is analogue-filtered and digitised.
The auditory stimulus in the patient’s headphones is produced at a rate of 6.122Hz. The
EEG is sampled at a frequency of 1kHz after passing through an analogue band-pass filter
(0.5-400 Hz), for a sweep period of 120 ms after each click (i.e. 121 data points). The
computer produces an average of 188 data sweeps plus calculation time, each 30 seconds.
This time was judged to be short enough to assume that surgical and anaesthetic influences
are static.
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The system used to collect the AEP displays only the averaged AEP and its double
differential value. The first step in the classification process is to consider the problem of
what discriminatory features to select and how to obtain these features, as discussed in
Chapter 2. In this research, the multiresolution analysis (MRA) using wavelet transforms
(WT) is used to analyse the AEP during anaesthesia, so as to reflect the changes in
amplitude and latency associated with DOA.
The WT is different from the Fourier transform, because it can zoom on arbitrary details of
signals. The Fourier analysis is a mathematical technique for transforming our view of the
signal from a time-based to a frequency-based one. In moving to the frequency domain,
time information is lost. When looking at a Fourier transform of a signal, it is impossible to
tell when a particular event took place. The wavelet analysis is a windowing technique with
variable-sized regions. It allows the use of long time intervals where we want more precise
low frequency information, and shorter regions where we want high frequency resolution
(Hess-Nielsen and Wickerhauser, 1996). Therefore, wavelet analysis is capable of revealing
aspects of data that other signal analysis techniques miss, aspects like trends and
breakdown points. Also it compresses or de-noises a signal without appreciable
degradation. All these positive points make wavelet analysis a good tool to analyse
biomedical signals. The MRA technique and the WT are described further in Appendix C.
The signal, made of 121 samples (corresponding to the first 120 ms of the EP
post-stimulus), is extended to 128 samples by padding the signal with extra zeros at the
end, so that six levels of decomposition may be achieved using the multiresolution
decomposition algorithm. The MRA decomposes the AEP into different resolutions
allowing a detailed analysis of the behaviour of the signal in its different spectral bands
(Rioul, 1993). The decomposed components were analysed for their energy content and
used as an indicator of the DOA. The Daubechies Wavelet with 12 filter coefficients was
used for decomposing the AEP signal (Mallat, 1999). Daubechies Wavelets have also been
used by Abbod et al. (1998) and Backory (1999). This filter was found to produce good
results and is of low order for the 121 discrete samples to be analysed.
Table 3-1 describes the different signal components obtained as a result of the MRA
decomposition. There are 6 detail signals and a residual component.
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Table 3-1: Table describing the different signal components obtained by MRA decomposition.
Signal Component Samples in sequence
S1 64
S2 32
S3 16
S4 8
S5 4
S6 2
residual 2
Component S1 has the shortest analysis time of 2 ms, while the lowest frequency detail
component S6 has an analysis time of 64 ms. However, the details in Table 3-1 contain the
samples making up the brainstem and the late latency waves, which do not contain
information related to DOA. Therefore, components in each detail regarding these waves
were removed after the MRA. The component 6 which represents the low frequency range
(8-16), and the residual contain a large amount of background EEG signal and are,
therefore, not used.
The average energy contained in each detail signal is calculated as follows:
Dk Ò 1nk Ó iÔ 1
nk |Sk Õ i Ö |2 3-26
where
Dk is the energy contained in detail component k;
nk is the number of samples in detail component k;
Sk is the detail sequence k;
i is the sample number.
Table 3-2 shows the features that have been analysed for correlation with DOA as well as
the samples making up the components (Backory, 1999). D1 is the energy contained in
samples 9 to 56 in S1, and is similar for S2, S3, S4 and S5. D31 is the energy contained in
samples 3 to 6 in S3, and is similar for the other features.
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Table 3-2: Table describing the samples in each component used
to create the features used in the validation process.
Energy Component Samples used
D1 9-56
D2 5-28
D31 3-6
D32 7-10
D33 11-13
D41 2-3
D42 4-5
D43 6-7
D51 2
D52 3
Different sets of features are used in different research works with different classification
methods, for example Abbod et al. (1998) and Linkens et al. (1997b) used 6 of these
features (D1, D2, D31, D32, D33, and D4) while Backory (1999) used a different set (D1, D2,
D3, D4, D51 and D52 × . These features have given good results using an ANFIS classifier
and a KSOM.
In this project 10 features are used in the classification process using the FRC. D41, D42 and
D43 are averaged to produce D4, and similar for D3 and D5. Several combinations of AEP
features were tested. However, the set of features D1, D2, D3, D31, D32, D33, D4, D5, D51
and D52 gave the best results considering the data available.
3.4.2 Haemodynamic Parameters
Anaesthetists have always used the cardiovascular system as an indicator of DOA,
therefore, it is reasonable to use these measurements to enhance the overall decision
making process.
The cardiovascular signals such as the heart rate (HR), the arterial pressure (i.e. systolic
(SAP), diastolic (DAP) and mean (MAP)) and the pulse rate are measured on-line using a
Datex-Engstrom AS/3 (anaesthesia monitor) connected to the computer through an RS232
port, at every 30 second interval.
SAP or MAP have been used for monitoring and control in anaesthesia. Robb et al. (1993)
reported that a simple control system designed to maintain SAP at a predetermined value
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produces a clinically acceptable state of anaesthesia (pattern of clinical signs). This
supports the idea that SAP is a major component of the clinical assessment of the
anaesthetic state. Other researchers use MAP as the indicator of cardiovascular stability
when using inhalational agents (Gentilini et al., 2001b) or intravenous agents such as
propofol (Linkens et al., 1993; Rao et al., 2000). The most prominent effect of propofol in
the haemodynamic responses is a drop in arterial pressure. During maintenance of
anaesthesia SAP remains 20% to 30% below baseline values and similar changes can be
seen in the mean pressure. This decrease in arterial pressure is associated with a decrease in
cardiac output (Sasada and Smith, 2000).
The features used are the change of the individual patient baseline of HR, SAP and MAP,
denoted by Ø HR, Ø SAP and Ø MAP. The use of the Ø values allows generalization, since
the patient baselines are available before the operation and are considered as an input to the
system. The variability between patients is high when considering haemodynamic
parameters. For example, the normal ranges for SAP oscillate between 100 mmHg to 150
mmHg. As a result, the use of Ø values facilitates classification and reflects the
cardiovascular depression independently of the patient baseline values.
3.4.3 Levels of Depth of Anaesthesia
According to the anaesthetist opinion the DOA was classified into five levels:
1- Awake;
2- OK/Light;
3- OK;
4- OK/Deep;
5- Deep.
Awake is when the patient response to surgical stimulus is not acceptable anymore.
OK/Light is when there is a slight patient response, i.e. clinical signs demonstrating that the
patient is getting lighter. OK is when no patient response is observed under surgical
stimulus, i.e. the patient is in the adequate level of DOA. OK/Deep is when there is no
patient response, but the patient is slightly deeper than necessary and still stable. Deep
level is when the patient is clearly in a deep level of DOA, this is not safe for all patients
and should be an indicator that something is wrong.
The OK and the OK/Deep levels are the most difficult to distinguish from one another and
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are also the ones that occur more frequently during anaesthesia. A certain overlap between
these two levels is expected through. While the arousal of clinical signs indicates that
anaesthesia is getting lighter, the deeper depression of these signs may already indicate a
Deep level of DOA. The OK/Deep level, which is often accepted by the anaesthetist as the
interchange between OK and OK/Deep, is very frequent and also depends on the amount of
surgical stimulation at the time. This is a very complex issue, since it is very difficult to
measure analgesia and even if theoretically analgesia and DOA are two different entities. In
practice, when confronted with a high surgical stimulus the anaesthetist tends to increase
the concentration of both drugs (i.e. anaesthetic and analgesic), since the effects of surgical
stimulation on the haemodynamic responses are the same as lighter anaesthesia (i.e.
increases in HR and SAP). The information about the CNS depression is very useful in this
situations, as it reflects the level of hypnosis. Therefore, the anaesthetist would easily
distinguish if the arousal in the cardiovascular parameters is or is not caused by surgical
stimulation, and if so, only the analgesic would be titrated accordingly.
In this research, the data were labelled by the anaesthetist based on the observed clinical
signs during anaesthesia. This information was obtained at regular intervals and when a
change in DOA level occurred, as to reflect the trend in anaesthetic depth of the patient.
However, the anaesthetist uses only his experience and the patient clinical signs to establish
the trend in anaesthetic depth. The information regarding AEP (i.e. depression in the CNS)
during anaesthesia is not available to the anaesthetist.
3.5 Implementation and Results
The data used to train and test the FRC were obtained from two patients undergoing general
surgery at the Royal Hallamshire Hospital in Sheffield. Anaesthesia was maintained using
propofol as the anaesthetic drug and remifentanil as the analgesic drug. The drug profiles
and the particular details of this surgical interventions are presented in Chapter 4. Figure
3-3 shows one of the AEP features from the data of patient Pat2 used to train and test the
FRC, other graphs of the wavelet extracted AEP features are presented in Chapter 5.
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Figure 3-3: Wavelet extracted AEP feature D1 from the data of patient Pat2.
The implemented FRC algorithm involves two distinct classifiers trained separately. The
first FRC was trained using a set of wavelet extracted features from the AEP as the input
pattern. In addition, the second FRC uses the cardiovascular parameters Ù HR and Ù SAP.
Figure 3-4 presents the overall classification diagram.
Figure 3-4: General classification algorithm.
Considering that the FRC may not reach a decision if multiple j’s satisfy Equation 3-22 or
the vector in Equation 3-21 is all zeros, alternatives to the wavelet AEP features have to be
considered. Therefore, the FRC is applied separately to the cardiovascular measurements
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and trained to obtain a decision based only on these measurements. In conclusion, the two
FRC’s (the first using the AEP features and the second using Ú HR and Ú SAP) work
separately. The main decision belongs to the AEP features classifier, if a decision is not
reached then the cardiovascular parameters are used to determine DOA.
In the original algorithm, Setnes and Babuska (1999) use a value of a Û 1 in Equation 3-21.
The value of a makes the decision restricted, i.e. it forces the membership Ü and the
relational value to be both high. For example, is
Ü
Û 0.75 and the associated relational
value is 0.2 the classifier will not reach a decision; this was found to work well for well
identified cluster/class groups. In the case of the AEP features where the feature space is of
high dimension and the cluster classification is not distinct or obvious, using a value of
a Û 1 restricts the classification to the prototypes (training set) and hence impedes the
generalization process. The objective is to obtain a general classifier that performs well for
different patients considering that different patients have different characteristics. For the
AEP there is no known baseline for the patient, therefore it is admissible that different
patients respond in slightly different ways with respect to brain signals. The AEP FRC was
tested for different values of a. The performance with the value of 0.75 proved to be better,
by improving the classification percentage and reducing the number of unclassified cases,
i.e. it helps to capture the variation between patients. Note that the value of a cannot be too
small, e.g. a value of 0.5 makes the incorrect classified cases increase drastically. This
change in the algorithm was applied only to the AEP classifier. When the cardiovascular
parameters are used (
Ú
HR and
Ú
SAP), a is kept equal to 1 since the patient variability is
expressed in the baseline and not in the parameters.
The training data for the FRC consisted of 2/3 of the available samples and the remaining
1/3 was used as the testing set. The number of samples used are presented in Table 3-3.
The samples of patient Pat1 used in the training data set correspond to the first part of the
surgical procedure while from patient Pat2 the last data samples were used. This is to allow
information of different scenarios in a surgical procedure (e.g. induction and recovery).
Table 3-3 Fuzzy relational classifier training and testing data sets.
Training data Testing data
Patient Pat1 134 67
Patient Pat2 142 71
Total 276 138
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3.5.1 AEP Features Selection
The set of AEP features needed for classification depends not only on the correlation with
the DOA level, but also on the type of classifier used and on the amount of data available.
First, the correlation between each AEP feature and the DOA level was computed and from
there different combinations of features were tested based on the performance of the FRC.
A correlation coefficient is a number between -1 and 1 which measures the degree to which
two variables are linearly related. If there is a perfect linear relationship between the two
variables with a positive slope, we have a correlation coefficient of 1; if there is a positive
correlation, whenever one variable has a high (low) value, the other has a high (low) value.
If there is a perfect linear relationship with a negative slope between the two variables, we
have a correlation coefficient of -1; if there is a negative correlation, whenever one variable
has a high (low) value, the other has a low (high) value. A correlation coefficient of 0
means that there is no linear relationship between the variables. The formula of the
correlation coefficient ( Ý xy) between two variables (X and Y) is:
Ý xy Þ
cov ß X,Y à
á
x
á
y
3-27
where cov â X,Y ã is the covariance between X and Y, ä x and ä y are the standard deviations of
X and Y respectively. Table 3-4 shows the correlation coefficients of all the AEP features
and the DOA level as classified by the anaesthetist.
Table 3-4: Correlation coefficient between the AEP features and the DOA level.
AEP Feature Correlation Coefficient
D5 -0.3732
D51 -0.1765
D52 -0.3764
D4 -0.3954
D3 -0.1757
D31 -0.1956
D32 -0.1077
D33 -0.1414
D2 -0.1602
D1 -0.0299
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The value of -0.3954 is the highest correlation coefficient amoung the AEP features. This is
not a very high value. However, this does not mean that there is no correlation between the
AEP features and DOA, only that there is a small linear correlation when comparing DOA
with individual features. Different AEP features represent different levels of resolution,
different frequencies and therefore different levels of information about the CNS. As a
result, it is not expected that a simple linear relation using only one of the features can
adequately describe the DOA level. All correlation coefficients in Table 3-4 have one
common feature, which is that they all have a negative value. This demonstrates (as
expected) that the lower values of the AEP are associated with deeper levels of DOA, i.e.
the depression of the CNS. As the DOA level increases from Awake to Deep (i.e. 1 to 5)
the MLAEP signal becomes more flat (Figures 1-1 and 1-2), this in accordance with the
fact that increasing MLAEP latencies are associated with increasing CNS depression
(Chapter 2).
The FRC was trained and tested with normalized AEP features. The AEP features vector (z)
is normalized using the following equation:
z å z æ zç
z
3-28
where, z is the mean and è z the standard deviation of vector z. This type of normalization
translates and scales the axes so that all the features have zero mean and unit variance. The
data should be appropriately normalized before clustering, since distance norms are
sensitive to variations in the numerical ranges of different features. The Euclidean distance,
used in the c-means algorithm, assigns more weighting to features with wide ranges than to
those with narrow ranges.
The Xie-Beni index (Equation 3-17) was used to determined the optimal values of c and m
for the unsupervised c-means algorithm. Different sets of AEP features were used as to
determine the best classification. Tables 3-5 to 3-10 show the results of the FRC using
different sets of AEP features on the testing data set (i.e. 138 samples). A correct
classification is assumed if the DOA level matches the anaesthetist classification. Selecting
appropriate features is very important for the optimization of performance of FRC for
inappropriate selection of features can lead to unclassified patterns.
Table 3-5 shows the performance of the FRC using AEP features with a higher correlation
coefficient (Table 3-4). The results show that these features are not sufficient for the
classification process. The number of unclassified cases is high and this suggests that the
feature set could be inappropriate or not reflecting all the aspects of the data. The
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complexity of DOA is not easy to detect and this may compromise the efficiency of any
classifier.
Table 3-5: Performance of the FRC using the D5, D52, D4 and D32 AEP features
on the testing data set. Xie-Beni optimum values of c é 11 and m é 2.6.
Correct Incorrect Unclassified
Number of samples 26 10 102
Percentage of samples 18.8% 7.2% 73.9%
Table 3-6: Performance of the FRC using the D5, D52, D4, D2 and D1 AEP features
on the testing data set. Xie-Beni optimum values of c é 9 and m é 2.6.
Correct Incorrect Unclassified
Number of samples 26 19 93
Percentage of samples 18.8% 13.8% 67.4%
Table 3-7: Performance of the FRC using the D51, D52, D4, D31 and D1 AEP features
on the testing data set. Xie-Beni optimum values of c é 5 and m é 2.6.
Correct Incorrect Unclassified
Number of samples 36 23 79
Percentage of samples 26.1% 16.7% 57.2%
Table 3-8: Performance of the FRC using the D5, D51, D52 and D4 AEP features
on the testing data set. Xie-Beni optimum values of c é 5 and m é 2.4.
Correct Incorrect Unclassified
Number of samples 37 20 81
Percentage of samples 26.8% 14.5% 58.7%
Table 3-9: Performance of the FRC using the D51, D52, D31, D32 and D1 AEP features
on the testing data set. Xie-Beni optimum values of c ê 5 and m é 2.6.
Correct Incorrect Unclassified
Number of samples 67 27 44
Percentage of samples 48.55% 19.6% 31.9%
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Table 3-10: Performance of the FRC using the D5, D51, D52, D4, D3, D31, D32, D33, D2 and D1
AEP features on the testing data set. Xie-Beni optimum values of c ë 11 and m ë 2.6.
Correct Incorrect Unclassified
Number of samples 85 53 0
Percentage of samples 61.6% 38.4% 0%
The second set of AEP features (Table 3-6) gave the same results as the first set. The
inclusion of more high frequency detail features proved to introduce more information, and
as a result the percentage of correct classified samples increased (Table 3-7). These results
are confirmed in Table 3-8, where all high frequency features are used. However, the
percentage of correct classified cases is still low. In Table 3-9, the low frequency feature D1
and the details D31 and D32 are included so as to provide information over a wider
frequency range. The number of correct classified samples increased drastically. This result
indicates that all the frequency bands should be used so as to grasp all the information
regarding DOA.
Finally, the whole set of AEP features was used. The results are presented in Table 3-10.
The percentage of unclassified samples was reduced to zero, and the percentage of correct
classified samples was greater than before when using different combinations of features.
The set of all the AEP features reflects the different levels of resolution of the AEP signal.
All the frequency bands are covered and the AEP details are decomposed to obtain all the
relevant information. In addition, the small number of data available can influence the
necessary number of AEP features for an adequate classification. A larger number of
features is necessary to describe the DOA levels.
The best classification performance was obtained using the 10 AEP features (D5, D51, D52,
D4, D3, D31, D32, D33, D2 and D1) with c ì 11 and m ì 2.6. This will be the set of AEP
features used throughout this project.
3.5.2 Cardiovascular Parameters Selection
The FRC using only the AEP features was able to classify all the samples. As a result, the
cardiovascular parameters would not have been used in the classification process.
Nevertheless, the FRC was trained and tested with different combinations of cardiovascular
parameters so as to determined the best classification.
The cardiovascular parameters í HR, í SAP and í MAP were studied for their correlation
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with DOA. Table 3-11 shows the correlation coefficients of the different parameters. î SAP
has the highest correlation coefficient, a value of -0.7 shows that there is a high linear
correlation between î SAP and DOA. The negative sign is common to all of the parameters,
describing the increasing cardiovascular depression as DOA becomes deeper. î MAP
presents a correlation coefficient of -0.6, which is still high. This result indicates that
arterial pressure reflects more variation with different DOA levels. î HR does not have a
high correlation coefficient, however, it may still introduce relevant information in the
classification process.
The systolic and mean arterial pressures were the first candidates as the FRC classification
features. However, both î SAP and î MAP alone did not give good classification results
(Figure 3-5). Hence, the next step was to include î HR in the classification process, for the
cardiovascular stability is one of the major concerns in anaesthesia and this is reflected in
the heart rate as well as in the arterial pressure. The anaesthetist uses both measures to
assess DOA and both must be regulated so as to ensure an adequate patient stability. Figure
3-5 shows the percentage of correct classified samples (testing data set) by the FRC using
the different sets of cardiovascular parameters ( î SAP plus î HR, î MAP plus î HR, î SAP
or î MAP).
Table 3-11: Correlation coefficient between the cardiovascular parameters and the level of DOA.
Cardiovascular Parameter Correlation Coefficient
î HR -0.0526
î MAP -0.6081
î SAP -0.7001
Figure 3-5: FRC percentage of correct classified samples (testing data set) using different parameters.
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ï
HR plus
ï SAP performed better for classification. It was found that these parameters
carry more relevant information considering the gradual changes in DOA levels.
The classifier which uses the cardiovascular parameters was able to classify 46.5% of the
samples correctly with the Xie-Beni optimum values of c ð 13 and m ð 2.6. This result is
hardly surprising since the AEP represent the brain depression of hypnosis. Nevertheless, a
value of 46.5% is a reasonable percentage considering all that is involved in anaesthesia.
The cardiovascular system has always been an indicator of DOA for the anaesthetist. The
use of these parameters is widely implemented, and the manual control of DOA is mainly
based upon them when no information about the CNS is available.
The FRC which uses only the wavelet extracted AEP features was able to classify all the
samples and as a result, the cardiovascular parameters were not used. However, they
represent patient vital signs that should not be disregarded. The FRC using ï SAP and ï HR
will remain as a reinforcement of the overall classifier.
3.5.3. General Results
The FRC using the AEP features was applied to the whole data of the two patients. Note
that data from both patients were used to train and test the classifier. The results are
presented in Table 3-12.
The percentage of correct classified samples is higher for patient Pat2 than for patient Pat1.
However, both results are acceptable. Figures 3-6 and 3-7 show the FRC results for both
patients Pat1 and Pat2 respectively. Analysing the figures, we can see that the majority of
the incorrectly classified cases are between the OK/Deep and OK DOA levels. These are
the two levels which were not easy to differentiate. In addition, there are less data from the
Awake and OK/Light levels, nevertheless, these are more distinguishable from the other
levels.
Table 3-12: Percentage of samples classified by the FRC using the AEP features.
Patient Correct Incorrect
Pat1 49.8% 50.2%
Pat2 59.6% 40.4%
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Figure 3-6: Results of the FRC using only the AEP features for the data of patient Pat1.
Figure 3-7: Results of the FRC using only the AEP features for the data of patient Pat2.
The FRC presents an acceptable performance and is capable of capturing the transition
from awake to anaesthetised. Ideally, data from another patient should be used to analyse
the overall efficiency of the classifier. However, this was not possible to gather due to
circumstances beyond our control.
During both surgical procedures there were incidents of diathermy (use of electrical
bisturi), which interfered with the recording of AEP. Diathermy is responsible for the
samples classified as Awake after the induction of anaesthesia. This is more noticeable with
patient Pat1. The electrical interference of diathermy on the AEP will be discussed in
Chapter 5 with the modelling of the effects of surgical stimulus.
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3.6 Comparison with other Classifiers
In this section, the results of the AEP features FRC are compared with the results of two
other classifiers. First, a Kohonen Self-Organizing Map (KSOM) will be presented and
secondly an Adaptive Network-Based Inference System (ANFIS) for the classification of
DOA.
The KSOM was used by Backory (1999) to assess DOA from the AEP. The KSOM uses six
of the AEP features presented in the previous section. This set of features was studied by
the same researcher and proved to give acceptable results when using the KSOM. The
KSOM developed by Backory (1999) will be applied to the data from patients Pat1 and
Pat2, and later a KSOM will be trained and tested with the same data sets used for the FRC.
The ANFIS was used by Linkens and Abbod (1998) and Linkens et al. (1998) to assess
DOA from a set of six wavelet extracted AEP features. The ANFIS uses a different set of
features than KSOM. This classifier was applied to the data from patients Pat1 and Pat2.
Finally, the ANFIS was trained and tested again with the same data sets used when
developing the FRC. The results are compared with the ones from the FRC using the AEP
features only.
3.6.1 Kohonen Self-Organizing Map
Kohonen Self-Organizing Map (KSOM) is an unsupervised learning method network. This
type of network forms its own classifications of the training data. However, two basic
assumptions about the network have to be made; the first is that class membership is
broadly defined as input patterns that share common features, the other is that the network
will be able to identify common features across the range of input patterns. KSOM works
upon these assumptions, and uses unsupervised learning to modify the internal state of the
network to model the features found in the training data. The learning algorithm organizes
the nodes in the grid into local neighbourhoods that act as feature classifiers in the input
data. The topographic map is autonomously organized by a cyclic process of comparing
input patterns to vectors stored at each node. No training response is specified for any
training input. Where inputs match the node vectors, that area of the map is selectively
optimized to represent an average of the training data for that class. From a randomly
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organized set of nodes the grid settles into a feature map that has local representation and is
self-organized. Self-organization refers to the ability to learn without being given the
corresponding output for an input pattern. Therefore, self-organizing networks modify their
connection strengths based only on the characteristics of the input patterns. A training set
has many input vectors that are similar, and the network should be trained to activate the
same Kohonen neuron for each of them.
Backory (1999) developed a KSOM for DOA using the data of nine patients. These data
were further balanced with data from three volunteers for the Awake and OK/Light levels.
In addition, statistical generation of data for the OK and OK/Deep levels was used. This
was necessary in order to achieve balanced training and testing data sets for the KSOM.
This neural network classifier used a set of AEP features formed by: D51, D52, D4, D3, D2
and D1. The KSOM developed and used by Backory (1999) was applied to the data from
patients Pat1 and Pat2, the classification results being presented in Table 3-13.
Table 3-13: Percentage of samples classified by the KSOM (Backory, 1999).
Patient Correct Incorrect
Pat1 9.5% 90.5%
Pat2 13.2% 86.8%
The KSOM has a very low performance, with a very low correct classification percentage.
Figures 3-8 and 3-9 show the KSOM classification for the two patients. The KSOM was not
able to correctly identify the DOA levels.
The data used by Backory (1999) was gathered during general anaesthesia with a different
combination of drugs, i.e. fentanyl as the analgesic drug, while with patients Pat1 and Pat2
remifentanil was the analgesic drug used. The effect of analgesics on the AEP is a study
under investigation and there are no clear results. However, some researches point out that
remifentanil may depress AEP in a dose dependent manner (Crabb et al., 1996; McGregor
et al., 1998). Therefore, the KSOM was trained again with the same data sets as for the
FRC (Table 3-3), so as to reflect the remifentanil influence. The results of these new
KSOM are presented in Table 3-14, considering the testing data set.
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Figure 3-8: Results of the KSOM (Backory, 1999) for the data of patient Pat1.
Figure 3-9: Results of the KSOM (Backory, 1999) for the data of patient Pat2.
Table 3-14: Performance of the new KSOM (trained with the data from patients Pat1 and Pat2) on the
testing data set.
Correct Incorrect
Number of samples 97 41
Percentage of samples 70.3% 29.7%
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Table 3-15: Percentage of samples classified by the new KSOM (using the same data set as the FRC).
Patient Correct Incorrect
Pat1 47.8% 52.2%
Pat2 64.3% 35.7%
Table 3-15 shows the results for patient Pat1 and Pat2 separately. The correct classification
percentage for the new KSOM is very high. However, Figures 3-10 and 3-11 show that
even with a high classification percentage the KSOM was not able to correctly classify the
DOA changes. In fact, the KSOM has labelled all the data samples as OK/Deep, indicating
that it is biased towards the OK/Deep level. This is due to the fact that the majority of the
training data samples are from the OK/Deep level, which predominates.
Figure 3-10: Results of the new KSOM (using the same data set as the FRC) for the data of patient Pat1.
Figure 3-11: Results of the new KSOM (using the same data sets as the FRC) for the data of patient Pat2.
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The KSOM needs a balanced training data set and a large number of samples, usually
above 1000. The amount of data available is very small, and this will compromise the
performance of any neural network; KSOM works best when the networks are very large,
and the smaller the network, the less accurate the statistical model will be.
3.6.2 Adaptive Network-Based Fuzzy Inference System
Jang (1993) proposed an Adaptive Network-Based Fuzzy Inference System (ANFIS) that
identifies a set of parameters through a hybrid learning rule combining the
back-propagation gradient-descent and a least-squared method. ANFIS is a graphical
network representation of Sugeno-Type fuzzy systems, endowed with neural learning
capabilities. This allows the fuzzy system to learn from the data they are modelling. The
membership function parameters are chosen so as to tailor the membership functions to the
input/output data. Therefore, ANFIS is used for tuning the rules of fuzzy systems. The
network is comprised of nodes and with duties collected in layers with specific functions. It
constructs a network realization of fuzzy rules. ANFIS structure is shown in Figure 3-12.
Layer 1 consists of membership functions with adaptable parameters. Layer 2 implements
the fuzzy AND operator while layer 3 acts to scale the firing strengths. The output of layer
4 is comprised of a linear combination of the inputs multiplied by the normalized firing
strength. Layer 5 is a simple summation of the outputs of layer 4.
Figure 3-12: ANFIS structure.
Linkens and Abbod (1998) and Linkens et al. (1998) used the ANFIS to classify DOA
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using six AEP features: D4, D31, D32, D33, D2 and D1. This set of features was studied for
correlation with DOA and classification performance. The data from several patients were
used to train the ANFIS, using the same drug combination as Backory(1999).
The classifier developed by these researchers was applied to the data of patients Pat1 and
Pat2 (Table 3-16). The results show that the ANFIS classifier performs well with the data
from patient Pat2. Patient Pat1 includes many DOA variations and incidents of Awake
classification (Figure 3-13). These sporadic samples could be partly due to diathermy.
However, many wrong classifications on the OK/Light level can induce the anaesthetist in
error. In addition, the Deep DOA level classifications are also misleading, since this level is
dangerous for the patient. Nevertheless, ANFIS performed better than the KSOM. Figure
3-14 shows the overall DOA classification for patient Pat2. The classifier performs
reasonably and is capable of distinguishing between the lighter and deeper DOA levels.
Table 3-16: Percentage of samples classified by the ANFIS (Linkens and Abbod, 1998).
Patient Correct Incorrect
Pat1 33.3% 66.7%
Pat2 59.6% 40.4%
Figure 3-13: Results of the ANFIS (Linkens and Abbod, 1998) for the data of patient Pat1.
In Abbod et al. (1998) a second measure of DOA was used. A rule-based fuzzy logic using
heart rate and arterial pressure is used to obtain another measure of DOA. This measure is
fused (using fuzzy logic rules) with the ANFIS DOA measure to obtain a final assessment
of DOA. The results with this data fusion of multi-anaesthetic depth measures improves the
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overall classification results presented in the same study.
Figure 3-14: Results of the ANFIS (Linkens and Abbod, 1998) for the data of patient Pat2.
The ANFIS classifier using the AEP features was trained again with the same data groups
as the FRC (Table 3-3). The objective was to compare the results with the results of the
FRC using the same resources. Table 3-17 shows the results of the new ANFIS on the
testing data set. The performance of the ANFIS is smaller than the FRC (Table 3-10).
Table 3-17: Performance of the new ANFIS (trained with the data from patients Pat1 and Pat2) on the
testing data set..
Correct Incorrect
Number of samples 29 109
Percentage of samples 21% 79%
The new ANFIS was applied to the data of patients Pat1 and Pat2 separately (Table 3-18).
The correct classification percentage has decreased for patient Pat2, but increased for
patient Pat1 when comparing with Table 3-16.
Table 3-18: Percentage of samples classified by the new ANFIS (using the same data set as the FRC).
Patient Correct Incorrect
Pat1 41.8% 58.2%
Pat2 28.2% 71.8%
Figures 3-15 and 3-16 show the overall classification results for patient Pat1 and Pat2
respectively. The ANFIS is able to distinguish between lighter and deeper DOA levels. The
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majority of the samples are classified in the OK DOA level. Notice that OK and OK/Deep
levels are most difficult to distinguish. Nevertheless, the ANFIS developed by Linkens and
Abbod (1998) has a better performance with the data from patient Pat2 than with the data
from Pat1.
Figure 3-15: Results of the new ANFIS (using the same data set as the FRC) for the data of patient Pat1.
Figure 3-16: Results of the new ANFIS (using the same data set as the FRC) for the data of patient Pat2.
3.6.3 General Results
Figure 3-17 shows the classification results of the classifiers presented previously, the
KSOM developed by Backory (1999) and the ANFIS developed by Linkens and Abbod
(1998). The ANFIS matches the performance of the FRC when considering patient Pat2.
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However, the ANFIS was not trained with data from this patient and such a high correct
classification percentage indicates the efficiency of the classifier. The KSOM has a poor
performance with the data from both patients.
Figure 3-17: Classification results using the FRC, the KSOM and the ANFIS.
The data used by these researchers to develop these two classifiers were gathered during
general anaesthesia when using a combination of propofol and fentanyl. While the FRC was
trained with the data from patients Pat1 and Pat2 which was obtained under general
anaesthesia with a combination of propofol and remifentanil. The two analgesics, i.e.
fentanyl and remifentanil, have different characteristics. Remifentanil is more potent than
fentanyl and it is known for reducing the cardiovascular parameters more than the other
analgesics. Whether remifentanil can influence the AEP is still a matter of debate, but it is
not unreasonable to think so.
It was discussed in Chapter 2 that the AEP show similar results with different anaesthetic
agents, reflecting the hypnotic effect. The synergistic interaction of propofol and
remifentanil will be discussed in Chapter 4. Remifentanil potentiates propofol, therefore,
the degree of unconsciousness will be different when using propofol alone and when the
same dose of propofol is combined with remifentanil. Consequently, the KSOM and the
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ANFIS were trained again with the same data as the FRC. Table 3-19 shows the percentage
of correct classified samples of the three classifiers on the same testing data set.
Table 3-19: Percentage of correct classified samples on the testing data set by the three classifiers.
FRC New KSOM New ANFIS
Testing data set 61.6% 70.3% 21%
Figure 3-18: Classification results using the FRC, the new KSOM and the new ANFIS.
Analysing Table 3-19 and recalling Figures 3-10 and 3-11, it is obvious that the KSOM is
biased to the OK/Deep level and that even with 70.3% of correct classified samples, the
classifier has a poor performance. Figure 3-18 shows the results of the classifiers on the
data from both patients. The ANFIS performs better than the KSOM, because it is not
biased. Overall, the FRC led to an acceptable performance and proved to work better than
the other classifiers on the available data.
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3.7 Summary
The classification of DOA is a complex task, but essential to develop efficient closed loop
control systems. However, direct measurements are unavailable and signal processing
techniques are required to determine the DOA level.
Research on MLAEP led to the investigation of feature extraction techniques and of
classifiers, so as to obtain a clear indicator of DOA. Any pattern that can be recognised and
classified, possesses a number of discriminatory features. The measured values do not
necessarily carry much discriminatory information; the data may even complicate the
classification scheme because of this deficiency. The first step in the classification task is to
consider the problem of what discriminatory features to select and how to obtain these
features. The use of MRA with WT proved to be very efficient in extracting relevant
features from the AEP. The MRA decomposes the AEP into different resolutions allowing
a detailed analysis of the behaviour of the signal in its different spectral bands. The
decomposed components were analysed for their energy content and these are used as an
indicator of the DOA. The next step is how to classify these detailed features into different
anaesthetic depths. The complexity of biomedical systems makes it a favourable space for
fuzzy logic based applications. In this specific case, there is a small amount of data
available; this can be proved useful when choosing an adequate type of classifier.
Neural networks are very popular as classifiers and have proved to be efficient in some
cases. However, they need a large number amount of data to be effective. Balanced training
data sets, representing all the classification classes with a similar amount of samples is
essential for a non-biased neural network classifier. This is reflected in the KSOM
performance, where there is also the risk of overtraining.
The trained FRC was used to classify a set of wavelet extracted AEP features into DOA
levels. The FRC uses fuzzy relations to establish the connection between natural data
clusters and the class identifiers. The nature of the FRC makes it adequate for high
dimension vector features and complex classification processes, when a small amount of
data is available; this is reflected in the classification results.
The ANFIS led also to acceptable results, however, these were no better than those of the
FRC. Note that ANFIS uses neural network training techniques allied to fuzzy logic
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decision making.
The results of the AEP features classifier have to be carefully analysed, since the
anaesthetist based his decision about DOA level on the clinical signs and his own
experience. Considering that the sampling time was 30 seconds, it was possible that
changes in the DOA level from OK to OK/Deep could go unnoticed to the anaesthetist.
Therefore, some samples attributed to a wrong classification could in fact be correct.
Nevertheless, the anaesthetist’s opinion is taken as the correct classification for there is no
other precise analysis to evaluate DOA. In conclusion, this is not an easy classification
problem where one knows the correct classification and the performance of the classifier
can only be judged on the percentage of the correct classified samples; the overall trend of
classification has to be accounted for. It is important that the classifier is able to distinguish
between the different levels of DOA, and specially to reflect the trend of anaesthetic depth
changes.
The FRC will be used throughout this project as the classifier of DOA from the wavelet
extracted AEP features. A second FRC was also trained with a set of cardiovascular
parameters, and will be used as a reinforcement to the overall decision scheme. The AEP
FRC did not present any unclassified cases.
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Chapter 4
Patients and Drug Pharmacology
4.1 Introduction
The concepts of DOA and AEP were presented in the previous chapters. However, in
anaesthesia the adopted drug profile plays an important role (i.e. anaesthetic and analgesic
drugs). The interaction of different drugs has also an influence on the overall efficacy and
efficiency of anaesthesia. The anaesthetist has to be aware of the drug effects and
interactions.
Anaesthesia involves the use of three drugs, a muscle relaxant, an anaesthetic (hypnotic)
and an analgesic. Since the main concern is the monitoring and control of DOA, and as
explained in Chapter 2 the muscle relaxant has no influence on the degree of hypnosis. The
analgesic drug is of more importance since it affects the pharmacodynamics of the
anaesthetic drug and there is no clear indicator of the degree of pain. The analgesic and
anaesthetic drugs are interconnected, since they interact with each other so as to achieve an
adequate level of DOA and analgesia.
The intravenous anaesthetic drug propofol is used in this project. The drug propofol can be
used as a sole anaesthetic agent. However, the required propofol concentration is associated
with severe haemodynamic responses. As a result, propofol is combined with specific
analgesic agents so as to reduce the dose requirements and diminish the side effects during
anaesthesia. The intravenous analgesic drug remifentanil is the analgesic agent used in this
project. Remifentanil is a new rapid-acting   -opioid that can be titrated to patient’s needs.
In this chapter, the patient’s demography is presented and the properties of the anaesthetic
(propofol) and analgesic (remifentanil) drugs used are explained in detail. In addition, a
review of research on drug interactions and its importance in balanced anaesthesia is
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presented. The different types of drug interactions are explained and main focus is given to
the drugs combination used in this project (i.e. propofol/remifentanil).
4.2 Patients Demography
The data used in this project were gathered during surgical interventions in the Royal
Hallamshire Hospital in Sheffield, with the supervision of Dr. J. Peacock, a senior
anaesthetist in the Department of Anaesthesia of the same hospital. The patients had an
ASA I or II status and gave previous explicit consent to be included in this study.
The data collection was restricted to patients who received the same anaesthetic/analgesic
drug profile, and to surgical interventions that did not need other drugs that could interact
with this particular drug profile. For instance, obese patients could not be used for the data
gathering, since these patients have different pharmacokinetic properties, and patients
having serious health problems and previously medicated with other drugs were also
excluded, since these could interfere with normal drug profile/interaction. In addition,
surgical procedures that require electrical equipment that could interfere heavily with the
AEP recording were excluded.
A clear profile of both drugs is of great importance when the interaction between the drugs
and its effects on DOA are being studied, hence, it was not easy to gather suitable data. In
addition, the Royal Hallamshire Hospital operation theatres were being restructured during
the course of this project, limiting even more the number of suitable cases.
The surgical data relating to three patients were collected for the project. In one of the
surgical interventions there was a fault in the AEP recording equipment. Therefore, patient
Pat3 was excluded from the study. The two other patients profiles are presented in Table
4-1.
The data from both patients were used to train and test the DOA classifier (Chapter 3).
However, when modelling the drug effects only the data from patient Pat1 will be used.
Patient Pat2 was excluded from the modelling part because of the drug profile used and its
possible implications. The use of a bolus of morphine could have added an extra interaction
with propofol, since the level of analgesia is not only provided by remifentanil. In addition,
there are some controversial results (Sasada and Smith, 2000) about the use of atracurium
(muscle relaxant) with propofol, indicating a possible physical incompatibility. This means
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that both drugs cannot be mixed together in the same syringe. However, when administered
separately into different veins there is little risk of incompatibility, considering that
atracurium was used in bolus doses and the speed of the blood flow. These facts could
interfere with the analysis of the interaction of propofol and remifentanil and lead to an
inadequate model. Therefore, it was considered best to exclude the data from patient Pat2
and only use the coherent data (i.e. Pat1) for the modelling part (Chapter 5).
Table 4-1: Particulars of the patients forming part of this study. The drugs used are partitioned in three
categories: muscle relaxant (vecuronium and atracurium), anaesthetic (propofol) and analgesic
(remifentanil and morphine).
Patient Date Age Sex Weight (kg) Surgical Procedure Drugs Used
Pat1 14/06/2000 75 M 82 Incision Retroperitoneal Vecuronium
Sarcoma Propofol
Remifentanil
Pat2 21/02/2001 66 F 61 Right Mastectomy and Atracurium
Axillary Node Clearance Propofol
Remifentanil
Morphine
Two GRASEBY 3500 anaesthesia syringe pumps from Graseby Medical Limited were
used. One for the infusion of propofol and the other for remifentanil. Both infusion profiles
were controlled by the anaesthetist. The GRASEBY 3500 incorporates a “Dipifusor” TCI
for propofol. Therefore, the anaesthetist targeted the propofol plasma concentration and the
TCI infusion algorithm decided upon the necessary infusion rate. Figure 4-1 shows the
syringe pump used, which has an RS232 output port for the interface with a computer.
Figure 4-1: GRASEBY 3500 anaesthesia syringe pump used for propofol and remifentanil.
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4.3 The Anaesthetic Propofol
Propofol (Diprivan) is used mainly for the induction and maintenance of general
anaesthesia, and also for sedation during intensive care and regional anaesthesia. It has also
been used for the treatment of refractory nausea and vomiting in patients receiving
chemotherapy and in the treatment of status epilepticus, but these are secondary uses of
propofol (Sasada and Smith, 2000). The effects of propofol are controlled by rapid hepatic
metabolism. A significant proportion of the drug is metabolised as soon as it passes through
the liver. Because of the rapid hepatic metabolism of propofol, accumulation does not
occur and so the waking time should be the same irrespective of the duration of the normal
maintenance infusion; recovery is pleasant, nausea and vomiting are rare (Carrie et al.,
1996).
Propofol is presented as a white oil-in-water emulsion containing 1% or 2% weight/volume
of propofol in sybean oil and purified egg phosphatide. Propofol is administered
intravenously in a bolus dose of 1.5-2.5 mg/kg for induction and as an infusion of 4-12
mg/kg/h for maintenance of anaesthesia. These doses are for normal patients, when
considering children or elderly the doses have to be adjusted according to the group drug
sensitivity. Children require higher doses of propofol to maintain adequate anaesthesia
(Marsh et al., 1991). Generally an increase of 25-50% is necessary. McFarlan et al. (1999)
explains that children require higher infusion rates than adults due to altered
pharmacokinetics in this age group. Some practical guidelines for the use of propofol in
paediatric anaesthesia are also presented in the same study. The influence of age on the
propofol requirements has been studied by several researchers (Peacock et al., 1990;
Schnider, 2000; Schnider et al., 1999; Schuttler and Ihmsen, 1993). When considering
elderly patients, gender also influences the pharmacokinetics of propofol. Vuyk et al.
(2001) reports that female elderly patients require approximately a 10% higher propofol
infusion rate than male patients, in order to ensure the same blood propofol concentration.
Female patients will regain consciousness more rapidly than male patients when they
experience similar propofol infusion schemes, in the presence of a similar
pharmacodynamic profile.
Propofol is a useful drug for induction and maintenance of hypnosis during total
intravenous anaesthesia. The drug’s fast distribution and rapid metabolism result in a short
plasma half-life. This explains the fast and clear-headed recovery after its use and makes it
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an ideal drug for use in continuous infusions.
Propofol produces a 15-25% decrease in blood pressure and systemic vascular resistance,
and a 20% decrease in cardiac output. This is one of the side effects of propofol. Profound
bradycardia and asystole may complicate the use of the drug (Chaudhri et al., 1992; Sasada
and Smith, 2000; Schulze et al., 1999).
Propofol decreases the amplitudes of the AEP due to its hypnotic effect (Chassard et al.,
1989; Palm et al., 2001). Kuizenga et al. (1998) studied the effects of propofol on the EEG,
when infused at a rate of 0.5 mg/kg/min for 10 minutes. They concluded that propofol
exerts a biphasic effect on the EEG amplitude in all frequency bands.
Computerized propofol infusion systems have been used in anaesthesia for some time.
Researchers like Russell et al. (1995) and White and Kenny (1989), evaluated the use of
manual versus TCI of propofol. Overall, controlled infusion of propofol have performed as
accurately as manual infusions. Roberts et al. (1988) developed a simple scheme for
manual control of a propofol infusion so as to approximate the program used by a computer
controller. This scheme proved to be efficient when the anaesthetist did not have access to a
microprocessor controller or a computer enabled volumetric infuser.
A drug general pharmacology is divided in pharmacokinetics and pharmacodynamics.
Pharmacokinetics are generally described as: “what the body does to a drug”, while
pharmacodynamics are described as: “what the drug does to the body” (Shieh, 1994). In the
next section the pharmacokinetics of propofol will be discussed.
4.3.1 Pharmacokinetic Model
Pharmacokinetics is the quantitative study of the absorption, distribution, metabolism and
elimination of chemicals in the body and the rate of these effects. Most drugs exhibit
multicompartment pharmacokinetic behaviour (Sheiner et al., 1979). A three-compartment
model best describes the distribution and elimination of propofol. This model is used to
predict the plasma concentrations. Figure 4-2 shows the general diagram of a
three-compartment model.
The pharmacokinetics of propofol appear to be linear within clinical dosage ranges. This is
necessary for the compartmental model to adequately describe the metabolism of propofol.
The shape of the drug concentration decay is unaffected by dose and the derived
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pharmacokinetic parameters are similar for the different doses used (Gepts, 1998).
Figure 4-2: The three-compartment model. The k ij are the inter-compartmental rate constants that govern
drug distribution and k10 is the rate constant of elimination. Compartment 1 is defined as the central
compartment.
The pharmacokinetic constants used in the propofol linear three-compartment model
(Figure 4-2) are shown in Table 4-2, and were used by Marsh et al. (1991). Vc is the central
compartment volume per kg of patient’s weight. Vc is used to derive V1 the volume of the
central compartment from the mass of the patient, using V1  Vc  mass. The
pharmacokinetic parameters describing the flow-rate of the drug between the various
compartments are as follows: k ij is the rate constant for drug transfer from compartment i to
compartment j; k10 is the rate constant of elimination from the central compartment (i.e.
compartment 1).
Table 4-2: Pharmacokinetic parameters for propofol described by Marsh et al., (1991) reflecting the
three-compartment patient model.
Vc (l kg  1  k10 (min  1  k12 (min  1  k13 (min  1  k21 (min  1  k31 (min  1 
0.228 0.119 0.112 0.0419 0.055 0.0033
Following a propofol injection to the central compartment, elimination and
inter-compartmental distribution can be defined by the following systems of equations,
considering m1  t  , m2  t  and m3  t  as the masses at time t in compartment 1, 2 and 3
respectively, and r

t  as the drug infusion rate at time t.
.
m1

t   k21m2

t  	 k31m3 
 t    k12  k13  k10  m1  t   r  t 
.
m2  t   k12m1  t   k21m2  t 
.
m3  t   k13m1  t   k31m3  t 
4-1
Assuming zero initial conditions and using the Laplace transform, the system in Equation
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4-1 becomes:
sM1  s   k21M2  s   k31M3  s    k12  k13  k10  M1  s   R  s 
sM2

s
 
k12M1

s

 k21M2

s

sM3  s   k13M1  s   k31M3  s 
4-2
Finally
M1  s 
R  s  
s2  ﬀ k21  k31 ﬁ s  k21k31
s3  p1s2  p2s p3
4-3
where
p1
ﬂ
k31
ﬃ
k21
ﬃ
k12
ﬃ
k13
ﬃ
k10 4-4
p2 ﬂ k21k31 ﬃ k12k13 ﬃ k13k21 ﬃ k10k31 ﬃ k10k21 4-5
p3
ﬂ
k21k31k10 4-6
The plasma concentration (i.e. concentration in compartment 1) is described as:
Cp ﬂ M1V1 4-7
Equation 4-3 is discretised using a ZOH (zero-order-hold) and a sampling rate of 30
seconds.
The values of the pharmacokinetic parameters are average population values. The
individual pharmacokinetic variability produces different pharmacological responses, when
patients are given identical doses of a drug. Therefore, the dose required to produce a
specific response may vary between individuals. Age, body weight and disease are some
factors that affect more the pharmacokinetic variability. Propofol infusion rates should be
set according to total body weight (Hirota et al., 1999). Plasma concentration of propofol is
dependent on the body weight during a fixed rate infusion (Equation 4-7). Special care is
necessary with obese patients, since the pharmacokinetic parameters are largely affected by
this.
The accuracy of the different sets of parameters was analysed by Glass et al. (1989). It was
found that, if the parameters are coherent then the compartmental model is valid.
In conclusion, the pharmacokinetics is the mathematical analysis of the drugs matabolite
levels in the body. The changes in drug concentration in relation to time are used to derive
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the pharmacokinetic constants that adequately account for the behaviour of drugs in the
body.
4.3.2 Effect Compartment
There is a temporal delay between changes in the plasma drug concentration and the
measured effect, because some drugs act at the sites which maybe remote from the blood
stream. This delay is a consequence of the finite time needed for drugs molecules to
equilibrate with the effect site. The effect site is modelled by adding an additional
compartment, linked to the central compartment of the three-compartment pharmacokinetic
model (Figure 4-2) by the single first-order process shown in Figure 4-3.
Figure 4-3: Effect compartment model. ke0 is the rate constant of drug elimination.
More accurately, the effect compartment is connected to the central compartment by a
first-order rate constant, k1e, while the drug dissipation from the effect compartment occurs
by means of a second first-order rate constant, ke0 (Sheiner et al., 1979). However, the
effect compartment is defined as being negligibly small and k1e is an arbitrary small
fraction of ke0. The hypothetical concentration in the effect compartment can only be
calculated if the value of ke0 is known, since ke0 will precisely characterize the temporal
effects of equilibration between the plasma concentration and the corresponding drug effect
(Mortier and Struys, 2000).
Bovill (2000) reports that a consequence of the delay in equilibration is that a plot of
pharmacodynamic response (effect) against plasma concentration measured during and
after a short i.v. infusion, will show an anticlockwise hysteresis loop. The underlying effect
site concentration and the blood-effect delay (i.e. the value of ke0), can be estimated by
manipulating the hysteresis loop so that the loop collapses.
The pharmacodynamic parameter ke0 for propofol was set by Linkens et al. (1993) as being
0.1 min  1. In the same study, these researchers used the same pharmacokinetic parameters
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shown in Table 4-2. The value of ke0
 
0.1 min ! 1 will be used in this project.
The concentration of drug at the effect site (Ce), not the plasma concentration, governs the
drug effect. Therefore, it is more accurate to use the effect concentration to model the drug
effect (Jacobs and Williams, 1993; Morita et al., 2000; Shafer and Varvel, 1991; Weiss,
2000).
Wakeling et al. (1999) compares the targeting of the effect compartment or central
compartment concentration of propofol for predicting the loss of consciousness. The
median time to loss of responsiveness was 3.02 minutes in the group targeted to a predicted
plasma concentration versus a 1.23 minutes in the group targeted to a predicted effect
compartment concentration. The effect site is the theoretical compartment in which a drug
exerts its action and thus the concentration at this site is a direct determination of the effect
of the drug.
4.4 The Analgesic Remifentanil
Opioids provide the analgesia required in balanced and total i.v. anaesthesia techniques to
block autonomic nervous system and somatic responses to noxious surgical stimuli.
Remifentanil (GI87084B) is one of the opioids used to provide the analgesic component of
general anaesthesia. It is a new synthetic opioid that exhibits classic " -agonist
pharmacologic effects including analgesia, sedation and respiratory depression.
Remifentanil is presented as a clear, colourless solution for injection, containing
remifentanil hydrochloride in a glycine buffer (Sasada and Smith, 2000).
A metabolism by nonspecific esterases gives remifentanil a pharmacokinetic profile unlike
that of any other opioid. The clinical advantage of this drug lies in its extremely rapid
clearance, and offset of effect, which is independent of excretory organ function.
Remifentanil can be closely titrated to patient need and could provide new methods of
combining large-dose opioid anaesthesia with risk reduction strategies (Camu and Royston,
1999).
Remifentanil is generally administered by continuous infusion because intermittent bolus
doses are inconvenient for all but shortest procedures. A continuous infusion approaches
steady-state concentration in only 10 minutes (Rosow, 1999). The titration of drug doses
according to each patient’s needs is facilitated by the rapid offset of action combined with a
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rapid onset of action (Westmoreland et al., 1993).
Accurate dosing of remifentanil is not quite so critical as with other opioids, because rapid
recovery is effectively dose-independent. Its clearance is unaffected by variables such as
hepatic or renal function, gender, drug interaction and duration of infusion. Hoke et al.
(1997) concluded that remifentanil elimination was independent of renal function (renal
disease). The other parameters that have been demonstrated to alter remifentanil clearance
such as age and weight, do not produce great changes in drug duration. Therefore, an
infusion of remifentanil produces a consistent steady-state blood concentration and the rate
of disappearance is more uniform within a patient population (Minto et al., 1997a; Rosow,
1993). However, Minto et al. (1997b) showed that age-related pharmacodynamic changes
occur in the peak effect site concentrations; because EEG showed an increase in brain
sensitivity to opioids with increasing age.
The reduction in pharmacokinetic variability with remifentanil is one of its major
advantages. Peacock et al. (1998) show that remifentanil can be used for a diverse patient
population as part of a balanced anaesthesia.
Reves (1999) suggests that practitioners should be educated about remifentanil. The unique
pharmacokinetic profile of remifentanil gives it unparalleled flexibility, but vigilance is
required to avoid problems. The rapid onset of analgesia can be accompanied by an equally
rapid onset of side effects if the dose given is too large if it is given too rapidly.
Remifentanil infusions have been evaluated by Williams (2000) for cardiac and vascular
anaesthesia. He presents a new method for calculating the remifentanil infusion rate based
on weight. This method was accompanied by Cort (2000), who presented an easy dilution
technique to simplify the administration of remifentanil by infusion to supplement
anaesthesia during cardiac surgery. Nevertheless, remifentanil is possible to use safely in
patients undergoing cardiac surgery (Michelsen, 2000).
Remifentanil has one major side effect: respiratory depression (Woods et al., 1999). In fact,
dose-dependent increases in analgesic efficacy and respiratory depression are reported by
Glass et al. (1993). Furthermore, remifentanil decreases mean arterial pressure and heart
rate by 20%. Myocardial contractibility and cardiac output may also decrease (Sasada and
Smith, 2000). Kallar et al. (1994) reported that remifentanil caused dose-dependent
reductions in blood pressure and heart rate. In the same study, remifentanil was found to be
more effective than alfentanil in attenuating the responses to anaesthetic and surgical
stimuli. Prakash et al. (2001) reports incidents of hypotension and bradycardia when using
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remifentanil during rigid bronchoscopy. Glass et al. (1999b) reports that remifentanil in the
presence of isoflurane, resulted in a 10-40% decrease in SAP and similar changes in heart
rate. They suggest that bradycardia could be prevented by pretreating patients with
glycopyrrolate.
Lower values of blood pressure and heart rate are reported with the use of remifentanil than
with other opioids, such as alfentanil and fentanyl (Natalini et al., 1999; Ng et al., 2000;
Peacock and Philip, 1999; Sneyd et al., 1998). However, the major difference between
remifentanil and other opioids is the smaller recovery time (Bekker et al., 2000; Dershwitz
et al., 1995; Egan et al., 1996; Fleisher et al., 2001; Monk et al., 1994). Ahonen et al.
(2000) reports that the times to awakening and tracheal extubation where more predictable
in patients receiving remifentanil compared with patients receiving alfentanil. Loop and
Priebe (2000) studied the recovery after anaesthesia with remifentanil combined with
different anaesthetics. They concluded that the use of remifentanil was characterized by
predictably rapid early and complete recovery with all the anaesthetics studied (i.e.
propofol, desflurane and sevoflurane).
Remifentanil has also been reported by its sedative effects. Sneyd (1999) states that
monitored anaesthesia care sedation with remifentanil is an effective technique which
worked reasonably well in clinical trials. However, this is not the primary action of the
opioid and should be considered as a side effect.
Remifentanil is also used as a sole agent, when only analgesia is required. Blair et al.
(2001) uses remifentanil in a patient-controlled analgesia system for labour. Litman (2000)
also used remifentanil for conscious sedation during painful medical procedures.
Remifentanil safely provides analgesia.
Glass et al. (1999a) used ventilatory depression as the measure of opioid effect, when
determining the potency of remifentanil. They concluded that remifentanil is approximately
40 times more potent than alfentanil, when remifentanil and alfentanil whole-blood
concentration are compared. In fact, remifentanil is also more potent than fentanyl and
sufentanil.
Remifentanil is not only used in combination with propofol. Several studies have been
published using different anaesthetics. Drover and Lemmens (1998), and Monk et al.
(1994) used remifentanil as a supplement to nitrous oxide (a volatile anaesthetic with good
analgesic properties) anaesthesia. Casati et al. (1999) used midazolam (i.v. anaesthetic)
with remifentanil, although, this is not a common combination, since midazolam is mainly
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used as a sedative for minor surgeries, as a premedication or to induce general anaesthesia.
Remifentanil has also been used as a supplement to isoflurane anaesthesia (Bekker et al.,
2000; Glass et al., 1999b; Maguire et al., 2001).
According to Egan et al. (1993) the potential advantages of an ultra-short acting opioid,
such as remifentanil, are:
# The ability to rapidly decrease the drug effect to an appropriate level intraoperatively,
# a decreased likelihood of undesirable opioid side effects postoperatively,
# the lack of drug accumulation with repeated bolus injections or prolonged i.v. infusion,
# the absence of a prolonged metabolism with hepatic or renal disease.
The theoretical disadvantages include:
# The necessity for administration by infusion techniques,
# the lack of prolonged opioid effect when such effects are desirable (e.g. postoperative
analgesia).
4.4.1 Pharmacokinetic Model
Remifentanil pharmacokinetics have been investigated following bolus doses and
continuous infusions. A three-compartment model (Figure 4-2) best describes the
pharmacokinetics of remifentanil, reflecting more closely the drug metabolism in the body
(Egan et al., 1996; Glass et al., 1999a, b; Mertens et al., 1999; Minto et al., 1997a, b).
The pharmacokinetic parameters used in this project for remifentanil are presented in Table
4-3 and were used by Egan et al. (1993).
Table 4-3: Pharmacokinetic parameters for remifentanil described by Egan et al., (1993) reflecting the
three-compartment patient model.
Vc (l kg $ 1 % k10 (min $ 1 % k12 (min $ 1 % k13 (min $ 1 % k21 (min $ 1 % k31 (min $ 1 %
0.0899 0.3955 0.3234 0.0222 0.1468 0.0155
The striking feature of the pharmacokinetics of remifentanil is the very rapid decay in
remifentanil blood concentration after termination of an infusion. Therefore, remifentanil
presents a new pharmacokinetic class of opioids. Remifentanil has a context-sensitive
half-time plateaus of 3-4 minutes in humans, and its effects are fully reversible by naloxone
antagonism (Dershwitz et al., 1995).
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The calculations in Equations 4-1 to 4-7 have also been used for remifentanil, since the
same structure of a three-compartmental model was used.
4.4.2 Effect Compartment
Even for remifentanil, which has a rapid effect site equilibration, there is a small, but
appreciable, benefit from targeting the effect site (Bovill, 2000). The peak effect of the drug
occurs within 1-3 minutes. The offset is rapid and predictable, even after prolonged
infusions.
The pharmacodynamic parameter ke0 for remifentanil was set by Vuyk et al. (1997) as
being 0.9242 min & 1. These researchers used the same pharmacokinetic parameters as in
Table 4-3. The value of ke0 ' 0.9242 min & 1 will be used throughout this project.
4.4.3 Effect of Remifentanil on the DOA Indicators
Remifentanil possesses minimal hypnotic or sedative activity. It produces EEG effects
similar to those of the other opioids, i.e. high-amplitude and low frequency activity. The
remifentanil effects on the AEP and BIS have been studied by several researches. A review
of this results will be presented next.
The addition of remifentanil to anaesthetics affects the CNS signals in the presence of a
painful stimulus. Crabb et al. (1996) studied the effect of remifentanil on the AEP and SEP
during isoflurane anaesthesia. Pa amplitude correlated inversely with remifentanil blood
concentrations before and after intubation and incision.
Guignard et al. (2000) studied the effect of remifentanil on the BIS change (( BIS) and
haemodynamic responses to orotracheal intubation. Remifentanil attenuated or abolished
increases in BIS after intubation in a dose-dependent fashion. Significant reduction of ( BIS
was reported. They concluded that ( BIS was as sensitive as changes in the haemodynamic
variables after a painful stimulus to detect a deficit in the analgesic component of
anaesthesia.
The effect of the combination of opioids and hypnotics on BIS was also studied by Strachan
and Edwards (2000). They combined different infusion doses of remifentanil with a steady
infusion of propofol. It was shown that BIS was reduced by increasing infusion rates of
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remifentanil, and that there was a strong correlation between BIS and sedation with this
combination of drugs. There was clearly a dose-related effect of remifentanil upon BIS,
which suggests that opioids reduce BIS when combined with propofol.
Lysakowski et al. (2001) studied the effect of several opioids (including remifentanil) on
the loss of consciousness and BIS during propofol induction of anaesthesia. The effect-site
concentrations of propofol required for loss of consciousness depend on the simultaneous
administration of opioids. They concluded that remifentanil, when added to propofol, did
not affect BIS before stimulation. However, there was a significant decrease in BIS value
after intubation.
The AEP reflect the balance between CNS depression, caused by anaesthetic drugs and
arousal caused by surgical stimulus. McGregor et al. (1998) reported that remifentanil was
able to abolish the response to laryngoscopy, intubation or incision, as measured by the
AEP. This is the main characteristic of a potent analgesic like remifentanil.
Remifentanil has a greater effect on the haemodynamic parameter compared with other
opioids. Howie et al. (2001) compared the use of fentanyl with remifentanil in an
isoflurane/propofol regimen. They reported that remifentanil study group had lower values
of HR and MAP than the fentanyl study group. In fact, HR was kept below baseline from
induction until the end of the remifentanil infusion, while in the fentanyl group there were
significant values above the baseline; the same was also true for MAP. Cafiero et al. (2000)
also evaluated the effects of remifentanil versus fentanyl on the haemodynamic response to
orotracheal intubation. Significant decreases in SAP at induction and 4 minutes after
intubation were recorded in the remifentanil group, while significant increases were
recorded in the fentanyl group. HR decreased significantly at induction in the remifentanil
group, while there was an increase in the fentanyl group. The values of HR were kept
below or on the baseline in the remifentanil groups while in the fentanyl groups, HR is
always above the baseline.
Kallar et al. (1994) compared remifentanil with alfentanil for outpatient surgery. They
reported that remifentanil caused dose-dependent reduction in HR and blood pressure.
These results are supported by Crabb et al. (1996). They also reported dose-related
decreases in SAP, DAP and HR after administration of remifentanil. In another study by
Thompson et al. (1998) it was observed that when using remifentanil blood pressure and
HR never went above baseline. For example, MAP increased significantly after intubation,
but in the remifentanil groups this increase was quantitatively less than with other
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analgesics and did not exceed the pre-induction values.
In conclusion, when added to a hypnotic an opioid prevents the somatic and autonomic
responses to noxious stimulus. Remifentanil has a depressive effect on HR, blood pressure,
and on the AEP and BIS. This is due to the potency of remifentanil, i.e. its
pharmacodynamic characteristics. Lower values of all variables are reported when using
remifentanil compared with other opioids. Therefore, the range of expected value during
anaesthesia is changed when using remifentanil. Special care is necessary to avoid
bradycardia and hypotension. In addition, remifentanil depressed the AEP, indicating that
deeper levels of anaesthesia will be reached. Loss of consciousness is achieved faster when
remifentanil is used.
4.5 Drug Interactions
General anaesthesia on the basis of a single agent is associated with significant side effects,
compromising haemodynamic and/or respiratory function, reducing operating conditions,
or postponing postoperative recovery. Another therapeutic advantage of combining an
anaesthetic with an analgesic is to achieve the analgesic component of anaesthesia. For an
hypnotic to be able to provide pain relief it has to be administered at a very high
concentration, which can be dangerous for the patient. Furthermore, general anaesthesia is a
process requiring a state of unconsciousness of the brain. If only unconsciousness is
achieved, a noxious stimulus will cause arousal/awakening as a result of the intensity of the
stimulus. The analgesic is used to prevent arousal, inhibiting the noxious stimulus from
reaching the brain (Glass, 1998).
One of the major concerns, when using a combination of drugs is the possible interactions
between them. Interactions are generally described as being synergistic or antagonistic.
According to Berenbaum (1989), synergy means “working together” and antagonism means
“working against each other”, and these terms imply the existence of some intermediate,
zero-interactive state in which agents do neither of the above. Formally, the combination is
termed ) da,db * where da and db are the doses (or concentrations) of the two drugs A and B,
respectively. The effect is treated as a mathematical function E; thus, E ) da,db * is the effect
of the combination. E is expressed as a fractional effect. Da and Db are the doses of A and
B separately that are isoeffective with the combination. Commonly, isoboles are used for
analysing interactions. Isoboles are iso-effect curves, in which the combination ) da,db * is
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represented by a point on a graph, the axes of which are the dose-axes of the individual
agents. It is expected that, if the agents do not interact, the isobole joining the point
representing the combination to those on the dose-axes representing doses isoeffective with
the combination (Da and Db) will be a strait line. Figure 4-4 shows the isobolar diagram
presenting the different interactions.
Figure 4-4: Isobolar diagram from Berenbaum (1989). A and B are two different drugs.
Da and Db are the doses of A and B separately, that are isoeffective with the combination.
The three different classes of pharmacodynamic interactions are defined as (Minto et al.,
2000; Vuyk, 2000):
+ Zero-interaction or additive interaction: the effect of the combination of the two drugs is
exactly the sum of the effects of the individual agents, the two agents simply provide their
action next to one another without influence;
+ Synergistic or potentiation (the isobole bows towards the origin): the effect of the
combination is greater than that expected as based on the concentration effect relationships
of the individual agents;
+ Antagonistic or infra-additive (the isobole bows away from the origin): the effect of the
combination is less than the sum of the effects of the individuals, it could even be less than
that of one of its constituents.
If the interaction is synergistic, smaller amounts of both drugs are needed to produce the
drug effect when administered together. On the other hand, if the interaction if antagonist,
greater amounts of both drugs are needed to produce the effect when administered together.
This approach is used to describe pharmacodynamic drug interactions, while
pharmacokinetic interactions are described by the interaction-induced changes on the
pharmacokinetic parameters.
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Pharmacokinetic drug interactions can be divided into interactions that occur during
absorption, distribution or elimination. According to Olkkola and Ahonen (2001),
pharmacodynamic interactions are far more common and have greater significance in
anaesthetic practice than pharmacokinetic interactions. In fact, modern balanced
anaesthesia is based on pharmacodynamic interactions, they can be regarded as desirable
and the variety of potential pharmacodynamic interactions is limitless. Pharmacodynamic
variability is typically quite large, reproducible, and often substantially exceeds the relative
magnitude of pharmacokinetic variability (Levy, 1998).
The incidence of adverse reactions increases exponentially as the number of drugs
prescribed rises, and this is probably at least partly caused by drug interactions (Olkkola
and Ahonen, 2001). Chyka (2000) compared the number of deaths attributed to adverse
drug reactions by death certificates and by the food and drug administration’s spontaneous
postmarketing surveillance system (MedWatch), in order to characterize national mortality
statistics in the United States of America in 1995. According to death certificates, 206
deaths were attributed to adverse drug interactions, whereas MedWatch tabulated 6894
deaths. These values were far below what was estimated by extrapolation from surveillance
programmes. It was estimated that the number of deaths attributed to adverse drug reactions
could be as high as 200,000 deaths per year. Of course, these numbers are more related to
normal patient medication or emergence procedures than to interactions during general
anaesthesia. However, this study is a clear indicator of the importance of defining drug
interactions for the patient’s safety.
In general anaesthesia it is clinically important to recognize the pharmacokinetic and
pharmacodynamic interaction between propofol (hypnotic) and the analgesic. The
improved knowledge of these interactions can be used to optimize the quality of
intravenous anaesthesia and to develop practical guidelines for optimal drug dosing.
Intravenous anaesthetic agents affect each other’s distribution and elimination. Vuyk
(1998) states that for propofol and the opioids, the relationship between dose and blood
concentration changes by approximately 10-20% due to these pharmacokinetic interactions.
He concludes that, this small variability is unlikely to be recognizable in clinical practice,
since the interindividual pharmacokinetic variability of simple agents is on the order of
70-80% and interindividual pharmacodynamic variability is 300-400%. The large
pharmacodynamic variability means that such interactions are of much greater importance
from a clinical point of view compared with pharmacokinetic interactions.
The hypnotic should be administered to concentrations, which at a minimum, equal the
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concentration producing loss of consciousness. To inhibit somatic and autonomic responses
to noxious stimuli of surgery, an opiate should be added, thereby lowering the
concentration of the hypnotic. However, a ceiling effect on the reduction of the hypnotic by
the opioid is reached, thus showing that opioids cannot be used as a sole anaesthetic agent
(Glass, 1998).
The pharmacodynamic interaction between propofol and the synthetic opioids is synergistic
(Vuyk, 1997, 1999). The pharmacodynamic synergistic interaction strengthens the action of
both agents even more. The optimal propofol concentration is affected by the choice of
opioid. The longer acting the opioid is, the lower the concentration of opioid one should
provide in the presence of equivalent higher propofol concentration.
Vuyk et al. (1997) evaluated the implication of opioid selection and duration of infusion on
the rate of recovery for combination with propofol. With a longer infusion duration, the
optimal target propofol concentration increases when combined with alfentanil, sufentanil
and fentanyl, but decreases when combined with remifentanil. Longer infusions increase
the time to awakening after termination of the infusion, more for the combination of
propofol with alfentanil, sufentanil and fentanyl, than for the combination of propofol and
remifentanil, due to a rapid recovery from effects of remifentanil and the possibility of
using lower target propofol concentrations.
Fentanyl and alfentanil have been shown to decrease the propofol requirements for
induction and maintenance of anaesthesia in a synergistic manner (Smith et al., 1994; Vuyk
et al., 1993, 1995, 1996). For both these analgesics the magnitude of the interaction with
propofol increases with the strength of the stimulus. The concavity of the isobole for loss of
eyelash reflex and consciousness , skin incision , intraabdominal surgery. The major
pharmacodynamic differences between these opioids are potency and rate of equilibration
between the plasma and the site of drug effect. The half-time of equilibration between the
effect site and the plasma for fentanyl is 5-6 minutes (same as for sufentanil) and for
alfentanil is of 1.5 minutes. For the three opioids, fentanyl, sufentanil and alfentanil, the
time required for recovery increases with the duration of the infusion (Shafer and Varbel,
1991). However, the decay in the effect site remifentanil concentration is much steeper than
that of the other opioids and that of propofol. Remifentanil also affects propofol in a
synergistic manner (Mertens et al., 2001).
The optimal propofol concentration is much lower when combined with remifentanil
compared with the other three opioids. Whereas the optimal propofol concentration when
combined with alfentanil is in the order of 3.5 - g/ml, when combined with remifentanil the
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optimal propofol concentration is in the order of 2.5 . g/ml. For a infusion duration of
15-600 minutes the context-sensitive half times of the opioids decrease in the order of
fentanyl / alfentanil / sufentanil / / remifentanil. Therefore, the optimal propofol
concentration decreases in the order of fentanyl / alfentanil / sufentanil / / remifentanil
(Vuyk, 2000).
For all concentration combinations of propofol and remifentanil and all durations of
infusion, recovery after propofol/remifentanil anaesthesia is much faster than when
propofol is combined with one of the other opioids at equipotent doses (Vuyk et al., 1997).
Vuyk (1999) gives the following guidelines:
0 fentanyl should be combined with a relatively high propofol dosage;
0 alfentanil and sufentanil with an intermediate propofol dosage;
0 remifentanil in a relatively high concentration, should be combined with a low propofol
infusion regimen.
Recovery after prolonged infusion is rapid, even at suboptimal propofol/remifentanil
concentrations. Return of consciousness after propofol/remifentanil anaesthesia is much
more caused by the decrease in the effect site concentration of the opioid than that of
propofol, since the effect site propofol concentration drops much slower than that of
remifentanil. The 60% decrement curve of remifentanil runs more or less parallel to the
25% decay curve of propofol (Vuyk, 2000).
The pharmacodynamic interaction between propofol and remifentanil as measured by
effects on BIS, was analysed by Ropcke et al. (2001), using a BIS of 50 as a measure of
“adequate” DOA. They concluded that the two drugs have a synergistic interaction for
maintenance of a BIS value between 45 and 55 during surgery. This was true, regardless of
whether concentrations or infusion rates were used as model input.
Minto et al. (2000) suggested the use of a response surface model for anaesthetic
interactions. The model is based on the assumption that there is a sigmoid relationship
between the effect and drug concentration at the site of action. The response surface model
considers any ratio of two drugs given simultaneously as behaving as a new drug. This
model is empirical and only assumes that the concentration-response relation for each of
the interacting drugs is described by a pharmacodynamic model. They apply the model
using data from a study of the interaction of midazolam, propofol, and alfentanil with loss
of consciousness. This is a recent and new approach in this research area and the work is
still under development. They propose to apply this model to a control system in
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anaesthesia.
Propofol also interacts with inhalational analgesics like nitrous oxide. Davidson et al.
(1993) reported that nitrous oxide reduced the blood propofol concentration at which 50%
of patients moved by approximately 30%. In fact, propofol has a synergistic relation with
other sedative agents and not just the synthetic opioids (Vuyk, 1998).
4.6 Simultaneous Administration of Propofol and Remifentanil
In the recent years, general anaesthesia with propofol and remifentanil has become more
popular. Because of its pharmacokinetic characteristics, remifentanil, a short-acting opioid
agonist, may be the ideal opioid to use in combination with propofol for continuous i.v.
administration (Olivier et al., 2000).
The use of this combination of drugs has been reported as efficacious (Bagshaw, 1999;
Domaingue, 2001; Grundmann et al., 2001; Kulkarni, 2000; Lehmann et al., 1999;
Rowbotham et al., 1998). The studies on anaesthetic drug interactions showed that the
optimal propofol concentration decreases more significantly with remifentanil as compared
with other opioids and recovery is much faster than when propofol is combined with other
opioids. For this reason, remifentanil has specific advantages over the other opioids.
Holas et al. (1999) studied the use of remifentanil, propofol or both for conscious sedation
during eye surgery under regional anaesthesia. The goal was a sedation level at which
patients were calm and comfortable but obeyed vocal commands during the entire surgical
procedure. When total anaesthesia is not considered the drug requirements are different.
However, they concluded that the combination of propofol and remifentanil, provided a
smooth haemodynamic profile and lacked untoward effects. Therefore, a continuous
infusion of remifentanil with propofol seems to be a useful and cost effective technique for
conscious sedation under regional anaesthesia. Smith et al. (1997) also compared the use of
propofol versus remifentanil for monitored anaesthesia care. However, the propofol group
lacked analgesia and the remifentanil group offered a low sedation level and was associated
with greater respiratory depression. A combination of both drugs seems to be preferable.
Olivier et al. (2000) used a continuous infusion of remifentanil and a TCI of propofol for
patients undergoing cardiac surgery. This combination resulted in haemodynamic stability
and good postoperative analgesia. The optimal infusion rate of propofol when combined
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with remifentanil is less than that normally used for maintenance of anaesthesia with other
opioids. The major impetus for low-dose propofol administration is decreasing the
haemodynamic effects of this drug (Hogue et al., 1996). This technique allowed physicians
to schedule the time of extubation in patients undergoing cardiac anaesthesia.
Intraoperative low-dose propofol associated with high-dose remifentanil should promote
rapid awakening as a result of the short, context-sensitive half-time of these drugs (Vuyk,
1997).
The use of this drug combination was also studied for elective non-cardiac surgery by
Pelosi et al. (1999). When combined with propofol, remifentanil effectively provided for
profound analgesia during surgery, stable anaesthetic conditions, simplicity of use and
predictable recovery. They concluded that, for an adequate level of anaesthesia low doses
of propofol are adequate if combined with remifentanil in a high dose range (0.25-0.5
1 g/kg/min) according to noxious stimulation; if signs of light anaesthesia are recorded,
remifentanil rescue could be the first choice solution.
Duce et al. (2000) evaluated the combination of propofol and remifentanil for short painful
procedures in children. Both drugs were given in bolus injection. This technique was found
simple, effective and predictable for procedures lasting less than 10 minutes. Propofol and
remifentanil are a simple alternative to inhalational anaesthesia for short painful
procedures. Inhalational agents are associated with postoperative nausea, vomiting and
agitation. The technique with propofol and remifentanil has a low incidence of these
side-effects. Another study in paediatric patient can be found in Grundmann et al. (1998).
They compared TIVA with propofol and remifentanil versus a desflurane-nitrous oxide
inhalational anaesthesia. They demonstrated that a combination of remifentanil/propofol is
suitable for children. It is a well-tolerated anaesthesia method, which can provide rapid
smooth induction of anaesthesia, intraoperative haemodynamic stability, a fast emergence
and a short postoperative recovery period. Keidan et al. (2001) studied the effect of adding
remifentanil to propofol anaesthesia in children. Remifentanil resulted in: a lower total
amount of propofol to prevent patient movement; a lower time interval to eye opening; an
improvement in the conditions during the procedure; fewer movements in response to the
insertion of the aspiration needle and required significant fewer additional doses of
propofol; and a significantly higher decrease in HR.
There are several studies evaluating the effects of this combination of drugs as measured by
the BIS. Hoymork et al. (2001) evaluated the accuracy of TCI systems for propofol and
remifentanil in a clinical surgical setting, with these two drugs as the only anaesthetics used
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for hypnosis and analgesia. BIS was not sensitive enough for evaluating drug effects to pick
out patients with deviating drug concentration at the deep level of anaesthesia. There was
no correlation between measured plasma concentrations and BIS, for both drugs. The same
conclusion was reached in a previous study when measuring serum drug levels (Hoymork
et al., 1999). BIS registration was not able to pick-out patients with highly deviating serum
levels from the others. Other researchers, such as Finianos et al. (1999a, b) and Hans et al.
(2000), concluded that BIS measured the level of sedation and did not correlate with
effect-site concentrations of the hypnotic propofol. This is not surprising, since remifentanil
potentiates propofol and the level of unconsciousness is different when different
concentrations of remifentanil are used with the same concentration of propofol.
Philip et al. (1997) compared remifentanil with alfentanil for ambulatory surgery using
propofol for TIVA. Remifentanil used with propofol was effective as the primary opioid in
TIVA. In this study, remifentanil provided better intraoperative haemodynamic stability
than alfentanil, because remifentanil was dosed to higher levels of opioid. For ambulatory
patients, short-acting drugs are needed for TIVA so as not to delay recovery.
O’Hare et al. (2001) examined recovery with the use of remifentanil to supplement
anaesthesia maintained with different preselected target plasma concentrations of propofol.
The results showed that adequate anaesthesia could be maintained by using different
proportions of the hypnotic and the opioid. It was also evident that the use of a short-acting
opioid, when given at a higher dose results in a more rapid, early recovery. Regardless of
the duration of infusion, the decrease in remifentanil plasma concentration to 50% has a
time of 3.6 minutes. This characteristic allows uncomplicated changes in infusion rates
with rapid effect, making remifentanil an ideal adjunctive for i.v. anaesthesia. These results
are also supported by Papilas et al. (1999).
The interaction of the remifentanil and propofol doses required to prevent patient response
during surgery was studied in patients undergoing arthroscopic surgery with a median
anaesthesia duration of 1 hour by Peacock and Philip (1999). They concluded that
remifentanil can be administered in comparatively larger doses as the opioid component of
ambulatory anaesthesia, which will reduce patient’s responses to surgery but will not delay
recovery. Remifentanil is also appropriate to use for patients or procedures that require a
brief, variable, or rapidly terminating intense opioid effect.
Space prohibits mentioning all other researches in this area but the following are worth
mentioning: Doyle et al., 2001; Fragen and Fitzgerald, 2000; Haughton et al., 1999;
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Kazmaier et al., 2000; Milne and Kenny, 1999; Peacock et al., 1998; Twersky et al., 2000.
4.7 Summary
General anaesthesia with intravenous drugs, is gaining increasing acceptance because of the
availability of short-acting hypnotics and opioids and improved infusion systems. With
TIVA, the analgesic and hypnotic components of anaesthesia can be titrated separately to
control DOA despite changing surgical stimulus.
The hypnotic propofol is the most suitable intravenous anaesthetic agent, and it is
frequently used in combination with synthetic opioids. The introduction of remifentanil, an
ultra short-acting opioid with a rapid onset and offset of action, leads to more stable
operating conditions. Remifentanil potentiates the effects of propofol, i.e. a decrease in the
haemodynamic parameters and depression of the CNS, which is reflected in the AEP.
Therefore, when combined with remifentanil the adequate propofol concentration is largely
reduced. The use of remifentanil provides a faster recovery without side effects (e.g.
nausea), enhancing the quality of anaesthesia. Due to its potency, remifentanil provides an
adequate analgesia and was proved to be suitable for various types of surgery, from cardiac
surgery to short interventions needing only regional anaesthesia, in adults or in children.
The combination of propofol and remifentanil is becoming more popular with anaesthetists.
However, the study of the pharmacodynamic interaction of these two drugs is necessary so
as to assure an adequate DOA level and pain relief. Remifentanil has a synergistic
interaction with propofol and this can be used to an advantage, which is titrating propofol
to lower infusion rates and speeding up recovery. However, special care is necessary
because if propofol is used to achieve high concentrations, the simultaneous administration
of remifentanil will increase drastically propofol side effects, leading to situations of
bradycardia or hypotension. It is of major importance to consider the pharmacodynamic
interaction of the two drugs.
Drug interactions can interfere with the anaesthetic conditions and patient safety. The
anaesthetist should be aware of these interactions and use this information to combine
properly the infusion doses of both drugs.
General anaesthesia techniques could take advantage of the pharmacodynamic interaction
between the hypnotic and the opioid to determine the optimal infusion profiles, controlling
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the amount of drug administered based on the level of DOA, and also on the
haemodynamic parameters. These parameters can be used to obtain simulation models for
the effects of the drug combination (propofol/remifentanil). The modelling of the patient’s
vital signs, based on the interaction of these drugs will be discussed in the next chapter. In
addition, effect concentrations will be used to model the effect of the two drugs. The effect
concentration governs the drug effects, since it is in the effect site that the drug exerts its
action.
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5.1 Introduction
A patient model is necessary to construct and test a closed-loop control system in
anaesthesia prior to any transfer of the design to the operating theatre. In Chapter 3, a fuzzy
relational classifier (FRC) for depth of anaesthesia (DOA) was presented. The FRC uses a
set of wavelet extracted auditory evoked potentials (AEP) features, and the cardiovascular
parameters change of heart rate (   HR) and change of systolic arterial pressure (  SAP), to
classify DOA into five different levels. This set of parameters is considered to be the effect
of the combination of the two drugs used (i.e. propofol and remifentanil) and of the surgical
stimulus.
The next step is to model the   HR,   SAP and the AEP features using the drug effect
concentrations and the surgical stimulus level. The effect concentrations are obtained using
the pharmacokinetic compartmental models combined with an effect compartment, as
explained in Chapter 4. The objective of this exercise is to model the pharmacodynamic
properties of both drugs and the interactions between them.
Overall, the patient model includes the pharmacokinetic compartmental models of both
drugs, and a pharmacodynamic model constituted by the effect compartment and by a
model describing the relationship between the effect concentrations and the different
effects. Furthermore, the patient model is different considering the two main phases of a
surgical procedure, i.e. induction and maintenance of anaesthesia. These two phases present
different characteristics, not just in the amount of drug used, but also in the degree of
stimulus. The absence of stimulus in the induction phase (except intubation) affects the
pharmacodynamic interaction between propofol and remifentanil (Chapter 4). In the
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maintenance phase, the surgical stimulus is a continuous event, from incision until suture,
with different degrees of intensity.
The induction phase was considered to be the initial 1500 seconds (25 minutes), when the
patient is still in the anaesthetic room. The maintenance phase was considered to be from
1500 seconds (assuming that the patient is stable and is already in the operating room) until
the infusion of propofol stops and recovery begins. In this project, the recovery phase is not
considered, since the major objective is the control of DOA using a combination of the two
drugs. In the recovery phase, the infusion of both drugs is usually stopped and there is no
control, however, this drug combination is notorious for providing a rapid recovery.
This chapter presents the different pharmacodynamic models for the induction and
maintenance phase, considering  HR,  SAP and the AEP features. The effect
concentrations of the two drugs are used to model the pharmacodynamic interaction of
remifentanil and propofol on the cardiovascular parameters, and on the AEP. Fuzzy
Takagi-Sugeno-Kang (TSK) models are used in the maintenance phase, which are trained
using the Adaptive Network-Based Fuzzy Inference System (ANFIS). In addition, a
stimulus model is used to establish the effects of the surgical stimulus on the cardiovascular
parameters, according to the level of analgesia. This stimulus model is constructed into a
Mamdani type fuzzy model, using the anaesthetist knowledge described by fuzzy IF-THEN
rules.
The hybrid patient model is constructed using the data from one surgical intervention
(patient Pat1). This model represents a typical procedure using the combination of propofol
and remifentanil. The limited amount of data available, restricts the choice of models and
the possibility of a wider generalization.
5.2 Patient Data
The data from patient Pat1 were used to obtain the pharmacodynamic patient models.
These data were gathered during a surgical procedure lasting 9685 seconds, approximately
2 hours, 41 minutes and 25 seconds. The infusion profiles of both drugs were determined
by the anaesthetist, according to his experience and the nature of the surgical stimulus
present at the time. Figure 5-1 shows the infusion profiles for propofol and remifentanil.
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Figure 5-1: Remifentanil and propofol infusion rate profiles used in the surgical procedure of patient
Pat1.
Figure 5-2: Propofol plasma (Cp) and effect (Ce) concentrations obtained from the infusion profile used
in the surgical procedure of patient Pat1 (Figure 5-1).
The plasma concentration of both drugs was obtained using the infusion rates in Figure 5-1
and the pharmacokinetic compartmental models described in Chapter 4, with the mean
population pharmacokinetic parameters. The effect compartment was used to establish the
effect concentration of propofol and remifentanil, using the parameter ke0. The
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pharmacokinetic interactions of the two drugs were not studied. Therefore, the
concentrations of propofol and remifentanil are determined separately. Figures 5-2 and 5-3
show the plasma and effect concentrations for propofol and remifentanil, respectively.
Figure 5-3: Remifentanil plasma (Cp) and effect (Ce) concentrations obtained from the infusion profile
used in the surgical procedure of patient Pat1 (Figure 5-1).
Figure 5-4: Cardiovascular parameters,  SAP and  HR, recorded during the surgical procedure of
patient Pat1.
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The effect concentrations of remifentanil and propofol will be used to model the effect of
both drugs on the cardiovascular parameters,  SAP and  HR and on the AEP features.
Figure 5-4 shows the parameters  SAP and  HR recorded during the surgical procedure
with patient Pat1. The SAP and HR baselines were 130 mmHg and 90 bpm respectively.
Figure 5-5: AEP feature D5. Figure 5-6: AEP feature D51.
Figure 5-7: AEP feature D52. Figure 5-8: AEP feature D4.
Figure 5-9: AEP feature D3. Figure 5-10: AEP feature D31.
97
_________________________________________________________________________________________________________________________________________________________
Chapter 5: A Hybrid Patient Model
Figure 5-11: AEP feature D32. Figure 5-12: AEP feature D33.
Figure 5-13: AEP feature D2. Figure 5-14: AEP feature D1.
The ten wavelet extracted AEP features, D5, D51, D52, D4, D3, D31, D32, D33, D2 and
D1, were obtained from the AEP sweeps recorded (204 sweeps in total) during the surgical
procedure, and are presented in Figures 5-5 to 5-14. Analysing the figures, the different
characteristics of the several AEP features are clear; they represent different frequency
bands and carry different information. However, some of them present a similar profile,
specially when comparing the low frequency components to the high frequency, e.g. D2 and
D1 with D5 and D4.
The DOA profile for patient Pat1 is presented in Figure 5-15, as classified by the
anaesthetist during the intervention. This is based on the anaesthetist experience and the
observed clinical signs.
The data gathered in the operating theatre are used to model the different parameters,
considering the induction and maintenance phase of anaesthesia. The data from patient Pat1
are used to train and test the different pharmacodynamic models, presented in the next
sections. The final patient model describes a typical surgical intervention with the
combination of propofol and remifentanil. This model will be used in Chapter 6, to
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substitute the patient when simulating a closed-loop control system for DOA.
Figure 5-15: Depth of anaesthesia (DOA) as classified by the anaesthetist, for Patient Pat1.
5.3 Induction-Phase Model
The surgical procedure is divided into induction and maintenance phases. The induction
phase was established as being the first 1500 seconds (25 minutes) of the whole procedure.
This is usually the time spend by the patient in the anaesthetic room, where the induction of
anaesthesia and the intubation of the patient takes place.
During induction of anaesthesia, high effect concentrations of the hypnotic are targeted. A
rapid intravenous bolus injection or a continuous infusion of a high dose for a limited short
time are usually used. Depth of anaesthesia increases rapidly causing loss of consciousness,
and then decreases as the hypnotic concentration declines.
The rapidly changing concentrations during induction cause a corresponding fluctuation in
the degree of CNS depression. The CNS depression lags behind the plasma concentration,
represented by hyteresis on curves plotting the effect against the concentrations. The
non-steady-state conditions produced by rapid administration of a drug, make assessment of
the relationship of the drug concentration and DOA difficult, if not impossible (Stanski,
1994).
The AEP latency appears erratic at the induction of anaesthesia, since the calibration of the
AEP waveform in an awake patient is difficult in the time available in the anaesthetic room.
In addition, the increase in latency at induction of anaesthesia is followed by a decrease due
to intubation of the trachea, which causes a stress response manifested by an increase in
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blood pressure and a decrease in latency (Allen and Smith, 2001).
The AEP signal is not normally used for the monitoring of DOA during the induction of
anaesthesia. However, immediately after induction of anaesthesia and tracheal intubation,
the AEP display a characteristic pattern (Thornton et al., 1989a). The AEP features
displayed in Figures 5-5 to 5-8 (the high frequency components) show the discrepancy
between the values at induction and during maintenance of anaesthesia. For these reasons,
the AEP will not be used during the induction phase. The patient model will only reflect the
changes in SAP and HR during this phase.
Induction agents, such as propofol, show a much stronger interaction with opioids for
suppression of responses intraoperatively, compared with the minor interaction seen during
the induction of anaesthesia (Vuyk, 1998). In addition, several researchers stated that the
influence of remifentanil on the haemodynamic parameters during the induction phase is
reflected on the response to intubation, the only strong stimulus during induction (Cafiero
et al., 2000; Casati et al., 2001; Grewal and Samsoon, 2001; Joo et al., 2001; McGregor et
al., 1998; Song et al., 1999).
Significant haemodynamic changes are associated to tracheal intubation. This response is
attenuated by the use of opioids such as remifentanil (Alexander et al., 1999a; Lee et al.,
2001). The effect of different doses of remifentanil on the cardiovascular response to
intubation, has been the focus of several researches (Grant et al., 1998; Hall et al., 2000).
Remifentanil prevents the movement and the increases in haemodynamic variables
associated with intubation is a concentration dependent fashion. Remifentanil has a more
significant reduction in the increases of MAP and HR after intubation compared to other
opioids (Guignard et al., 2000; Thompson et al., 1998).
The induction phase patient model is presented in Figure 5-16, including the
pharmacokinetic and pharmacodynamic models. Section 5.3.1 shows how  SAP and  HR
can be modelled using the propofol effect concentration, and Section 5.3.2 presents the
effect of intubation on the cardiovascular parameters and the action of remifentanil.
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Figure 5-16: Block diagram of the induction phase model. Prop_Cp and Remi_Cp are the plasma
concentrations of propofol and remifentanil, respectively, whereas Prop_Ce and Remi_Ce are the effect
concentrations.
5.3.1 Cardiovascular Parameters
The cardiovascular parameters  SAP and  HR were modelled using a set of data from
patient Pat1. The data set used is presented in Figure 5-17 and represents the time period
from 2018 seconds to 6576 seconds (termed Group1). During this time, the remifentanil
infusion rate and effect concentration were constants (Figures 5-1 and 5-3). Therefore, only
the effect of the changes in propofol infusion rate are considered.
Figure 5-17: Propofol infusion rate and effect concentration, of the time period in Group1.
A Hill equation model (described by Sheiner et al. (1979)) was used to model the influence
of propofol on  SAP and  HR. The Hill equation used is of the form:
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Effect  Emax CeCe  Cp50	 5-1
where Emax, 
 and Cp50 are constants, Ce is the propofol effect concentration, and Effect
represents  SAP or  HR.
The Nonlinear Control Design (NCD) MATLAB Toolbox was used to optimize the
parameters of Equation 5-1. The NCD is a time-domain-base optimization approach to
system design. It automatically converts time-domain constraints and time responses into
an optimization problem, and then solves the problem using a gradient method with a
modified line-search algorithm. Successive simulations and sequence quadratic
programming solve the optimization problem. Monte Carlo methods can also be used to
increase the system robustness.
The difference between the Hill equation value and the actual effect (  SAP or  HR) during
the time period of the data set was used as the signal to be constraint to a minimum (ideally
zero). The parameters Emax, 
 and Cp50 were automatically tuned based on the performance
constraint. Several simulations were performed with different initial values, uncertainty and
error margins, so as to obtain the best approximation to the values of  SAP and  HR of
patient Pat1, using the specified data set (Group1, Figure 5-17).
5.3.1.1 Systolic Arterial Pressure
After several interactive optimizations, the NCD allowed the following values to be
obtained
Emax   69.61
  3.18
Cp50  2999.4
Therefore the  SAP Hill equation model is:

SAPmodel   69.61 Ce
3.18
Ce3.18  2999.43.18
5-2
where Ce is the propofol effect concentration.
The model results on the training data set (Group1) are presented in Figure 5-18. The mean
absolute error of the model was of 3.37 mmHg, this low value represents a reasonable
model approximation. This set of parameters captures well the

SAP changes. However,
the value of SAP is not the result of the drug effect only, but surgical stimulus is also
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responsible for the SAP variations. Therefore, a model using only the effect concentration
of the drug will not reproduce the data exactly.
Equation 5-2 was applied to the data of the induction phase and the result is shown in
Figure 5-19. The model has a reasonable performance when modelling the induction phase.
This result shows that the propofol effect concentration is sufficient to describe the
behaviour of  SAP during the induction phase. The high  SAP values (peaks) at
approximately 810 seconds and 1025 seconds were caused by tracheal intubation.
Figure 5-18:  SAP from patient Pat1 (*) and the result of the Hill equation model (solid line),
considering the data of Group1.
Figure 5-19:  SAP from patient Pat1 (solid line) and  SAP from the Hill equation model (dashed line),
considering the induction phase.
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5.3.1.2 Heart Rate
The optimized parameters of Equation 5-1, when considering  HR, where established by
the NCD blockset as:
Emax   40.91


1.84
Cp50  2990.8
Therefore the  HR Hill equation model is:
 HRmodel


40.91 Ce
1.84
Ce1.84  2990.81.84
5-3
where Ce is the propofol effect concentration.
Figure 5-20:  SAP from patient Pat1 (*) and the result of the Hill equation model (solid line),
considering the data of Group1.
Figure 5-20 shows the model results and the  HR of patient Pat1, considering the data set
Group1. The mean absolute error of the model for this set of data was of 3.66 bpm. The
reasonable model approximation and low error, show that the Hill equation is suitable to
model the effect of propofol on the  HR, when remifentanil is kept at a constant level.
The Hill equation model of Equation 5-3 was applied to the induction phase data, and the
result is presented in Figure 5-21. The model of  HR has an acceptable performance,
representing the  HR trend during the induction phase.
Propofol has a depressive effect on both  HR and  SAP, and this is reflected when using
the Hill equation models. However, it is necessary to note that the pharmacokinetic
parameters and the ke0 value used to model the plasma and effect concentrations of
propofol are mean population values. Therefore, it is expected that small changes may
occur between the modelled concentrations and the real concentrations that lead to the
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observed effect ( SAP or  HR). The plasma propofol concentration was not measured,
therefore, the model results are the best available approximation.
Figure 5-21:  HR from patient Pat1 (solid line) and  HR from the Hill equation model (dashed line),
considering the induction phase.
The peak in  HR present in the patient data (Figure 5-21) was diagnosed by the
anaesthetist as being related to intubation. The haemodynamic response to intubation is
more predominant in the blood pressure than in the heart rate, this is discussed in detail in
the following subsection.
5.3.2 Remifentanil and the Haemodynamic Response to Intubation
Remifentanil interacts with propofol in the presence of surgical stimulus. However, in the
induction phase the only stimulus was tracheal intubation. This is a very strong stimulus
which is associated with haemodynamic changes. Opioid drugs are administered at the time
of induction of anaesthesia in an attempt to attenuate the cardiovascular response to
intubation.
Guignard et al. (2000) reported that remifentanil attenuated or abolished increases in MAP
and HR after intubation in a comparable dose-dependent fashion. Thompson et al. (1998)
also assessed the effect of remifentanil on the  SAP and  HR after intubation. They
reported that intubation had no significant effect on HR in the remifentanil groups and SAP
increased significantly in all groups, but in the remifentanil groups this increase was
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quantitatively less than with other opioids, and did not exceed pre-induction values.
The influence of remifentanil in  SAP and  HR could be described as a function of the
effect concentration at the time of intubation. Considering that the remifentanil effect is
dose/concentration dependent. In order to obtain the relation between remifentanil effect
concentration and the effect in

SAP and

HR, the data from two researches was used
(McAtamney et al., 1998; O’Hare et al., 1999). These researches reported the effects of
remifentanil bolus doses on the haemodynamic responses to tracheal intubation.
Figures 5-22 and 5-23 show the percentage of change in mean SAP and HR respectively,
compared with the baseline values for the data in McAtamney et al. (1998). Three different
remifentanil bolus doses were used: 0.25, 0.5 and 1  g/kg administered at induction over a
period of 30 seconds. Tracheal intubation occurred 1 minute after induction. A group of 80
patients were assigned by random allocation to one of four treatment groups, receiving:
0.25, 0.5 or 1.0

g/kg of remifentanil or placebo (10 ml 0.9% saline). Analysing the figures,
it is clear that the major effect is observed 1 minute after intubation (i.e. 2 minutes after
induction). At minute 4, the SAP and HR values seem to go back to normal values.
Figure 5-22: Percentage of change from baseline in mean SAP, after induction of anaesthesia. Data from
McAtamney et al. (1998). Intubation was performed 1 minute after induction.
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Figure 5-23: Percentage of change from baseline in mean HR, after induction of anaesthesia. Data from
McAtamney et al. (1998). Intubation was performed 1 minute after induction.
Figure 5-24: Percentage of change from baseline in mean SAP, after induction of anaesthesia. Data from
O’Hare et al. (1999). Intubation was performed 1 minute after induction.
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Figure 5-25: Percentage of change from baseline in mean HR, after induction of anaesthesia. Data from
O’Hare et al. (1999). Intubation was performed 1 minute after induction.
Figures 5-24 and 5-25 show the percentage of change in mean SAP and HR respectively,
compared with baseline values for the data in O’Hare et al. (1999). The same profile as in
McAtamney et al. (1998) was used by O’Hare et al. (1999). However, the remifentanil
bolus doses used were 0.5, 1 and 1.25 ﬀ g/kg. The same number of patients was analysed
(i.e. 80 patients) considering four different groups, the three different doses of remifentanil
and a saline group. In this study, they concluded that the remifentanil dose of 0.5 ﬀ g/kg was
ineffective in controlling the increase in HR and arterial pressure after intubation but the 1
and 1.25 ﬀ g/kg doses were effective in controlling the response.
Remifentanil seems to have a possible linear dose/effect relationship when considering the
SAP signal 2 minutes after induction (1 minute after intubation). The reduction on the SAP
increase to intubation is notorious. In the saline group there is a change of 25-30% of
baseline, while in the remifentanil groups there is a smaller increase. The amplitude of the
SAP change decreases as the remifentanil dose increases. In the remifentanil group of 1.25
ﬀ g/kg the increase in SAP is minor, in fact the SAP values remain below the baseline.
However, there does not seem to be a linear relation between dose/effect when considering
HR. In Figure 5-25, there is a reduction in the HR response to intubation when remifentanil
is used compared with the saline group, but this reduction is not linear. In order to establish
a clear relationship between remifentanil and haemodynamic effect, the remifentanil effect
concentrations were calculated using the pharmacokinetic compartmental model and effect
compartment model described in Chapter 4. Tables 5-1 and 5-2 show the remifentanil
effect concentration for all the time samples and data of McAtamney et al. (1998) and a
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O’Hare et al. (1999), respectively.
Table 5-1: Remifentanil effect concentration (ng/ml) for the data in McAtamney et al. (1998). In the
following order: at baseline, pos-induction, pre-intubation, 1 to 5 minutes after intubation.
Group baseline pos-ind. pre-int. 1 min 2 min 3 min 4 min 5 min
0.25 ﬁ g/kg 0 0.3416 0.9739 1.1062 0.8301 0.5698 0.3949 0.2893
0.5 ﬁ g/kg 0 0.6833 1.9478 2.2123 1.6603 1.1396 0.7897 0.5785
1 ﬁ g/kg 0 1.3665 3.8955 4.4247 3.3206 2.2792 1.5794 1.157
Table 5-2: Remifentanil effect concentration (ng/ml) for the data in O’Hare et al. (1999). In the following
order: at baseline, pos-induction, pre-intubation, 1 to 5 minutes after intubation.
Group baseline pos-ind. pre-int. 1 min 2 min 3 min 4 min 5 min
0.5 ﬁ g/kg 0 0.6833 1.9478 2.2123 1.6603 1.1396 0.7897 0.5785
1 ﬁ g/kg 0 1.3665 3.8955 4.4247 3.3206 2.2792 1.5794 1.157
1.25 ﬁ g/kg 0 1.7081 4.8694 5.5308 4.1507 2.849 1.9743 1.4463
In this research, the effect concentration of remifentanil is in the range 0-10 ng/ml, in
accordance with the anaesthetist and the drug profile used (remifentanil/propofol).
Alexander et al. (1999b) reported that a remifentanil effect concentration of 12 ng/ml at 1
minute after intubation (bolus doses of 3 ﬁ g/kg at induction) block the haemodynamic
changes to intubation. This value of 12 ng/ml will be used as the limit of the remifentanil
effect concentrations, since it is known that there is a ceiling effect.
The O’Hare et al. (1999) data for the bolus doses of 0.5, 1 and 1.25 ﬁ g/kg and saline group
(i.e. zero effect concentration of remifentanil), and the information from Alexander et al.
(1999b) (i.e. at a concentration of 12 ng/ml there is 0% of effect) were used to described the
relationship between effect concentration and percentage of change in SAP and HR from
intubation time to 1 minute after intubation. A 1st and 2nd order polynomials were fitted to
the data using the least-squares method.
Figures 5-26 and 5-27 show the percentage change in SAP and HR , respectively, versus
the remifentanil effect concentration at 1 minute after intubation. The 2nd order polynomial
approximation (solid line) has a better fit to the data from both variables. It seems to
capture the ceiling effect in remifentanil and presents a smaller error. The relationship for
HR is not so clear as for SAP, and the 1st and 2nd order polynomials have poorer
approximations. Nevertheless, considering the patient variability and smaller change in HR
values, the 2nd order polynomial was considered to be reasonable.
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Figure 5-26: Percentage of change in SAP and the remifentanil effect concentration at 1 minute after
intubation: 1st order polynomial (dashed line); 2ndorder polynomial (solid line); (*) data from O’Hare et
al. (1999) and Alexander et al. (1999b).
Figure 5-27: Percentage of change in HR and the remifentanil effect concentration at 1 minute after
intubation: 1st order polynomial (dashed line); 2ndorder polynomial (solid line); (*) data from O’Hare et
al. (1999) and Alexander et al. (1999b).
Comparing with the 1st order polynomials, the 2nd other polynomials gave smaller error and
a better fitness to the overall data. The expressions for these functions are as follows:
ﬂ SAP
% Change (SAP) ﬃ 0.1346Ce2  3.6388Ce  24.3267 5-4
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! HR
% Change (HR)" 0.029Ce2 # 1.0787Ce $ 8.458 5-5
where Ce is the remifentanil effect concentration. The above functions represent the effect
of remifentanil on the haemodynamic changes at 1 minute after intubation. The influence of
intubation is reflected during approximately 3 minutes, after which the haemodynamic
parameters return to the normal values.
5.4 Maintenance-Phase Model
The maintenance phase starts at 1500 seconds, after which the patient is stable in the
operating room and the surgical procedure is about to start.
The interaction between propofol and remifentanil is of crucial importance during the
maintenance phase, due to the continuous presence of stimulus and the properties of the
two drugs. It is known that remifentanil potentiates the effects of propofol, therefore,
reducing the required propofol effect concentration. The cardiovascular parameters % HR
and
%
SAP, and the wavelet extracted AEP features are the result of the drugs concentration,
the surgical stimulus and the patient’s individual parameters. Therefore, it is necessary to
use simultaneously the effect concentrations of both drugs to establish the effect on the
different parameters.
Figure 5-28 shows the block diagram of the proposed maintenance phase patient model.
The pharmacodynamic model for the maintenance phase, describing the effect of the drugs
in the body, is divided into two parts. First, Takagi-Sugeno-Kang (TSK) fuzzy models are
used to describe the relationship between the effect concentrations of both drugs (including
the drug interactions) and
%
HR,
%
SAP and the AEP features. Secondly, a stimulus model is
used to establish the stimulus perceived by the patient and its effect on the cardiovascular
parameters. The stimulus model is described in Section 5.5. In the following sections the
TSK fuzzy models will be explained in more details.
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Figure 5-28: Block diagram of the maintenance phase model. Prop_Cp and Remi_Cp are the plasma
concentrations of propofol and remifentanil, respectively, whereas Prop_Ce and Remi_Ce are the effect
concentrations.
The maintenance phase of anaesthesia has different characteristics than induction. The drug
profiles used are aimed to maintain a stable DOA level considering the surgical stimulus
present. Before automatic or TCI systems, a steady continuous infusion of anaesthetic was
administered during maintenance of anaesthesia, supplemented with bolus doses of the
analgesic when required. At the moment, the anaesthetist targets the propofol plasma
concentration according to his knowledge about the patient’s conditions and the surgical
procedure. However, when remifentanil is used the anaesthetist also has to establish the
adequate dose for a continuous infusion of analgesic. In addition, the interaction of the two
drugs will alter the required amount of each of them. As studied by different researchers,
the presence of different doses, therefore different concentrations, of remifentanil alters the
optimal propofol concentration to adequately maintain DOA (Peacock and Philip, 1999;
Peacock et al., 1998; Vuyk et al., 1997).
Figure 5-29 shows a data density diagram for the combination of effect concentrations of
propofol and remifentanil, during the surgical procedure of patient Pat1 (Figures 5-2 and
5-3). Analysing this graph, it is clear that the existent data is concentrated in certain areas,
and these do not cover the whole space. In fact, several combinations of the two drugs
effect concentrations are not used during the maintenance phase. For example, low
concentrations of remifentanil are only obtained in the end of the surgical procedure
(recovery), since there is only a minimal, if any, surgical stimulus. A medium to high
concentration of remifentanil is used to provide the analgesic component of anaesthesia,
considering the continuous stimulus present. At the same time, very high concentrations of
remifentanil would increase the effects of propofol leading to a probable Deep level of
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DOA, and undesired side effects.
Figure 5-29: Data density graph for the data of patient Pat1 (combination of propofol/remifentanil effect
concentrations).
The propofol effect concentration during the maintenance phase does not reach the same
high values used for induction (Figure 5-2), the maximum value does not reach the 4000
ng/ml. Low effect concentrations of propofol ( & 2000 ng/ml) are not combined with high
remifentanil concentrations, since a minimum amount of propofol is required throughout
the maintenance phase, so as to produce unconsciousness. In conclusion, the data gathered
during the maintenance phase are limited not only by the existence of a single patient, but
also by the specific anaesthetic requirements during this phase of the procedure.
The maintenance phase is a very important phase, if not the most important, of anaesthesia.
It is during this time that the surgical procedure takes place. The objective is, therefore, to
model the effect of the existent combinations of propofol and remifentanil effect
concentrations on the ' HR, ' SAP and the AEP features, i.e. on the patient’s cardiovascular
and CNS.
The Adaptive Network-Based Fuzzy Inference System (ANFIS) was used to construct TSK
models for
'
HR,
'
SAP and the AEP features (Figure 5-28). The TSK fuzzy system
comprises of the following rules:
If x1 is C1l and ... and xn is Cnl , then fl ( c0l ) c1l x1 ) . . . ) cnl xn 5-6
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where Cil are fuzzy sets, c jl are constants, l * 1, . . . ,m, i * 1, . . ,n and j * 0, . . . ,n. The
antecedent parts of the rules are the same as in the ordinary fuzzy IF-THEN rules, but the
consequent parts are linear functions of the input variables (see Appendix B).
Given an input x * + x1, . . . ,xn , T - U . / n, the output f 0 x 1 2 V 3 / of the TSK fuzzy
system is computed as the weighted average of the fl’s in Equation 5-6, i.e.:
f 0 x 1 4
5
l6 1
m f lw l
7
l 6 1
m
w l
5-7
where the weights wl are computed as:
wl 8 9 i : 1
n ;
C il < x i = 5-8
;
C il < x i = are the input membership functions of x i (Takagi and Sugeno, 1985). Therefore, the
output of each rule is a linear combination of input variables plus a constant term, and the
final output is the weighted average of each rule’s output.
The ANFIS designed by Jang (1993), constructs a TSK Fuzzy Inference System (FIS) using
a given input/output data set. See Figure 3-12 in Chapter 3 for the general ANFIS structure
diagram.
The membership function parameters are tuned using a hybrid learning rule, which
combines the gradient method and the least-squares estimator for fast identification of
parameters (Jang and Sun, 1995). This allows the fuzzy systems to learn from the data they
are modelling.
The ANFIS was built through the Fuzzy Toolbox available for MATLAB. The following
properties were used when running ANFIS:
> Subtractive clustering was used to generate the initial FIS structure;
> Gaussian input membership functions;
> Hybrid optimization method (i.e. back-propagation gradient-descent and least squares
method).
These properties were found to provide the best results for the models. Since, subtractive
clustering determines the initial FIS based on the training data set and the natural clusters in
it, this method is deemed to be the safest option when no information is available so as to
determine adequately the initial FIS, or the data is not equally distributed in the input space
(such as in this case, Figure 5-29).
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The TSK models use as input the effect concentrations of remifentanil and propofol and as
output ? SAP, or ? HR, or one of the AEP features. The available data were divided into
training and checking data sets, 2/3 and 1/3 of the data respectively.
The detailed TSK models for the cardiovascular parameters and the AEP features will be
presented in the next sections.
5.4.1 Cardiovascular Parameters
The cardiovascular parameters ? HR and ? SAP were modelled separately, using the same
ANFIS structure. The available data from patient Pat1 were divided into training and
checking data sets. The training data set should represent the features of the data that the
trained TSK system is intended to model. Therefore, the checking data set consists of four
different pieces of the data, making up 1/3 of the total number of samples, the remaining
samples are used as the training data set. This choice of checking and training data sets,
was necessary to assure that both sets were balanced and representative of the data, but
distinct.
5.4.1.1 Systolic Arterial Pressure
Figure 5-30 shows the input membership functions for the effect concentrations of propofol
and remifentanil of the trained TSK model for ? SAP.
a) b)
Figure 5-30: Input membership functions describing the propofol effect concentration ( a) ) and the
remifentanil effect concentration ( b) ), for the ? SAP TSK fuzzy model.
The input membership functions parameters were tuned by ANFIS after determining the
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initial FIS using subtractive clustering. Table 5-3 shows the rule-base of the @ SAP TSK
model.
Table 5-3: Rule-base table for the fuzzy TSK model of @ SAP. RCe is the remifentanil effect
concentration, PCe is the propofol effect concentration. fi is the i output membership function,
i A 1, . . . , 5.
PCe RCe
mf1 mf2 mf3 mf4
mf1 f1
mf2 f2
mf3 f3
mf4 f4
mf5 f5
The output membership functions f1, . . . , f5 are static linear functions of the inputs (i.e.
propofol and remifentanil effect concentrations). The tuned output membership functions
are:
f1 B 0.0223PCe C 2.0627RCe D 149.7138
f2 B 0.4169PCe
D
159.467RCe
D
566.9308
f3 B PCe D 78.3RCe D 1418 5-9
f4 B
D
0.2486PCe
D
74.2046RCe C 832.3579
f5 B
D
0.0366PCe D 138.4659RCe C 99.3317
The output surface of the E SAP TSK fuzzy model is presented in Figure 5-31. The input
space was restricted to the maintenance phase values. Analysing the figure, one can notice
that in the areas where there are not data (recall Figure 5-29), the TSK model surface
presents distorted peaks or valleys. For example, around a remifentanil effect concentration
of 8 ng/ml with a corresponding low effect concentration of propofol, the TSK model gives
positives values of E SAP (i.e. SAP is above baseline), which was not present in the data
from patient Pat1. It is not expected that SAP would raise above baseline during the
surgical procedure under general anaesthesia with this drug profile. The peak in the output
surface is due to the non existence of data in that area of the input space. ANFIS cannot
model the response to unseen data, therefore, the TSK model is only valid in the accepted
effect concentration ranges for the maintenance phase. If for any abnormal reason the effect
concentrations of the two drugs would be outside the typical maintenance phase ranges,
then an alarm is activated to advise and warn the anaesthetist of the invalid (i.e. not
accurate) model responses.
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Figure 5-31: Output surface for F SAP TSK fuzzy model, considering the maintenance phase.
Figure 5-32: Results of the F SAP TSK fuzzy model on the training and checking data set (strong solid
line) and F SAP from patient Pat1 (solid line), considering the maintenance phase.
The results of the F SAP TSK model on the training and checking data sets are presented in
Figure 5-32. The mean absolute errors on the training and checking data sets were 2.26 and
6.53 mmHg, respectively. As expected, the model has a reasonable performance on the
training data set with a low error. The results on the checking data set reflect the
F
SAP
trend and appear to smooth out the disturbances due to stimulus.
Figure 5-33 shows the results of the
F
SAP TSK model on the whole data of patient Pat1
(i.e. training and checking data sets). The TSK model reflects the F SAP trend in response
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to the effect concentrations. The smooth response reflects the smooth changes in the
concentrations. Overall, the model presents an acceptable performance.
Figure 5-33: Results of the G SAP TSK fuzzy model (dashed line) and G SAP from patient Pat1 (solid
line), considering the maintenance phase.
5.4.1.2 Heart Rate
The G HR TSK model was also trained using 2/3 of the data. The remaining 1/3 was used as
the checking data set, which represented four different pieces of data. Figure 5-34 shows
the model input membership functions for the propofol and remifentanil effect
concentrations.
a) b)
Figure 5-34: Input membership functions describing the propofol effect concentration ( a) ) and the
remifentanil effect concentration ( b) ), for the G HR TSK fuzzy model.
The G HR TSK model rule-base is presented in Table 5-4. The output membership functions
are the following:
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f1
H I
0.1PCe J 433.6RCe
I
2231
f2 H 0.014PCe J 0.1826RCe
I
83.1286
f3
H
4.4PCe
I
436.7RCe J 1327.4 5-10
f4 H
I
0.0502PCe J 58.5949RCe
I
72.8725
f5
H I
1.5PCe
I
1645.8RCe J 7312.6
Table 5-4: Rule-base table for the fuzzy TSK model of K HR. RCe is the remifentanil effect
concentration, PCe is the propofol effect concentration. fi is the i output membership function,
i
H
1, . . . , 5.
PCe RCe
mf1 mf2 mf3 mf4 mf5
mf1 f1
mf2 f2
mf3 f3
mf4 f4
mf5 f5
Figure 5-35 shows the output surface of the
K
HR TSK model, considering the maintenance
phase. As in K SAP, the TSK model surface presents distortions in the areas where there are
no data.
Figure 5-35: Output surface for K HR TSK fuzzy model, considering the maintenance phase.
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Figure 5-36: Results of the L HR TSK fuzzy model on the training and checking data set (strong solid
line) and L HR from patient Pat1 (solid line), considering the maintenance phase.
Figure 5-36 shows the results of the L HR TSK model on the training and checking data
sets. Note that the peak in the
L
HR at approximately 9200 seconds (Figure 5-4) was
removed from the training data set. According to the anaesthetist, this outlier in the data
was caused by an external disturbance, and would damage the modelling procedure. The
mean absolute errors on the training and checking data set were of 1.12 and 4.54 bpm
respectively.
Figure 5-37: Results of the L HR TSK fuzzy model (dashed line) and L HR from patient Pat1 (solid line),
considering the maintenance phase.
The
L
HR model results on the whole data of patient Pat1 (training plus checking data sets)
are presented in Figure 5-37. The model reflects the trend in L HR and has a reasonable
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overall performance. Note that the models reflect the changes in effect concentrations and
interaction between the two drugs, therefore, the changes in M HR and M SAP due to outside
disturbances (including surgical stimulus) are not reflected in the results. For example the
deep valley in M HR at about 4200 seconds is not the result of the drugs, since there is no
drastic change in the effect concentrations.
5.4.1.3 Comparison with a Linear Model
A linear model was developed using the Nonlinear Control Design (NCD) MATLAB
Toolbox (mentioned in Section 5.3.1) and genetic algorithms optimization to describe
M
SAP and
M
HR. These models were obtained using selected pieces of the data where the
concentration of one of the drugs was constant and the other varied, and vice versa.
The data in Group1 (Section 5.3.1, Figure 5-17) were used to consider the effect of the
changes in propofol concentration. The data in the time period from 5998 to 8905 seconds
(termed Group2) were used to analyse the influence of remifentanil. During this period the
propofol concentration was constant, therefore, the effect of remifentanil on the
cardiovascular parameters can be analysed (Figures 5-2 and 5-3).
Considering M SAP, the following equations were obtained with the NCD blockset:
N Influence of propofol (Group1):
M
SAPpropofol O 11.2254 P 0.0153PCe 5-11
N Influence of remifentanil (Group2):
M
SAPremifen tan il O P 26. 2855 P 1. 7622RCe 5-12
where PCe and RCe are the propofol and remifentanil effect concentrations, respectively.
Figure 5-38 shows the results of the linear model for M SAPpropofol (Equation 5-11) on the
data of Group1. The mean absolute error is of 3.93 mmHg, reflecting the reasonable
approximation of the model to the data in this group.
Figure 5-39 shows the results of the linear model for
M
SAPremifen tan il (Equation 5-12) on the
data of Group2. The mean absolute error is 9.52 mmHg, reflecting the poor results. The
remifentanil effect concentration does not seem to reflect the
M
SAP changes, this is not
surprising since remifentanil is used for clinical stability, therefore very small changes in
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Q SAP are expected. According to the anaesthetist, remifentanil blocks the response (i.e. the
effect), whereas propofol reflects the changes in Q SAP and Q HR.
Figure 5-38:
Q
SAP from patient Pat1 (*) and the result of the linear model from Equation 5-11 (solid
line), considering the data of Group1.
Figure 5-39:
Q
SAP from patient Pat1 (*) and the result of the linear model from Equation 5-12 (solid
line), considering the data of Group2.
Considering Q HR the following equations were obtained with the NCD blockset:
R Influence of propofol (Group1):
Q
HRpropofol S T 1.8727 T 0.0061PCe 5-13
R Influence of remifentanil (Group2):
Q
HRremifen tan il S T 23.3519 U 2. 1674RCe 5-14
where PCe and RCe are the propofol and remifentanil effect concentrations, respectively.
Figure 5-40 shows the results of the linear model for Q HRpropofol (Equation 5-13) on the
data of Group1. The mean absolute error is of 3.66 bpm, reflecting the reasonable
approximation of the model to the data in this group.
Figure 5-41 shows the results of the linear model for Q HRremifen tan il (Equation 5-14) on the
data of Group2. The mean absolute error is 6.47 bpm, reflecting the poor results. The
Q
HRremifen tan il model results are fairly flat, with very small changes. From Figures 5-39 and
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5-41 it appears that the two effects are not linked to the changes in the effect concentrations
of remifentanil.
Figure 5-40: V HR from patient Pat1 (*) and the result of the linear model from Equation 5-13 (solid line),
considering the data of Group1.
Figure 5-41: V HR from patient Pat1 (*) and the result of the linear model from Equation 5-14 (solid line),
considering the data of Group2.
The effects of the two drugs have to be accounted for, when modelling the cardiovascular
parameters. Remifentanil alone seems to have little influence on
V
HR and
V
SAP, however
remifentanil has an interaction with propofol. A linear combination of these models
(Equations 5-11 to 5-14) was obtained using a genetic algorithm, which optimized the
contribution of the two drugs to the values of the cardiovascular parameters. The results of
the optimization were as follows:
V
SAP linear W 0.7036V SAPremifen tan il X 0. 3945 V SAPpropofol 5-15
V
HR linear
W
0.0575
V
HRremifen tan il
X
0. 8453
V
HRpropofol 5-16
The results of these optimized linear models are presented in Figures 5-42 and 5-43,
considering
V
SAP and
V
HR respectively. The results of the linear models are compared
with the results of the TSK fuzzy model (described in the previous subsections), and plotted
versus the data of patient Pat1. The objective is to analyse the performance of the two
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models with respect to the maintenance phase data.
Figure 5-42: Y SAP from patient Pat1 (solid line) and the results of the TSK fuzzy model (dashed line)
and the results of the linear model (dash-dot line), considering the maintenance phase.
Figure 5-43: Y HR from patient Pat1 (solid line) and the results of the TSK fuzzy model (dashed line) and
the results of the linear model (dash-dot line), considering the maintenance phase.
Analysing Figures 5-42 and 5-43, it is clear that the two drugs interact. The linear model
does not perform well, nevertheless, it reflects the relation between the effect
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concentrations of the drugs and the cardiovascular parameters, assuming that there is no
interaction between them. The TSK model seems to capture the synergism between
propofol and remifentanil. This is more evident, when considering the time period of
7000-8000 seconds. Indeed, the decrease in Z SAP and Z HR is not due to an increase in
propofol concentration. In fact, the propofol effect concentration is almost constant during
this time. The depression in the cardiovascular parameters is associated with the increase in
remifentanil concentration which potentiates the effect of propofol. If propofol would be
used alone during this time, there would be a clear relation between effect concentration
and effect. Therefore, an increase in the remifentanil effect concentration increases the
depressive effect of propofol on the cardiovascular parameters.
In conclusion, ANFIS was able to optimize the parameters of the TSK models, leading to
an adequate description of the effects and interaction of the two drugs. It is important that
the model reflects the synergistic interaction between propofol and remifentanil, to be an
adequate representation of the body’s behaviour.
5.4.2 Wavelet Extracted AEP Features
The wavelet extracted AEP features were modelled using the same ANFIS structure (i.e.
same properties) as the cardiovascular parameters. Ten TSK models were obtained, one for
each of the AEP features, using the propofol and remifentanil effect concentrations as
inputs. The training and checking data sets are 2/3 and 1/3 of the whole data, respectively.
Considering the characteristics of the AEP features (Figures 5-5 to 5-14), the checking data
set is represented by one sample in every three. The approach used with the cardiovascular
parameters, i.e. the checking data set represented by four different pieces of data, was not
suitable for these type of data. The AEP features are a set of spikes and they do not reflect
trends. The nature the AEP features signal is very different from the cardiovascular
parameters, as reflected in the AEP features graphs (Figures 5-5 to 5-14) and Figure 5-4.
The AEP features D1, D3, D5 and D51 TSK models will be presented in the next sections.
These features were selected to show the models behaviour and details, considering
different frequency features. The TSK models for the other six features, D2, D31, D32, D33,
D4 and D52, were obtained in the same way and are presented in Appendix D.
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5.4.2.1 AEP Feature D1
Figure 5-44 shows the input membership functions for the effect concentrations of propofol
and remifentanil of the trained D1 TSK model. The model rule-base in presented in Table
5-5.
a) b)
Figure 5-44: Input membership functions describing the propofol effect concentration ( a) ) and the
remifentanil effect concentration ( b) ), for the AEP feature D1 TSK fuzzy model.
Table 5-5: Rule-base table for the fuzzy TSK model of the AEP feature D1. RCe is the remifentanil
effect concentration, PCe is the propofol effect concentration. fi is the i output membership function,
i[ 1, . . . , 3.
PCe RCe
mf1 mf2 mf3
mf1 f1
mf2 f2
mf3 f3
The output membership functions are the following:
f1 \ 0.0007PCe ] 0.0182RCe ^ 0.4700
f2
\
]
0.0001PCe ] 0.0294RCe
^
0.4792 5-17
f3 \ 0.0001PCe ] 0.0504RCe ] 0.0834
The D1 TSK model output surface is presented in Figure 5-45. The surface presents a sharp
decrease into negative values in the area of high remifentanil effect concentrations versus
low propofol effect concentrations. As explained in the previous sections with the
cardiovascular parameters, this is due to the lack of data in that area. Note that D1
decreases as the propofol and the remifentanil effect concentrations increase, showing the
depression of the CNS at deeper levels of DOA (i.e. higher concentration of propofol and
126
_________________________________________________________________________________________________________________________________________________________
Chapter 5: A Hybrid Patient Model
the synergistic effect of remifentanil).
Figure 5-46 shows the results of the model on the training and checking data sets. The
mean absolute errors for the training and checking data sets were 0.055 and 0.043,
respectively. The lower error on the checking data sets shows the efficiency of the model
and demonstrates that there was no overtraining.
Figure 5-45: Output surface of the AEP feature D1 TSK fuzzy model.
Figure 5-46: Results of the AEP feature D1 TSK fuzzy model on the training and checking data sets
(dashed line) and the AEP feature D1 from patient Pat1 (solid line), considering the maintenance phase.
The TSK model does not reflect the highest spikes in the data, there is an increase in the D1
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value as a result of the concentrations. However, an external disturbance (probably surgical
stimulus) is affecting the values of D1.
5.4.2.2 AEP Feature D3
Figure 5-47 shows the input membership functions for the propofol and remifentanil effect
concentrations of the trained D3 TSK model. The rule-base of the model is presented in
Table 5-6.
a) b)
Figure 5-47: Input membership functions describing the propofol effect concentration ( a) ) and the
remifentanil effect concentration ( b) ), for the AEP feature D3 TSK fuzzy model.
Table 5-6: Rule-base table for the fuzzy TSK model of the AEP feature D3. RCe is the remifentanil
effect concentration, PCe is the propofol effect concentration. fi is the i output membership function,
i
_ 1, . . . , 3.
PCe RCe
mf1 mf2 mf3
mf1 f1
mf2 f2
mf3 f3
The output membership functions are the following:
f1
` a
0.0021PCe
a
0.2615RCe b 6.5268
f2 `
a
0.0006PCe
a
0.2793RCe b 4.4771 5-18
f3
` a
0. 001PCe
a
0.3518RCe b 3.1850
Figure 5-48 shows the output surface of the D3 TSK model, considering the maintenance
phase. The shape of the surface is similar to the one from D1, representing a similar trend in
the data when the effect concentrations change.
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The model was applied to the training and checking data sets, the results are presented in
Figure 5-49. The mean absolute errors of the training and checking data sets were 0.52 and
0.41, respectively. Once more the checking error is smaller than the training error.
Figure 5-48: Output surface of the AEP feature D3 TSK fuzzy model.
Figure 5-49: Results of the AEP feature D3 TSK fuzzy model on the training and checking data sets
(dashed line) and the AEP feature D3 from patient Pat1 (solid line), considering the maintenance phase.
The D3 feature appears to have the same high spikes as feature D1. In fact, the overall data
is similar in trend but with different amplitude values. These are both low frequency
features.
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5.4.2.3 AEP Feature D5
Figure 5-50 shows the input membership functions for the propofol and remifentanil effect
concentrations of the trained D5 TSK model. Table 5-7 presents the rule-base of the model.
a) b)
Figure 5-50: Input membership functions describing the propofol effect concentration ( a) ) and the
remifentanil effect concentration ( b) ), for the AEP feature D5 TSK fuzzy model.
Table 5-7: Rule-base table for the fuzzy TSK model of the AEP feature D5. RCe is the remifentanil
effect concentration, PCe is the propofol effect concentration. fi is the i output membership function,
i
c 1, . . . , 4.
PCe RCe
mf1 mf2 mf3
mf1 f1
mf2 f2
mf3 f3
mf4 f4
The output membership functions are the following:
f1 d e 0.0315PCe f 20.2944RCe e 22.7108
f2
d
e
0.008PCe
f
1.3529RCe
f
28.4694
f3 d 0.0906PCe f 19. 1609RCe e 349.0115 5-19
f4
d
e
0.0179PCe
f
9.6614RCe
f
20. 5424
Figure 5-51 shows the output surface of the D5 TSK model. The surface presents a different
shape than the previous models (Figures 5-45 and 5-48), showing the different nature of the
AEP feature. There is a distortion in the surface around 3000 ng/ml propofol effect
concentration versus low remifentanil effect concentrations, this is, once more, due to the
lack of data in that area.
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The D5 TSK model was applied to the training and checking data sets. The results are
presented in Figure 5-52. The mean absolute errors on the training and checking data set
are 3.09 and 3.41, respectively. In contrast with the previous two features, the error on the
checking data set is slightly higher than on the training data set.
Figure 5-51: Output surface of the AEP feature D5 TSK fuzzy model.
Figure 5-52: Results of the AEP feature D5 TSK fuzzy model on the training and checking data sets
(dashed line) and the AEP feature D5 from patient Pat1 (solid line), considering the maintenance phase.
The high frequency D5 AEP feature is more oscillatory than the low frequency features.
Analysing Figure 5-52, one can see that the TSK model is capturing the fluctuation of the
signal. The high spikes in the data are less predominant than with the low frequency
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features, presenting a smaller amplitude change compared with the rest of the signal.
5.4.2.4 AEP Feature D51
Figure 5-53 shows the input membership functions for propofol and remifentanil effect
concentrations of the TSK model of the AEP feature D51. Table 5-8 presents the rule-base
of the model.
a) b)
Figure 5-53: Input membership functions describing the propofol effect concentration ( a) ) and the
remifentanil effect concentration ( b) ), for the AEP feature D51 TSK fuzzy model.
Table 5-8: Rule-base table for the fuzzy TSK model of the AEP feature D51. RCe is the remifentanil
effect concentration, PCe is the propofol effect concentration. fi is the i output membership function,
i g 1, . . . , 4.
PCe RCe
mf1 mf2 mf3
mf1 f1
mf2 f2
mf3 f3
mf4 f4
The output membership functions are the following:
f1
h i
0.0439PCe
i
10.7005RCe j 157.5113
f2 h
i
0.0418PCe
i
2.2590RCe j 182.4764
f3
h
0.1638PCe j 2. 1645RCe
i
360.4773 5-20
f4 h 0.0196PCe
i
17.4224RCe j 11.3201
In contrast with the low frequency features (D1 and D3), the features D5 and D51 are
modelled using more rules and membership functions, this may represent the higher
variability of these features. Figure 5-54 shows the output surface of the D51 TSK model.
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The results of the model on the training and checking data sets are presented in Figure 5-55.
The mean absolute errors were 6.5 and 4.6 on the training and checking data sets,
respectively.
Figure 5-54: Output surface of the AEP feature D51 TSK fuzzy model.
Figure 5-55: Results of the AEP feature D51 TSK fuzzy model on the training and checking data sets
(dashed line) and the AEP feature D51 from patient Pat1 (solid line), considering the maintenance phase.
The detailed feature D51 is clearly influenced by some factor, not related with the effect
concentrations. The very sharp peaks at approximately 3200 seconds and 4000 seconds
have very high amplitudes compared with the rest of the signal. The D51 values are
generally below 25, however this disturbances are of values greater than 100. As a result,
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the model is not able to cope with these very high values.
In conclusion, the TSK models obtained from the wavelet extracted AEP features describe
the relationship between the effect concentrations and the AEP features. The models have
different characteristics according to the high and low frequency features. The AEP features
are affected by other factors besides the effect concentrations. In general, the sharp peaks in
the AEP features are the responses to surgical stimulus, this is discussed in detail in the
next section.
5.5 Stimulus Model
Surgical stimulus increases the value of SAP and HR. Tassorelli et al. (1995) reported on
the haemodynamic responses to stimulation, using a cold-pressor test. Increases in both
blood pressure and HR were observed throughout the test. Schwender et al. (1994) reports
changes in HR, SAP and DAP after skin incision as well as sternotomy, with different
anaesthetised groups. In addition, Pinerua-Shuhaibar et al. (1999) demonstrated the
cardiovascular modulation of pain perception in humans.
The final value of the cardiovascular parameters is the result of the effect of the two drugs
and of the surgical stimulus present. Propofol provides unconsciousness, while remifentanil
provides pain relief. Remifentanil action can be viewed as a reduction on the patient’s
perception of surgical stimulus. In fact, remifentanil effect concentration determines the
quality of analgesia and therefore the level of stimulus perceived by the patient. In the
previous section, the interaction of propofol and remifentanil was modelled, considering the
effect on k SAP, k HR and the AEP features. In this section, the objective is to model the
surgical stimulus effect on the cardiovascular parameters, considering the analgesic
component of anaesthesia (i.e. the remifentanil effect concentration). Figure 5-56 presents a
diagram illustrating the overall stimulus model scheme. Note that only the effect of
stimulus during the maintenance phase is modelled. The stimulus effect present in the
induction phase (i.e. intubation) was analysed according to the remifentanil action in
Section 5.3.2.
In Figure 5-56, the Fuzzy Model 1 describes the analgesic component of remifentanil in
reducing the level of stimulus perceived by the patient (i.e. the perceived stimulus). Fuzzy
Model 2 comprises two fuzzy models describing the effect of the perceived stimulus on
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SAP and HR, respectively.
The surgical stimulus also affects the AEP (Thornton et al., 1988). However, modulation of
such effect is an unexplored subject. The effect of stimulation on the wavelet extracted
AEP features will be discussed in Section 5.5.4. First, the perceived stimulus model will be
presented (Fuzzy Model 1 in Figure 5-56). Secondly the fuzzy model for the changes in
SAP will be presented, followed by the fuzzy model for HR, using the perceived stimulus.
The overall stimulus model comprises three Mamdani type fuzzy models based on the
anaesthetist knowledge and presented in IF-THEN rules. Details of the Mamdani type fuzzy
systems are presented in Appendix B.
Figure 5-56: Block diagram of the stimulus model.
5.5.1 Perceived Stimulus
The surgical stimulus intensity was described as Zero, Low, Medium and High, considering
the following events as labelled by the anaesthetist:
Intubation - high intensity stimulus
Incision - high intensity stimulus
Retractors - high intensity stimulus
Cutting - medium intensity stimulus
Diathermy - low to medium intensity stimulus
Suture - low intensity stimulus.
The remifentanil effect concentration was established as being between 0-10 ng/ml
throughout the procedure. However, in the maintenance phase this is more restrict. The
remifentanil effect concentration was labelled by the anaesthetist as Zero, Low, Medium,
High and VeryHigh.
The surgical stimulus and the remifentanil effect concentration are the inputs to the fuzzy
model. The output is the perceived stimulus, obtained using the rule-base in Table 5-9. The
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perceived stimulus is labelled Zero, VeryLow, Low, Medium and High.
Table 5-9: Perceived stimulus fuzzy rule base. Surgical stimulus l m 0,1 n , remifentanil effect
concentration o p 0,10 ng/mln and perceived stimulus q p 0,1n .
Surgical Remifentanil Effect Concentration (ng/ml)
Stimulus Zero Low Medium High VeryHigh
Zero Zero Zero Zero Zero Zero
Low Low VeryLow Zero Zero Zero
Medium Medium Low VeryLow Zero Zero
High High Medium Low VeryLow Zero
Figures 5-57 and 5-58 show the membership functions for the remifentanil effect
concentration and surgical stimulus, respectively. Figure 5-59 shows the perceived stimulus
membership functions. The output surface of the perceived stimulus fuzzy model is
presented in Figure 5-60. The centre of gravity defuzzifier was used as the defuzzification
method (details of this method are presented in Appendix B).
Figure 5-57: Remifentanil effect concentration (CRemi) membership functions, normalised between 0
and 1, scaling factor of 0.1 (0 to 10 ng/ml).
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Figure 5-58: Surgical stimulus membership functions.
Figure 5-59: Perceived stimulus membership functions.
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Figure 5-60: Perceived stimulus fuzzy model output surface. CRemi is the remifentanil effect
concentration and PStimulus is the perceived stimulus.
The membership function VeryLow for the perceived stimulus, is necessary so as to
describe the effect of a low surgical stimulus in the presence of a low remifentanil effect
concentration. In other words, a low remifentanil concentration does not suppress
completely a low stimulus.
The model output surface reflects the smooth decrease in the perceived stimulus as the
remifentanil concentration increases. The stimulus profile present in the procedure of
patient Pat1, was labelled by the anaesthetist and stored in a data file. This file will be used
in the simulation system, Note that during the maintenance phase of anaesthesia the
surgical stimulus is continuous, with different degrees of intensity.
The perceived stimulus model was applied to the data profile from patient Pat1 (i.e. the
remifentanil effect concentration in Figure 5-3). The result is presented in Figure 5-61. The
surgical stimulus profile (solid line) from the data file was transformed into the perceived
stimulus (dashed line) according to the remifentanil effect concentration. Note that
sometimes the perceived stimulus is slightly above the surgical stimulus when it is of very
low intensity. This is due to the defuzzification method used, since the centre of gravity
defuzzifier uses the centre of area of the triggered membership functions, hence providing
smoother outputs. However, at such low intensity the difference is not significant,
considering its effect on the cardiovascular parameters and that the stimulus is continuous
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throughout the maintenance phase (i.e. after incision until suture).
Figure 5-61: Surgical stimulus (solid line) and perceived stimulus (dashed line) in the maintenance phase,
using the surgical profile of patient Pat1.
5.5.2 Systolic Arterial Pressure
The effect of the perceived stimulus on the SAP values is modelled using the anaesthetist
knowledge described by IF-THEN rules. Figure 5-62 presents the block diagram for the
fuzzy model describing the effect of the perceived stimulus on SAP. The inputs to the
model are: PrevSAP, the value of SAP (i.e. baseline SAP plus r SAP) from the maintenance
phase model described in Section 5.4 (Figure 5-28); and PerStimulus, the perceived
stimulus level obtained from the perceived stimulus fuzzy model described in the previous
section (Fuzzy Model 1 in Figure 5-56).
After considering the effect of the perceived stimulus the value of SAP is described using
the rule base in Table 5-10, constructed with the cooperation of the anaesthetist. The
perceived stimulus was labelled as Zero, Low, Medium and High, according to the
membership functions of Figure 5-63.
139
_________________________________________________________________________________________________________________________________________________________
Chapter 5: A Hybrid Patient Model
Figure 5-62: Block diagram of the fuzzy model describing the effect of surgical stimulus on SAP.
Table 5-10: Rule base for the new value of SAP after the stimulus. PrevSAP is the value of SAP from the
maintenance phase model.
Perceived Previous value of SAP (PrevSAP)
Stimulus (PerStimulus) Low Medium High
Zero Low Medium High
Low Low Medium High
Medium Medium High VeryHigh
High High VeryHigh VeryHigh
Figure 5-63: Input membership functions describing the perceived stimulus (PerStimulus).
The values of the different SAP classes are described as follows:
s Situation A: baseline SAP t 130 mmHg
Low: SAP u 70% of baseline;
Medium: SAP between 70-80% of baseline;
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High: SAP v 80% of baseline.
w Situation B: baseline SAP between 120-130 mmHg
Low: SAP x 75% of baseline;
Medium: SAP between 75-85 % of baseline;
High: SAP v 85% of baseline.
w Situation C: baseline SAP x 120 mmHg
Low: SAP x 90 mmHg;
Medium: SAP between 90-120 mmHg;
High: SAP v 120 mmHg.
This class division was established by the anaesthetist and also used by Shieh (1994) and
Linkens et al. (1996b).
The membership functions for the previous value of SAP (PrevSAP) are presented in Figure
5-64, taking into account Situations A and B. These two situations can be modelled
together considering a normalized range between [0,1], and using different scaling factors.
In Situation A, the SAP range is 50-120% of baseline value, and for Situation B a range of
55-125% is considered.
Figure 5-64: Input membership functions describing the previous value of SAP (PrevSAP), considering
situations A and B. The range is normalised between [0,1].
After considering the perceived stimulus effect, the new value of SAP (i.e. output of the
fuzzy system) is labelled Low, Medium, High and VeryHigh according to the membership
functions in Figure 5-65, for Situations A and B. The SAP output surface is presented in
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Figure 5-66. The center of gravity defuzzifier was used as the defuzzification technique.
Figure 5-65: Output membership functions describing the new value of SAP, considering situations A and
B. The range is normalised between [0,1].
Figure 5-66: Output surface for SAP fuzzy model, situations A and B. PerStimulus is the perceived
stimulus and PrevSAP is the previous value of SAP.
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Figure 5-67: Input membership functions for the previous value of SAP (PrevSAP), considering situation
C.
Situation C is treated separately, since it is not expressed in terms of a percentage from the
baseline. Figure 5-67 shows the membership functions for the previous value of SAP, and
Figure 5-68 shows the membership functions of the output value of SAP, considering
Situation C. Note that, the input and output ranges are not normalized, i.e. they are
represented in mmHg. The output surface for SAP is presented in Figure 5-69, considering
Situation C. The output surface is different from the one obtained for Situations A and B
(Figure 5-66), but reflects the same change trend.
Figure 5-68: Output membership functions for the new value of SAP, considering situation C.
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Figure 5-69: Output surface for SAP fuzzy model, considering situation C. PerStimulus is the perceived
stimulus and PrevSAP is the previous value of SAP.
The shape and values of the membership functions were chosen so as to reproduce the
anaesthetist knowledge reflected in the classification of SAP.
The fuzzy model was applied to the results of the simulation using the maintenance phase
model for the profile of patient Pat1. Figure 5-70 shows the SAP value before and after the
stimulus model, solid and dashed line respectively. Note how the presence of the stimulus
is affecting the value of SAP, introducing changes and peaks to the smooth output of the
maintenance phase model.
Figure 5-71 shows the observed SAP from patient Pat1 (solid line) versus the value of SAP
after the stimulus model (dashed line). The results of the model including the stimulus
effect have a reasonable approximation to the observed value of SAP. This was expected,
since the stimulus level affects the cardiovascular responses. However, there is a small
delay between the model results and the observed SAP. This happens because in reality it
takes 2-5 minutes for the stimulus effect to be reflected in the SAP value; meaning that the
influence of the stimulus is not instantaneous. This time-delay has not been included in the
SAP model. Therefore, the stimulus model responds immediately to the stimulus, altering
the SAP value. The existing time-constant is different for SAP and HR, and to our
knowledge there are no studies defining its value. In addition, it was not considered
adequate to estimate the time-delay based only on the data of a single patient, knowing the
high variability between patients.
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Figure 5-70: SAP from patient model without stimulus (solid line) and SAP after the stimulus model
(dashed line). The profile of patient Pat1 was used for the simulation, considering the maintenance phase.
Figure 5-71: SAP from patient Pat1 (solid line) and SAP from patient model including the stimulus model
(dashed line), in the maintenance phase.
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5.5.3 Heart Rate
The effect of the perceived stimulus on the HR values is modelled using the anaesthetist
knowledge by describing the change in HR using fuzzy rules. Figure 5-72 shows the block
diagram describing the change in HR as a result of the perceived stimulus. PrevHR is the
HR value from the maintenance phase model (HR baseline plus y HR); PerStimulus is the
perceived stimulus value. The effect of the perceived stimulus on the HR is described as a
change in its value. This change in HR is labelled as Zero, Little and Large according to the
anaesthetist opinion. A little change represents a change of 5% of the previous value, and a
large change could be as big as 10%. Therefore, the value of HR after the stimulus model
will be increased by a certain percentage.
Figure 5-72: Block diagram of the fuzzy model describing the effect of surgical stimulus on HR.
The change in HR is modelled using the rule-base in Table 5-11, with the previous value of
HR (PrevHR) and the perceived stimulus (PerStimulus) as the inputs of the fuzzy model.
Table 5-11: Rule base for the change in HR after the stimulus. PrevHR is the value of HR from the
maintenance phase model.
Perceived Previous value of HR (PrevHR)
Stimulus (PerStimulus) Low Medium High
Zero Zero Zero Zero
Low Zero Zero Little
Medium Zero Little Large
High Little Little Large
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The perceived stimulus membership functions are the same as the ones used for SAP
(Figure 5-63), labelled Zero, Low, Medium and High. The HR class values were classified
by the anaesthetist as follows:
Low: HR z 70% of baseline;
Medium: HR between 70-90% of baseline;
High: HR { 90% of baseline.
The PrevHR membership functions according to this description, are presented in Figure
5-73. The HR has lower normal values when using remifentanil than with other opioids,
due to its depressive effect. This was taken into consideration when establishing the HR
ranges. Note that in Figure 5-73 the HR range represents 50-110% of baseline.
Figure 5-73: Input membership functions describing the previous value of HR (PrevHR).
Figure 5-74 shows the output membership functions for the change in HR. The change in
HR is presented as a percentage of the previous value (i.e. PrevHR). The output surface for
the change in HR fuzzy model is presented in Figure 5-75. The center of gravity defuzzifier
was used as the defuzzification method.
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Figure 5-74: Output membership functions for the change in HR (effect of stimulus). The range of 0-10
represents 0-10% change.
Figure 5-75: Output surface for the change in HR fuzzy model. PerStimulus is the perceived stimulus and
PrevHR is the previous value of HR from the maintenance phase model.
The described fuzzy model was applied to the results of the simulation using the
maintenance phase model for the profile of patient Pat1. Figure 5-76 shows the HR value
before the stimulus model (solid line) versus the HR after considering the change resulting
from the stimulus model (dashed line). The HR value was increased throughout due to the
stimulus effect. The peaks resulting from the stimulus are quantitatively less than the ones
on SAP, which demonstrates that HR is a more stable variable.
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Figure 5-76: HR from patient model without stimulus (solid line) and HR after the stimulus model
(dashed line). The profile of patient Pat1 was used for the simulation, considering the maintenance phase.
Figure 5-77: HR from patient Pat1 (solid line) and HR from patient model including the stimulus (dashed
line), in the maintenance phase.
Figure 5-77 shows the HR observed for patient Pat1 (solid line) versus the HR from the
patient model after the inclusion of the stimulus effect. The model approximation has
improved, considering the result before the stimulus model. This reflects the
appropriateness of a stimulus model. In addition, the HR model seems to be averaging-out
disturbances in the HR signal. When considering the time period of 4000 to 6000 seconds,
the model HR is reflecting the HR trend but smoothing the sharp “valley” in the data.
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Overall, the model has an adequate performance.
The time-delay for HR is different from the one for SAP. It appears that the HR reacts
faster than SAP to the stimulus. Due to the same reasons as for SAP, no time-constant was
included in the HR model. In contrast, the AEP respond faster to the stimulus effect, this is
demonstrated in the following section.
5.5.4 Auditory Evoked Potentials
The surgical stimulus affects the auditory evoked potentials (AEP) and, hence, the wavelet
extracted AEP features. However, the effect of different surgical stimuli (i.e. different
intensity) is not trivial to analyse. The anaesthetist has not enough knowledge to describe
this effect on the AEP. Figures 5-78 to 5-83 show several AEP features in contrast with the
existence of different surgical stimuli.
Figure 5-78: Wavelet extracted AEP feature D2 from the data of patient Pat1, considering the
maintenance phase and the different surgical stimulus.
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Figure 5-79: Wavelet extracted AEP feature D1 from the data of patient Pat1, considering the
maintenance phase.
Figure 5-80: Wavelet extracted AEP feature D3 from the data of patient Pat1, considering the
maintenance phase.
The low frequency AEP features D2, D1 and D3 present similar changes to the same
stimulus (Figures 5-78 to 5-80). The amplitude of the AEP features response to stimulus is
different according to the different features, nevertheless, these features (D2, D1 and D3)
seem to reflect the same trend. The surgical stimulus produces clear peaks, and the
amplitude of these peaks is related with the intensity of the stimulus. The response of D2
(Figure 5-78) to the use of retractors is notorious compared with the response to a low
stimulus such as a suture. When the surgical procedure is at the end and the patient starts to
swallow (i.e. awaking), the AEP feature rises to higher values. In fact, they have a similar
response to recovery and to stimulus. This leads to the conclusion that surgical stimulus
could lead to an arousal of the patient.
Figures 5-81 to 5-83 show some of the high frequency AEP features, D5, D51 and D4. The
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effect of surgical stimulus is different in the low and high frequency AEP features. In the
detailed feature D51 (Figure 5-82), is clear the effect of diathermy. In fact, the change
produced by diathermy obscures all the effects of other stimuli, considering the amplitude
of the change.
The AEP features D5 and D4 present a greater variability during the surgical procedure than
the low frequency features (Figures 5-81 and 5-83). The effect of the surgical stimulus is
not easy to detect. For example, the use of retractors at approximately 6500 seconds does
not have a great effect on the feature D5, and is not detected in features D51 and D4.
However, this stimulus has a clear effect on the low frequency features.
Figure 5-81: Wavelet extracted AEP feature D5 from the data of patient Pat1, considering the
maintenance phase and the different surgical stimulus.
Figure 5-82: Wavelet extracted AEP feature D51 from the data of patient Pat1, considering the
maintenance phase and the different surgical stimulus.
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Figure 5-83: Wavelet extracted AEP feature D4 from the data of patient Pat1, considering the
maintenance phase.
In conclusion, the AEP features react to stimulus with an increase in amplitude and this
appears to be an instant reaction, i.e. there is no time-delay as was observed with the
cardiovascular parameters.
The low frequency AEP features, D1, D2 and D3, show a clear effect of the surgical
stimulus. This could be used to quantify the stimulus effect if more data would be available,
since there are no previous studies on the subject, and the anaesthetist knowledge cannot be
used. In addition, the remifentanil analgesic action, when preventing the response to
surgical stimulus, is not clear when considering the CNS. It is not possible to compare these
results with experiments without the use of remifentanil, therefore, the relationship between
surgical stimulus cannot be reasonably modelled.
The high frequency AEP features, D4, D5 and D51, are not affected by surgical stimulus in
the same way as the low frequency features. The effect of several stimuli cannot be
identified clearly, and there is no trend between the response and the stimulus intensity.
A future study on the relationship between surgical stimulus, analgesia and the CNS, would
be challenging and promising when considering data from several patients under different
conditions. In this research, the effect of surgical stimulus on the AEP features will not be
considered further.
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5.6 Summary
The effects of the analgesic and anaesthetic drugs on the cardiovascular and central nervous
systems, were modelled using different techniques according to the two main phases of a
surgical procedure, i.e. induction and maintenance.
The induction phase of anaesthesia was modelled using the optimized Hill equation
models, and characterizing the influence of remifentanil on the haemodynamic responses to
intubation. In this phase, only the cardiovascular parameters | HR and | SAP were
modelled, since the AEP cannot be monitored adequately during induction.
The maintenance phase was modelled using TSK fuzzy models which were trained using
ANFIS. These models reflect the effect and interaction of the two drugs on
|
SAP,
|
HR and
the wavelet extracted AEP features. The synergistic interaction between propofol and
remifentanil has a major importance on the drugs effect, in the presence of surgical
stimulus. During the maintenance phase, the surgical stimulus can be considered
continuous, therefore, the responses of the patient are heavily influenced by the drugs
interaction.
The
|
SAP and
|
HR TSK models were compared with optimized linear models, which
model the effects of propofol and remifentanil independently. The results show that there is
a synergistic interaction between the two drugs, which is reflected in the results of the TSK
models.
The TSK models performed adequately with all the parameters (i.e.
|
SAP,
|
HR and the
AEP features) presenting small errors and reflecting the drugs effect. However, these
models are only valid in the specified drug ranges for the maintenance phase. The drug
infusion rates during maintenance of anaesthesia follow a specific profile, so as to maintain
a stable DOA in the presence of surgical stimulus.
The effect of surgical stimulus on the cardiovascular parameters was modelled via
Mamdani type fuzzy models, using the anaesthetist knowledge expressed with IF-THEN
rules. First, the stimulus perceived by the patient was modelled, in order to reflect the
analgesic action of remifentanil. Finally, the change on the value of SAP and HR was
modelled so as to reflect the effect of the perceived stimulus.
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The response of the AEP features to surgical stimulus was also studied. The AEP features
have different responses to the different stimuli, according to its nature and intensity. There
is a major difference between the behaviour of the low frequency versus the high frequency
AEP features. The effect of the stimulus on the AEP features was not modelled due to the
lack of information and data. In addition, it was found that there is a time-delay in the
cardiovascular responses to stimulus, while the AEP features respond immediately.
In conclusion, the patient model is constituted by an induction phase model plus a
maintenance phase model, describing the difference between these two phases of
anaesthesia. The models presented an adequate performance on the training and checking
data sets, and seem to reflect the effect of the drugs and surgical stimulus. This patient
model describes a typical patient’s behaviour during a surgical procedure.
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Fuzzy Control of Depth of Anaesthesia
6.1 Introduction
The infusion rate of the anaesthetic drug is titrated according to the patient’s requirements,
so as to maintain a certain level of depth of anaesthesia (DOA). The patient’s clinical signs
and/or brain signals are used by the anaesthetist to determine the adequate infusion rate. In
addition, the anaesthetist also establishes the required infusion rate of the analgesic drug,
based on the patient’s response to surgical stimulus.
A closed-loop control system of DOA will help the anaesthetist, adjusting simultaneously
the infusion rates of the anaesthetic and analgesic drugs. The majority of the researches in
the area are mainly concerned with the automatic control of the anaesthetic drug, whereas
the analgesic is controlled manually by the anaesthetist. However, in this research the
objective is a multivariable control structure for both drugs.
The patient model presented in Chapter 5, described adequately the effects and interactions
of the two drugs in the presence of surgical stimuli. This model will be used to construct a
control algorithm relating to the administration of both drugs. The study of the interactions
between propofol and remifentanil helps to determine the ideal combination of infusion
rates. This study will also represent a practical guide for the anaesthetist, which would help
him/her learn how to adjust the amount of drug infused and hence improve the patients
comfort.
In this chapter, a multivariable fuzzy controller will be developed to establish the required
infusion rates of propofol and remifentanil. First, the patient model will be tested using a
series of open-loop simulations with different infusion profiles. Second, the closed-loop
structure will be presented, showing the links between the patient model, the DOA
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classifier (i.e. the fuzzy relational classifier presented in Chapter 3) and the controller.
Third, a SISO (single-input-single-output) fuzzy PI controller of DOA is developed. This
controller adjusts the infusion rate of propofol according to the level of DOA with the
infusion rate of remifentanil kept constant. The results of the fuzzy PI controller are
compared with the results of a conventional PI controller. The parameters of both
controllers are optimized using a genetic algorithm (GA).
Finally, a multivariable fuzzy controller developed with the anaesthetist’s cooperation, is
presented. This controller establishes the infusion rates of propofol and remifentanil
simultaneously based on the level of DOA, the concentrations of the drugs and the surgical
stimuli. The performance of the controller is tested under different conditions.
6.2 Open-Loop Simulation Results
The patient model developed in Chapter 5 was tested in open-loop simulations with
different infusion profiles for propofol and remifentanil. The open-loop results with three
different infusion profiles are presented in the following sections.
The simulations were performed for 7200 seconds (120 minutes) with a sampling time of
30 seconds. The first 1500 seconds relate to the induction phase, followed by the
maintenance phase. It is worth noting that the recovery phase is not simulated.
The fuzzy relational classifier (FRC) for DOA developed in Chapter 3 is applied to the
wavelet extracted AEP features, as determined by the maintenance phase model. In the
induction phase, the FRC uses only the cardiovascular parameters   SAP and   HR for the
classification of DOA, since the AEP features are not modelled during this phase.
6.2.1 Infusion Profile 1
Figure 6-1 shows the infusion rate profiles for propofol and remifentanil used in the first
simulation, and denoted as Infusion Profile 1. The propofol infusion rate is very similar to
the profile of patient Pat1, while the remifentanil infusion rate follows a typical profile
during a surgical procedure (i.e. high at induction and constant during maintenance).
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Figure 6-1: Propofol and remifentanil infusion rate profiles (Infusion Profile 1).
Figure 6-2 shows the effect concentration of propofol as determined by the effect
compartment model using mean population parameters (see Chapter 4). As expected, the
effect concentration of propofol is similar to that of patient Pat1 (Figure 5-2).
The effect concentration of remifentanil for this infusion profile is presented in Figure 6-3.
The constant concentration level during the maintenance phase leads to a steady level of
analgesia.
Figure 6-2: Propofol effect concentration for the infusion rate profile in Figure 6-1.
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Figure 6-3: Remifentanil effect concentration for the infusion rate profile in Figure 6-1.
Figure 6-4: Systolic arterial pressure (SAP) and heart rate (HR) as determined by the patient model, using
the infusion profiles in Figure 6-1.
Figure 6-4 shows the HR and SAP as simulated by the patient model, using the Infusion
Profile 1. The perceived stimulus level, according to the stimulus model and the
remifentanil effect concentration, is presented in Figure 6-5.
The wavelet extracted AEP features as simulated by the patient model are used to classify
the DOA level by the FRC during the maintenance phase. The DOA level is shown in
Figure 6-6.
The model performs adequately, describing the effects of the stimulus level on SAP and
HR. The effect concentrations are within the ranges of the maintenance phase and this is
reflected in the model’s response.
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Figure 6-5: Surgical stimulus (solid line) and perceived stimulus (dashed line) for the remifentanil effect
concentration in Figure 6-3, during the maintenance phase.
Figure 6-6: Depth of anaesthesia (DOA) as classified by the Fuzzy Relational Classifier (FRC) using the
wavelet extracted AEP features (Infusion Profile 1).
The DOA level as determined by the FRC cannot be compared with the anaesthetist’s
classification, since this is a simulated infusion profile. However, the classification is not
unreasonable as it reflects the AEP features from the model.
6.2.2 Infusion Profile 2
Figure 6-7 shows the infusion rate profiles used in the second simulation, and will be
referred to as Infusion Profile 2. It is worth noting that the remifentanil infusion rate profile
is the same as in the previous simulation (Figure 6-1). The propofol infusion rate profile
includes more changes than the one used in the previous section. Therefore, the model
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response can be analysed according to the different propofol changes.
Figure 6-7: Propofol and remifentanil infusion rate profiles (Infusion Profile 2).
Figure 6-8: Propofol effect concentration for the infusion rate profile in Figure 6-7.
Figure 6-8 shows the effect concentration of propofol, reflecting the changes in infusion
rate. The remifentanil effect concentration is the same as in Figure 6-3. Therefore, the
perceived stimulus is the same as in Figure 6-5, since the same surgical stimulus profile is
used.
The cardiovascular parameters SAP and HR are presented in Figure 6-9. Analysing the
figure, one can see the first increase in SAP and HR in response to the decrease in the
propofol effect concentration, and the subsequent decrease in SAP due to the increase in
concentration. This is also noticeable after 6000 seconds, when the increase in the propofol
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concentration leads to a decrease in the cardiovascular parameters. Therefore, the patient
model reflects the propofol effect concentration trend, if one considers the constant
remifentanil effect concentration. It is also worth noting that the different simulations use
different baseline for SAP and HR, proving that the model is not dependent on the baseline
values since it uses  values.
The DOA level, as classified by the FRC using the modelled AEP features, is shown in
Figure 6-10.
Figure 6-9: Systolic arterial pressure (SAP) and heart rate (HR) as determined by the patient model, using
the infusion profiles in Figure 6-7.
Figure 6-10: Depth of anaesthesia (DOA) as classified by the Fuzzy Relational Classifier (FRC) using the
wavelet extracted AEP features (Infusion Profile 2).
162
_________________________________________________________________________________________________________________________________________________________
Chapter 6: Fuzzy Control of Depth of Anaesthesia
6.2.3 Infusion Profile 3
Figure 6-11 shows the infusion rate profiles of propofol and remifentanil for the third
simulation, which will be referred to as Infusion Profile 3. In contrast with the other
simulations, the remifentanil profile is not constant here. The propofol infusion rate is the
same as in the Infusion Profile 2 (Figure 6-7), with the respective effect concentration in
Figure 6-8.
Figure 6-11: Propofol and remifentanil infusion rate profiles (Infusion Profile 3).
Figure 6-12: Remifentanil effect concentration for the infusion rate profile in Figure 6-11.
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The remifentanil effect concentration for this infusion profile is presented in Figures 6-12.
The changes in the remifentanil infusion rate produce variations in the effect concentration.
The effect of such variations will be analysed by comparing the model results using
Infusion Profile 3 with the results using Infusion Profile 2.
Figure 6-13: Systolic arterial pressure (SAP) and heart rate (HR) as determined by the patient model,
using the infusion profiles in Figure 6-11.
Figure 6-13 shows the cardiovascular parameters SAP and HR as determined by the patient
model using Infusion Profile 3. The increase in SAP and HR at approximately 2000
seconds is due to the decrease in the propofol effect concentration. There is a gradual
change in the values of SAP representing the gradual decrease in propofol concentration
(see Figure 6-8). The change in HR is more moderate, this is expected since HR is less
sensitive to such changes. The remifentanil effect concentration shows a rapid trend
compared with propofol, due to the rapid onset and offset of the action of the analgesic.
These sharp variations in the remifentanil concentration result in abrupt changes in SAP.
For example, the sharp decrease in SAP at approximately 4400 seconds is due to the
increase in the remifentanil concentration, potentiating the effect of propofol at a medium
concentration. This is also noticeable at approximately 3400 seconds when the remifentanil
effect concentration reaches the lowest value, and there is an increase in SAP. As expected,
the effect of propofol is predominant and reflected in the gradual changes of SAP and HR
following the increases and decreases of the effect concentration (see the time between
5500 and 7000 seconds).
Figure 6-14 shows the perceived stimulus and the surgical stimulus, determined by the
stimulus model according to the effect concentration of remifentanil for Infusion Profile 3.
The perceived stimulus is similar to that obtained with the constant remifentanil profile (see
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Figure 6-5), since the remifentanil effect concentration is still within the Medium range of
the stimulus model (see Figure 5-57).
Figure 6-14: Surgical stimulus (solid line) and perceived stimulus (dashed line) for the remifentanil effect
concentration in Figure 6-12, during the maintenance phase.
Figure 6-15: Depth of anaesthesia (DOA) as classified by the Fuzzy Relational Classifier (FRC) using the
wavelet extracted AEP features (Infusion Profile 3).
The wavelet extracted AEP features as determined by the patient model, were used by the
FRC to classify the DOA level during the maintenance phase. The result is presented in
Figure 6-15. The DOA profile is the same as in the previous simulation (Figure 6-10) until
approximately 4100 seconds due to the effect of propofol. However, the DOA level using
Infusion Profile 3 returns to the OK level later than that of Infusion Profile 2. This is due to
the higher remifentanil concentration that potentiates the effect of propofol. The level of
DOA reaches the OK level at approximately 4900 seconds, when the remifentanil effect
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concentration stabilizes.
6.3 Closed-Loop Structure
The final objective of an advisor system in anaesthesia is to determine the infusion rate of
the anaesthetic and analgesic drugs, in order to achieve and maintain an adequate level of
DOA. Figure 6-16 shows the implementation diagram of the advisor system in the
operating theatre. The system (implemented on a PC) gathers information from the AEP
amplifier and the anaesthesia monitor (in this case the Datex-Engstrom AS/3) which
measures the cardiovascular parameters.
Figure 6-16: Implementation diagram of the advisor system in the operating theatre.
The AEP are processed by averaging and filtering, after which multiresolution wavelet
analysis is used to extract a set of features. This set of wavelet extracted AEP features and
the cardiovascular parameters  HR and  SAP are used by the fuzzy relational classifier
(FRC) to determine the DOA. The DOA level in addition to the information about the
surgical stimulus introduced to the system by the anaesthetist, are used to determine the
adequate infusion rate of the two drugs (i.e. propofol and remifentanil). In other words, a
multivariable controller would advise the anaesthetist about the required changes in the
infusion rate of both drugs. This information would be transmitted to the two infusion
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pumps (Graseby 3500), which administer the drugs to the patient.
An advisor system needs to be developed and tested in simulations before transfer to the
operating theatre. Therefore, an adequate patient model is paramount for such real-time
software development.
The closed-loop simulation system links the patient model, the FRC of DOA and the
control algorithms. Figure 6-17 shows the block diagram comprising of the different
components of the closed-loop system during the maintenance phase of anaesthesia. The
patient model is divided into pharmacokinetic and pharmacodynamic models. The
compartmental pharmacokinetic models, which use the mean population parameters,
determine the plasma concentration of both drugs independently. The pharmacodynamic
model comprises the effect compartments of the two drugs and a structure of fuzzy models.
This fuzzy structure models the wavelets extracted AEP features and the cardiovascular
parameters from the effect concentrations and the surgical stimulus, according to the drugs
interaction and the effects of the different stimuli intensity. These modelled parameters are
then used by the FRC to classify DOA. Finally, a control structure maintains an adequate
DOA level by adjusting the infusion rates of propofol and remifentanil, which are the inputs
to the patient model.
Figure 6-17: Block diagram of the closed-loop simulation system.
The following sections focuses on the development of the DOA controller. First, a SISO
fuzzy PI controller is developed using only the infusion rate of propofol, and by assuming
that the analgesic drug is manually controlled by the anaesthetist. Second, a multivariable
control structure is developed, which establishes the infusion rate of both drugs
simultaneously. It is worth noting that the control action concerns only the maintenance
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phase due to the differences between induction and maintenance as explained in Chapter 5.
6.4 SISO Fuzzy PI Controller
Feedback control has proved to be an effective and convenient clinical tool for optimizing
the routine delivery of anaesthetics (Westenskow, 1997). Control systems should reduce the
induction time, deliver a minimum amount of drug, and avoid costly delays from failing to
keep the patient in a desired state.
A fuzzy logic controller may be regarded as a means of emulating a skilled human operator.
It provides a means of converting a linguistic control strategy based on expert knowledge
into and automatic control strategy (Lee, 1990a, b). Appendix B presents the basic concepts
of fuzzy logic and fuzzy logic based control.
A fuzzy proportional-integral (PI) controller is designed to control the change in the
infusion rate of the anaesthetic drug propofol, in order to achieve and maintain a steady
level of DOA and to reduce the amount of drug infused. Figure 6-18 shows the closed-loop
system diagram with the implementation of the fuzzy PI controller.
Figure 6-18: Implementation diagram of the fuzzy PI controller of DOA.
The controller is activated only at the start of the maintenance phase. The propofol infusion
profile, during the induction phase, was set by the anaesthetist. In other words, the loop
remains open during induction but is closed during maintenance. The recovery phase is not
simulated here for during this phase no drugs are administered.
The analgesic drug remifentanil is administered at a fixed profile as set by the anaesthetist
according to a typical surgical procedure. Figure 6-19 shows the remifentanil infusion rate
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used in closed-loop simulations. The corresponding remifentanil effect concentration is
presented in Figure 6-20. The steady effect concentration of remifentanil during the
maintenance phase provides a constant level of analgesia.
Figure 6-19: Remifentanil infusion rate set for a typical surgical procedure.
Figure 6-20: Remifentanil effect concentration for the infusion profile in Figure 6-19.
In general, researchers are only concerned with the control of the anaesthetic drug,
developing different types of complex controllers (Asteroth et al., 1997; Backory, 1999;
Gentilini et al., 2001a; Linkens and Rehman, 1992). However, simple fuzzy logic
controllers have been proven to give also good control (Allen and Smith, 2001; Huang et
al., 1999; Mortier et al., 1998; Webb et al., 1996).
In this research, a fuzzy PI controller determines the infusion rate of propofol during the
maintenance phase based on a patient model which considers the drug’s interaction with
remifentanil. The structure of the fuzzy PI controller is presented in the next section.
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6.4.1 Fuzzy PI Controller Structure
The fuzzy PI controller uses the error (target DOA minus measured DOA) and the change
of error as inputs. The output of the controller is the change in propofol infusion rate.
Figure 6-21 shows the structure of a fuzzy PI controller: w is the target DOA level (i.e. the
OK level  3); e is the error;  u is the change in infusion rate; u is the infusion rate and y is
the DOA level (output of the FRC). G1 and G2 are the scaling factors for the error and the
change of error, respectively. As mentioned previously, five DOA levels are considered and
represented as: 5-Deep; 4-OK/Deep; 3-OK; 2-OK/Light and 1-Awake.
Figure 6-21: Structure of a fuzzy PI controller.
The fuzzy PI controller uses a set of 25 IF-THEN rules to control the change in infusion
rate, with five output membership functions. The controller’s rule-base is presented in
Table 6-1.
Table 6-1: Rule-base of the fuzzy PI controller for DOA. The inputs are the error and the change of error,
and the output is the change in propofol infusion rate.
Change of error
Error NB NS ZE PS PB
NB NB NB NB NS ZE
NS NB NS NS ZE PS
ZE NB NS ZE PS PB
PS NS ZE PS PS PB
PB ZE PS PB PB PB
The membership functions are labelled as: Negative Big (NB), Negative Small (NS), Zero
(ZE), Positive Small (PS) and Positive Big (PB). Figures 6-22 and 6-23 show the
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membership functions for the controller inputs, error and change of error, respectively. The
input variables are normalized between [-1, 1].
Figure 6-22: Input membership functions describing the error, in the fuzzy PI controller.
Figure 6-23: Input membership functions describing the change of error, in the fuzzy PI controller.
Figure 6-24 shows the output membership functions for the change in propofol infusion
rate, which is normalized between [-1, 1]. The maximum level for the change in the
infusion rate was set to 4000 mg/h considering the maximum conditions pre-set by the
anaesthetist. The output control surface of this fuzzy PI controller is shown in Figure 6-25.
The next step in the controller’s design is to obtain adequate values for the scaling factors
G1 and G2. The performance of the fuzzy PI controller is affected by the choice of the input
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scaling factors, hence, an optimization process is required.
Figure 6-24: Output membership functions describing the change of propofol infusion rate, in the fuzzy
PI controller.
Figure 6-25: Output surface of the fuzzy PI controller.
6.4.2 Performance Index
The scaling factors G1 and G2 were optimized using a performance index and a genetic
algorithm (GA).
A performance index is a quantitative measure of the performance of a system, and is
chosen so that emphasis is given to the important system specifications. The integral of
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time versus the absolute error index (ITAE) is shown in Equation 6-1. This index matches
the intuitive expectations, by penalizing the error according to time.
ITAE   k  0
N  1 k|e 	 k 
 | 6-1
The ITAE index was modified to include information about the control action, this new
index is referred to as ITAEM. The following formula was used:
ITAEM   1  k  0
N  1 k|e  k  |   2  k  0N  1 u  k  6-2
where e  k  is the error, u  k  is the propofol infusion rate and N is the number of simulation
samples. The weighting parameters
 1 and  2 were chosen to place more emphasis on the
error or on the infusion rate, so that an ideal balance between both can be reached (i.e.
stable DOA and a smooth infusion rate). The ITAEM was chosen as the performance index
to evaluate the fuzzy PI controller’s performance.
The objective is to obtain a set of values for G1 and G2 that minimize the performance
index. Genetic algorithms (GAs) are search algorithms based on the mechanics of natural
selection and natural genetics. They do not require a precise mathematical model of the
system (which does not exist in this case) but instead use the objective function values
associated with individual strings (Goldberg, 1989; Linkens and Nyongesa, 1995).
The GAs work with a coding of the parameter set (not the parameters themselves), search
from a population of points, use payoff (i.e. objective function) information; derivations or
other auxiliary knowledge are not required, and use probabilistic transition rules. These
factors differentiate GAs from the other search methods. A simple GA has three operators:
reproduction, crossover, and mutation. The general structure of a GA is presented in Figure
6-26.
A simple GA was used to minimize the ITAEM index (fitness). The GA was implemented
using MATLAB for a population size of 40 strings (representing a pair of values G1 and
G2) each of length 20 (i.e. 20 bits), with a probability of crossover of 0.95 and a probability
of mutation of 0.06. The implemented GA was allowed to run for 50 generations. Figure
6-27 shows the fitness curve relating to an experiment.
The optimization was run with the parameters
 1  0.4 and  2  0.6, which were found to
be representative of the specifications for the control system, giving a bigger weight to the
infusion rate profile. The following intervals were used: G1  ﬀ 0,10 ﬁ and G2 ﬂ ﬃ  10,10  .
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The GA based optimization led to the values of G1 ! 0.3754 and G2 ! 7.7713 with a
minimum ITAEM index of 16.82.
Figure 6-26: General structure of a genetic
Figure 6-27: Fitness curve of the 50 generations of the GA. The performance index was calculated with
"
1
#
0.4 and $ 2
#
0.6.
6.4.3 Results
The results of the closed-loop simulation using the fuzzy PI controller with the GA
optimized parameters (G1 % 0.3754 and G2 % 7.7713), are shown in Figures 6-28 to 6-31.
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The propofol infusion rate profile used during the induction phase is the same as the one
used with patient Pat1 (see Figure 5-1). The controller is activated at 1500 seconds, i.e. at
the beginning of the maintenance phase.
Figure 6-28 shows the level of DOA for the closed-loop simulation. The OK DOA level is
achieved at 1740 seconds and maintained constant thereafter.
Figure 6-28: DOA level using the fuzzy PI controller with G1 & 0.3754 and G2 & 7.7713.
Figure 6-29 shows the propofol infusion rate for the simulation. The fuzzy PI controller
kept a constant infusion rate of 0.1923 mg/s after 1740 seconds. The total amount of drug
infused during the maintenance phase was of 536.5 mg. Figure 6-30 shows the propofol
effect concentration during the simulation. The constant propofol infusion rate led to what
can be described as a steady effect concentration.
Figure 6-29: Propofol infusion rate for the fuzzy PI controller with G1
&
0.3754 and G2
&
7.7713.
The cardiovascular parameters for this simulation are shown in Figure 6-31. The
haemodynamic stability during the maintenance phase is the result of the steady effect
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concentrations of the two drugs. The small peaks in the SAP and HR data are due to the
surgical stimulus model.
This combination of propofol and remifentanil effect concentrations results in a stable
DOA level, corresponding to a steady cardiovascular and CNS depression.
Figure 6-30: Propofol effect concentration for the infusion rate profile in Figure 6-29.
Figure 6-31: Systolic arterial pressure (SAP) and heart rate (HR) from the patient model using the
propofol infusion profile in Figure 6-29.
6.4.4 Comparison with a Conventional Controller
The fuzzy PI controller performance will be compared with the performance of a
conventional PI controller. The ITAEM index will be used to analyse the performance of
both controllers. Some researchers use conventional PID controllers, however, in medical
applications the derivative term can be a problem because of noise. The derivative term
reacts to the noise in the measurement of the controlled variable, changing the controller
output as a function of noise (Westenskow, 1997).
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The next section presents the structure of the conventional PI controller and its results
during a closed-loop simulation.
6.4.4.1 Conventional PI Controller
The output of a conventional PI controller can be written as follows:
u
'
t
( )
Kpe ' t ( * Ki + e , t - dt 6-3
du . t /
dt 0 Kp
de 1 t /
dt 2 Kie 3 t 4 6-4
where Kp and Ki are the proportional and integral terms relating to the controller, and e is
the error. For a digital controller one can write:
5
u 3 k 4
0
u 3 k 4 6 u 3 k 6 1 4
0
Kp
5
e 3 k 4
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Kie 3 k 4 6-5
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0
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2
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5
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Kie 3 k 4 6-6
The conventional PI controller has the change in control action as the output, i.e. the
change in the propofol infusion rate.
The GA was also used to optimized the parameters Kp and Ki for the conventional PI
controller, using the ITAEM index with 7 1
0
0.4 and 7 2
0
0. 6 (Equation 6-2). The same
specifications as for the fuzzy PI controller were used in the GA parameter optimization for
the conventional PI controller.
The GA based optimization led to the values of Kp
0
0.7918 and Ki
0
1.3763 with a
minimum ITAEM index of 17.07.
The closed-loop simulation results for the conventional PI controller are presented in
Figures 6-32 to 6-35. Figure 6-32 shows the DOA level for the closed-loop simulation. The
OK DOA level is achieved at the same time as with the fuzzy PI controller (i.e. 1740
seconds). Figure 6-33 presents the propofol infusion rate, which is kept at a constant level
of 0.1979 mg/s after 1740 seconds. The total amount of drug infused during the
maintenance phase was of 552.1 mg.
Figure 6-34 shows the corresponding propofol effect concentration. The graph shows a
continuous increase in the effect concentration after approximately 2000 seconds.
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Figure 6-32: DOA level using the conventional PI controller with Kp 8 0.7918 and Ki 8 1.3763.
Figure 6-33: Propofol infusion rate for the conventional PI controller with Kp 8 0.7918 and Ki 8 1.3763.
Figure 6-34: Propofol effect concentration for the infusion rate profile in Figure 6-33.
The cardiovascular parameters for this simulation are presented in Figure 6-35. There is a
slight decrease in SAP corresponding to the increase in the propofol effect concentration.
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Figure 6-35: Systolic arterial pressure (SAP) and heart rate (HR) from the patient model using the
propofol infusion profile in Figure 6-33.
The DOA level is the same using the conventional or the fuzzy PI controller. However, the
performance index is smaller for the fuzzy PI controller due to the smaller amount of drug
infused, 536 mg versus 552 mg of the conventional PI controller. In addition, the higher the
infusion rate used by the conventional PI controller the greater the depression in the
cardiovascular parameters will be. The mean value of SAP during the maintenance phase
was of 92.7 mmHg using the fuzzy PI controller versus a mean value of 91 mmHg with the
conventional PI controller. Therefore, the fuzzy PI controller can be considered to be a
more effective option for the patient due to the smaller amount of drug infused.
The fuzzy PI controller has the ability to respond to unexpected disturbances, which can
happen in the operating theatre and that are reflected in the DOA level. In the next section,
the results of both controllers to set point changes (i.e. DOA target level) are compared.
6.4.4.2 General Results
The performance of the fuzzy PI controller is compared with the performance of the
conventional PI controller, considering the response to a change in the DOA target level.
For test purposes, the DOA target level was changed to OK/Deep (i.e. 4) at 3000 seconds
and changed back to the OK level (i.e. 3) at 3210 seconds. The responses of both
controllers to this set point change are shown in Figures 6-36 and 6-37.
The DOA level (Figure 6-36) using the fuzzy PI controller achieves the OK/Deep level at
3120 seconds (i.e. 2 minutes after the set point change to OK/Deep) and returns to the OK
level at 3720 seconds (i.e. 8.5 minutes after the set point change to OK), while the
conventional PI controller reaches the OK/Deep level at 3090 seconds and returns to the
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OK level at 4230 seconds. The conventional PI controller is faster in responding to the first
set point change to OK/Deep, 1.5 minutes versus 2 minutes in the case of the fuzzy PI
controller. Nevertheless, this is a small time difference of only 30 seconds. However, the
conventional PI controller takes more 8.5 minutes to return to the OK level than the fuzzy
PI controller. In total, the conventional PI controller needs 17 minutes to reach the OK level
after the set point change at 3210 seconds; the DOA level is a reflection of the propofol
infusion rate of both controllers (see Figure 6-37).
Figure 6-36: DOA level using the fuzzy PI controller (solid line) and the DOA level using the
conventional PI controller (dashed line) during the maintenance phase. Set point change to OK/Deep at
3000 seconds and back to OK at 3210 seconds.
Figure 6-37: Propofol infusion rate of the fuzzy PI controller (solid line) and the propofol infusion rate of
the conventional PI controller (dashed line) during the maintenance phase. Set point change to OK/Deep
at 3000 seconds and back to OK at 3210 seconds.
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The conventional PI controller responds to the set point change from OK to OK/Deep with
a significantly higher propofol infusion rate than the fuzzy PI controller, which leads to a
higher propofol effect concentration (see Figure 6-38). The fuzzy PI controller is able to
maintain the OK/Deep level at a smaller effect concentration leading to a faster return to
the OK level when required. The total amount of propofol infused during the maintenance
phase was of 548.5 mg and 621.5 mg with the fuzzy and conventional PI controller,
respectively.
Figure 6-38: Propofol effect concentration using the fuzzy PI controller (solid line) and the propofol
effect concentration using the conventional PI controller (dashed line) during the maintenance phase. Set
point change to OK/Deep at 3000 seconds and back to OK at 3210 seconds.
The DOA level obtained using the conventional PI controller has a significant larger
duration in the OK/Deep level, as a results of the high propofol infusion rate and
corresponding effect concentration, this is considered to be unsafe. Overall, the fuzzy PI
controller performs better than the conventional PI controller.
6.5 Multivariable Fuzzy Control
In general, propofol is used for maintenance of anaesthesia in combination with an opioid,
hence, the anaesthetist is confronted with the dilemma of whether to vary propofol or the
opioid. Zhang et al. (1998) reported on a closed-loop system for total intravenous
anaesthesia by simultaneously administering propofol and fentanyl. They studied the
interaction between propofol and fentanyl for loss of response to surgical stimuli using an
unweighted least squares nonlinear regression analysis with human data. A look-up table of
optimal and awakening combinations of concentrations was built, and used to determine
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the fentanyl set point according to the propofol set point. To our knowledge, this is one of
the only studies in simultaneous control of anaesthetic and analgesic drugs.
Multivariable controllers are not easy to design. There are several studies on the design of
multivariable controllers, however, very few target biomedical systems. Yeh (1999)
designed a multivariable fuzzy logic controller using a systematic method based on the
negative gradient of a system performance index. This approach was applied to a
two-inverted pendulum system.
King et al. (1994) described an integrated development system which permits the controller
designer to test hypothesis, examine the effect of changes in the controller parameters and
perform a complete off-line simulation of a proposed multivariable fuzzy controller. This
system was applied to industrial processes and tested off-line with mathematical models.
Another study on multivariable fuzzy control systems is the one by Jeon and Lee (1995).
They developed a coordinator for the controller, which decides the dimension of the
relational matrix using indices of applicability. A numerical example is presented showing
that the coordinator could prevent a large amount of inference error.
Guan et al. (2001) designed a multivariable fuzzy controller for the laminal cooling process
of hot rolled glab. This is a hybrid/statistical multivariable control system tested in
simulation and practical experiments. The controller led to a robust performance.
Linkens and Nyongesa (1996) developed a hierarchical multivariable fuzzy controller for
learning with GAs. This controller was applied to a simulation case study in anaesthesia,
using mathematical models describing the action of atracurium and isoflurane (i.e. a muscle
relaxant and an inhalational anaesthetic). This structure decomposes a complex
multivariable fuzzy controller into several simple fuzzy controllers.
Fuzzy controllers are also used as gain scheduling approximators for multivariable
controllers (Blanchett et al., 2000; Chang and Fu, 1997; Chen and Chen, 1991; Palm and
Rehfuess, 1997). Fuzzy rules and reasoning can be utilized on-line to determine the
controller parameters based on the error signal and its first difference (Zhao et al., 1993).
A review of conventional and fuzzy gain scheduling techniques is presented by Tan et al.
(1997). They report on the improvement of the new neuro-fuzzy gain scheduling over other
gain scheduling methods. Viljamaa (2000) did his PhD thesis on fuzzy gain scheduling and
tuning of multivariable fuzzy control, with an overview of the methods of fuzzy computing
in control systems. The examples presented by Viljamaa (2000) have well defined
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mathematical models and information about the models is used in the tuning process.
Many of the researches mentioned above rely on mathematical models. The complexity of
biomedical systems renders the task of control design more difficult. The highly nonlinear
system behaviour and partly unknown dynamics are an area where fuzzy modelling and
control methods can play an important role. The available qualitative operator and design
knowledge can be implemented using fuzzy logic (Verbruggen and Bruijn, 1997).
The anaesthetist’s knowledge and experience can be incorporated into the fuzzy control
system as a set of linguistic rules. In addition, the interaction between remifentanil and
propofol introduces information that could be used to determine the adequate combination
of the two drugs.
A multivariable fuzzy controller was developed with the anaesthetist coordination. A
simplified linguistic scheme of the controller can be described as follows:
9 If DOA is OK then no change;
9 If DOA is light and if:
: stimulus then increase remifentanil;
: no stimulus then increase propofol;
; If DOA is deep and if:
: no stimulus and remifentanil high then decrease remifentanil;
: no stimulus and remifentanil normal and propofol high then decrease propofol;
: no stimulus and remifentanil normal and propofol normal then decrease remifentanil;
: stimulus and propofol high then decrease propofol and increase remifentanil;
: stimulus and propofol normal then decrease remifentanil.
It is important to note that a minimum effect concentration of propofol and remifentanil is
required at all times, in order to ensure unconsciousness and prevent arousal.
The structure of the multivariable fuzzy controller for DOA, with simultaneous
administration of propofol and remifentanil is presented in more details in the next sections.
6.5.1 Multivariable Fuzzy Controller Structure
The multivariable fuzzy controller for DOA comprises three different blocks,
corresponding to the three possible values of DOA, i.e. the DOA level is the target level
(i.e. OK), or the DOA is lighter than the desired (i.e. OK/Light or Awake level), or the
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DOA is deeper than the desired (i.e. OK/Deep or Deep level). The controller will act
differently according to these three stages.
Considering the three different possibilities for the level of DOA, the structure of the
multivariable fuzzy controller is as follows:
< If DOA is at the target level:
- = upropofol is determined by the SISO fuzzy PI controller;
- = uremifen tan il > 0.
< If DOA is light:
- no stimulus present: = upropofol is determined by the SISO fuzzy PI controller, and
=
uremifen tan il
>
0;
- stimulus present:
=
upropofol
>
0, and
=
uremifen tan il is increased using the remifentanil
rule-base 1.
< If DOA is deep:
- no stimulus present and Ceremifen tan il is high: = upropofol > 0, and
=
uremifen tan il
> ?
0.025 @ g/kg/min;
- no stimulus present and Ceremifen tan il is normal and Cepropofol is high: A upropofol is
determined by the SISO fuzzy PI controller, and A uremifen tan il B 0;
- no stimulus present and Ceremifen tan il is normal and Cepropofol is normal:
A upropofol
B
0, and A uremifen tan il
B C
0.001 @ g/kg/min;
- stimulus present and Ceremifen tan il is high and Cepropofol is normal: A upropofol
B
0, and
A uremifen tan il B
C
0.025 @ g/kg/min;
- stimulus present and Ceremifen tan il is normal and Cepropofol is normal: A upropofol B 0,
and A uremifen tan il
B C
0.001 @ g/kg/min;
- stimulus present and Cepropofol is high: A upropofol is determined by the SISO fuzzy PI
controller, and A uremifen tan il is increased using the remifentanil rule-base 2.
where A upropofol is the change in propofol infusion rate, A uremifen tan il is the change in
remifentanil infusion rate, Ceremifen tan il is the remifentanil effect concentration, and Cepropofol
is the propofol effect concentration. The SISO fuzzy PI controller is the controller
developed in Section 6.4. The remifentanil rule-base 1 and rule-base 2 which determine the
change in the remifentanil infusion rate according to the perceived stimulus intensity and
the change in DOA error, are presented in the following sections.
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The presence of stimulus is established according to the stimulus intensity. A value below
0.25 is considered as no stimulus, because a stimulus intensity below this value has very
little, if any, influence in the cardiovascular parameters. The value of 0.25 is the peak of the
VeryLow membership function in the perceived stimulus model (see Figure 5-59).
The ranges of the remifentanil effect concentration were established according to the
perceived stimulus model and are the following:
D High: Ceremifen tan il E 6 ng/ml;
F Normal: Ceremifen tan il between 4-6 ng/ml;
F Low: Ceremifen tan il
G
4 ng/ml.
The propofol effect concentration was classified as follows:
H High: Cepropofol
I
3520 ng/ml;
H Normal: Cepropofol between 2500-3520 ng/ml;
H Low: Cepropofol
G
2500 ng/ml.
The decrements in the remifentanil infusion rate of 0.025 J g/kg/min were decided upon
using literature results. The value of 0.001 J g/kg/min was considered adequate, so as to
produce the desired effect without any detrimental effect on the level of analgesia.
Minimum propofol and remifentanil effect concentrations are required. The minimum
values were established as 2250 ng/ml and 3.5 ng/ml for propofol and remifentanil,
respectively. If the effect concentrations reach these minimum values, then the infusion rate
of propofol and remifentanil will be increased by 0.2 mg/s and 0.025 J g/kg/min,
respectively. The increment of 0.2 mg/s for propofol was chosen based on the infusion
profiles analysed.
The next two sections describe the remifentanil rule-base 1 and rule-base 2 of the
multivariable fuzzy controller structure.
6.5.2 Remifentanil Rule-Base 1
The remifentanil rule-base 1 determines the increment in the remifentanil infusion rate
when the DOA level is light in the presence of stimulus. The rule-base is shown in Table
6-2, and uses the perceived stimulus and the change in DOA error to establish the increase
in the remifentanil infusion rate.
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The stimulus intensity is labelled Low, Medium and High, according to the membership
functions in Figure 6-39. Figure 6-40 shows the membership functions for the change in
DOA error labelled as: Negative (N), Zero (ZE), Positive Small (PS) and Positive Big (PB).
These fuzzy partitions reflect the change in DOA error considering that the level of DOA is
lighter than the set point. While a negative value is only the result of a change from the
Awake to the OK/Light level, there are different possibilities for a positive change of DOA
error. Therefore, one needs to differentiate between the positive values of the change of
error.
Table 6-2: Rule-base 1 describing the change in remifentanil infusion rate using the stimulus level and
the change of DOA error.
Change of error
Stimulus N ZE PS PB
Low PS PS PM PB
Medium PS PM PM PB
High PM PB PB PB
Figure 6-39: Input membership functions describing the stimulus level.
Figure 6-40: Input membership functions describing the change of DOA error, for rule-base 1.
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The change in remifentanil infusion rate is described as: Positive Small (PS), Positive
Medium (PM) and Positive Big (PB). The output membership functions for the change in
remifentanil infusion rate are shown in Figure 6-41, followed by the output surface of
rule-base 1 in Figure 6-42. The output surface shows how the remifentanil infusion rate
changes according to the stimulus intensity and the change in DOA error. When DOA is
light, higher changes in remifentanil infusion rate are required in order to respond to
stimulus and increase the level of DOA.
Figure 6-41: Output membership functions describing the change in remifentanil infusion rate.
Figure 6-42: Output surface of rule-base 1, describing the change in remifentanil infusion rate.
The change in remifentanil infusion rate is normalized between [0,1], however, the
maximum value of the variable was established as 0.03 K g/kg/min.
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6.5.3 Remifentanil Rule-Base 2
The remifentanil rule-base 2 is used when the DOA is deep, however, there is stimulus
present and an increment on the remifentanil infusion rate is necessary. Rule-base 2 is
shown in Table 6-3. The perceived stimulus level and the change in DOA error are used to
determine the change in remifentanil infusion rate, similarly to rule-base 1. The
membership functions for the stimulus intensity are the same as for rule-base 1, and are
shown in Figure 6-39.
Table 6-3: Rule-base 2 describing the change in remifentanil infusion rate using the stimulus level and
the change of DOA error.
Change of error
Stimulus NB NS ZE P
Low PS PS PS PS
Medium PS PS PM PM
High PS PM PM PB
The change of error is labelled Negative Big (NS), Negative Small (NS), Zero (ZE) and
Positive (P), according to the membership functions in Figure 6-43. The differences
between rule-base 1 and rule-base 2, with respect to the ranges and membership functions
of the change in DOA error, are due to the pre-defined fact that the DOA level is lighter or
deeper than the target level.
Figure 6-43: Input membership functions describing the change of DOA error, for rule-base 2.
The change in the remifentanil infusion rate is denoted in the same way as for rule-base 1,
with the membership functions in Figure 6-41. In rule-base 2, the smaller increment in the
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infusion rate is predominant, since the DOA is deep and the remifentanil is increased for its
analgesic properties. In rule-base 1, the DOA is light, hence, remifentanil is increased as a
response to stimulus and for its synergistic properties with propofol in order to increase the
DOA level.
Figure 6-44 shows the output surface for rule-base 2, describing the change in remifentanil
infusion rate. Analysing Figures 6-44 and 6-42 (output surface for rule-base 1), the
difference in the value of the increment is significant. When DOA is light, higher changes
in remifentanil infusion rates are used. If DOA is deep one needs to respond to stimulus,
however, the DOA level should not increase.
Figure 6-44: Output surface of rule-base 2, describing the change in remifentanil infusion rate.
The membership functions used in the multivariable controller, and even in the SISO fuzzy
PI controller, are Gaussian. This is to obtain smoother control actions.
6.6. Simulation Results
The multivariable fuzzy controller was used in closed-loop simulations with the patient
model. The results of three simulations are presented in the following sections, including
the controller reactions to external disturbances. Note that the controller only starts acting
at 1500 seconds (i.e. during the maintenance phase).
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6.6.1 Simulation 1
In this simulation, the infusion profile for both drugs which was used during the induction
phase was the same as the one used in the simulations with the SISO fuzzy PI controller.
The DOA level for this simulation is shown in Figure 6-45. The OK DOA level is achieved
at 1740 seconds.
Figure 6-46 shows the propofol and remifentanil infusion rates during this simulation. The
corresponding effect concentrations are presented in Figures 6-47 and 6-48, respectively.
Figure 6-45: DOA level using the multivariable controller in simulation 1.
Figure 6-46: Propofol and remifentanil infusion rates as determined by the multivariable controller in
simulation 1.
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Figure 6-47: Propofol effect concentration for the infusion profile in Figure 6-46, simulation 1.
Figure 6-48: Remifentanil effect concentration for the infusion profile in Figure 6-46, simulation 1.
The multivariable fuzzy logic controller performed as well as the SISO fuzzy PI controller.
In fact, the same infusion profiles were used. The OK DOA level was rapidly achieved, and
the controller maintained efficiently a stable DOA level by keeping both infusion rates
constant.
The cardiovascular parameters of simulation 1 are shown in Figure 6-49. The results of the
patient model are the same as in Figure 6-31, corresponding to the same infusion profile as
with the SISO fuzzy PI controller.
The multivariable controller reacts to changes in the system output, i.e. the DOA level,
when the set point has been reached and the subsequent control action maintained a zero
error, then it is not necessary to change the control output. In the next section, a change in
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DOA target (set point) is introduced in order to assess the controller’s performance.
Figure 6-49: Systolic arterial pressure (SAP) and heart rate (HR) for simulation 1.
6.6.1.1 Change in DOA Target
The same conditions as in simulation 1 were considered, but with a set point change to the
OK/Deep level at 3000 seconds. Figure 6-50 shows the infusion rates of propofol and
remifentanil as determined by the multivariable controller during the maintenance phase.
The DOA level is shown in Figure 6-51.
Figure 6-50: Propofol and remifentanil infusion rates as determined by the multivariable controller,
during the maintenance phase. DOA target change to OK/Deep at 3000 seconds.
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Figure 6-51: DOA level using the multivariable controller, during the maintenance phase. DOA target
change to OK/Deep at 3000 seconds.
The OK/Deep DOA level is reached at 3060 seconds, i.e. only 60 seconds after the set point
change. The multivariable controller reacts to the set point change by increasing the
remifentanil infusion rate, due to the high stimulus level present in the system (see e.g.
Figure 6-5). This increase in the remifentanil infusion rate, increases the level of analgesia
and also potentiates the effect of propofol. This increases the DOA level faster than in the
SISO fuzzy PI controller case. Figure 6-52 shows the SAP during the maintenance phase.
The decrease in SAP following an increase in the remifentanil infusion rate shows how a
deeper level of depression is achieved, leading to the OK/Deep DOA level. Therefore, the
multivariable controller is taking advantage of the synergism between propofol and
remifentanil for an efficient control of DOA.
Figure 6-52: Systolic arterial pressure (SAP) during the maintenance phase. DOA target change to
OK/Deep at 3000 seconds.
In order to analyse the response of the controller under different conditions, a set point
change to the OK/Deep level at 3720 seconds was considered. Figure 6-53 shows the
propofol and remifentanil infusion rates during this simulation. At the time of the change in
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the set point (i.e. 3720 seconds) the perceived stimulus intensity is very low, therefore, the
controller reacts by increasing the propofol infusion rate.
Figure 6-53: Propofol and remifentanil infusion rates as determined by the multivariable controller,
during the maintenance phase. DOA target change to OK/Deep at 3720 seconds.
The DOA level for this simulation is shown in Figure 6-54. The OK/Deep DOA level is
reached at 3870 seconds, i.e. 2.5 minutes after the set point change.
Figure 6-54: DOA level using the multivariable controller during the maintenance phase. DOA target
change to OK/Deep at 3720 seconds.
The controller is able to achieve the OK/Deep DOA level in both situations in a relatively
short time. In the first case, i.e. an increase of the remifentanil infusion rate, the OK/Deep
level is reached faster due to the rapid onset of the action of remifentanil, a subsequent
reduction in the perceived stimulus, and a synergism with propofol. In the second case, i.e.
an increase of the propofol infusion rate, the OK/Deep level is the response to the increase
in the propofol effect concentration.
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6.6.2 Simulation 2
Simulation 2 considers a different propofol infusion profile during the induction phase,
hence, different initial conditions for the multivariable fuzzy controller. The remifentanil
infusion profile is the same as for simulation 1.
The DOA level for simulation 2 is shown in Figure 6-55, followed by the infusion profiles
of propofol and remifentanil in Figure 6-56. The effect concentrations of propofol and
remifentanil are presented in Figures 6-57 and 6-58, respectively.
At the beginning of the maintenance phase the DOA is at the OK level, i.e. the target level.
The propofol and remifentanil infusion rates are kept constant by the controller. However,
at approximately 1900 seconds the DOA level increases to OK/Deep. The multivariable
controller responds with a decrease in the remifentanil infusion rate, since the propofol
effect concentration is within the normal range.
Figure 6-55: DOA level using the multivariable controller in simulation 2.
Figure 6-56: Propofol and remifentanil infusion rates as determined by the multivariable controller in
simulation 2.
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Figure 6-57: Propofol effect concentration for the propofol infusion profile in simulation 2 (Figure 6-56).
Figure 6-59 shows the decrease in the remifentanil infusion rate, which was not easily
observed in Figure 6-56. The remifentanil effect concentration also decreases (see Figure
6-60), resulting in an effective return to the OK DOA level.
Figure 6-58: Remifentanil effect concentration for the remifentanil infusion profile in simulation 2
(Figure 6-56).
Figure 6-59: Remifentanil infusion rates as determined by the multivariable controller in simulation 2,
during the maintenance phase (zoom on Figure 6-56).
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Figure 6-60: Remifentanil effect concentration during the maintenance phase in simulation 2 (zoom on
Figure 6-58).
The decrease in the remifentanil infusion rate is very small, but it is proved sufficient in
order to achieve the OK DOA level. The multivariable controller shows a smooth and
gradual reaction to the change in DOA level, which has proved to be efficient in
maintaining a stable level of DOA.
Figure 6-61 shows the stability of the cardiovascular parameters during this simulation.
Figure 6-61: Systolic arterial pressure (SAP) and heart rate (HR) in simulation 2.
6.6.2.1 Disturbance Tests
Considering the same conditions as for simulation 2, a disturbance to the OK/Light DOA
level was introduced at 3600 seconds. In a real situation, this could be due for instance to a
high stimulus interference. Figure 6-62 shows the DOA level for this simulation, during the
maintenance phase. The first OK/Deep DOA level (at approximately 1900 seconds) is the
same as in the previous simulation.
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Figure 6-62: DOA level using the multivariable controller (maintenance phase only). Disturbance to the
OK/Light DOA level at 3600 seconds.
Figure 6-63 shows the propofol and remifentanil infusion rates for this simulation. The
propofol infusion rate is kept at a constant level from the start of the simulation. The
remifentanil infusion rate is shown in Figure 6-64 in order to analyse the controller’s
behaviour. The first decrease in the remifentanil infusion rate is the same as in simulation
2.
Figure 6-63: Propofol and remifentanil infusion rates using the multivariable controller (maintenance
phase only). Disturbance to the OK/Light DOA level at 3600 seconds.
The controller responds to the OK/Light disturbance with an increase in the remifentanil
infusion rate, which leads to an OK/Deep DOA level. Therefore, the controller
subsequently decreases remifentanil in order to stabilize the effect concentration and lead to
an OK DOA level. Figure 6-65 shows the remifentanil effect concentration for this
simulation.
The fast onset of action of remifentanil allows the controller to manipulate the infusion rate
in order to achieve rapidly the desired DOA level. Therefore, the controller is able to
respond adequately to the external disturbance. Once again, only small changes in the
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remifentanil infusion rate are used and proved to be efficient in achieving the OK DOA
level.
Figure 6-64: Remifentanil infusion rate using the multivariable controller (maintenance phase only).
Disturbance to the OK/Light DOA level at 3600 seconds.
Figure 6-65: Remifentanil effect concentration for the infusion profile in Figure 6-64.
6.6.3 Simulation 3
Simulation 3 considers a different remifentanil infusion profile during the induction phase,
while the propofol infusion profile is the same as the one used in simulation 1 (i.e. the one
from patient Pat1). In other words, simulation 2 and 3 analyse the reaction of the controller
to different initial conditions. The first changes the propofol infusion rate during induction,
and the second changes the remifentanil profile.
Figure 6-66 shows the DOA level in simulation 3, while the propofol and remifentanil
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infusion rates are shown in Figure 6-67. In contrast with the previous simulations, the
multivariable controller changes both infusion rates in response to the OK/Deep DOA level
at approximately 1700 seconds.
Figure 6-66: DOA level using the multivariable controller in simulation 3.
Figure 6-67: Propofol and remifentanil infusion rates as determined by the multivariable controller in
simulation 3.
Figure 6-68: Propofol and remifentanil infusion rates as determined by the multivariable controller in
simulation 3, during the maintenance phase (zoom on Figure 6-67).
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Figure 6-68 shows the infusion rate of both drugs during the maintenance phase (zoom on
Figure 6-67). The multivariable controller decreases the propofol infusion rate first and
then gradually decreases the remifentanil infusion rate. The effect concentrations of
propofol and remifentanil are presented in Figures 6-69 and 6-70, respectively.
The controller is able to determine the adequate combination of the two drugs, achieving
and maintaining the OK DOA level.
The cardiovascular parameters for simulation 3 are presented in Figure 6-71. A stable
haemodynamic profile is achieved throughout the maintenance phase. There is a small
gradual decrease in SAP and HR due to the increase in the propofol effect concentration,
however, the SAP and HR values were never below the pos-induction minimum values.
Figure 6-69: Propofol effect concentration for the propofol infusion rate in simulation 3 (Figure 6-67).
Figure 6-70: Remifentanil effect concentration for the remifentanil infusion rate in simulation 3 (Figure
6-67).
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Figure 6-71: Systolic arterial pressure (SAP) and heart rate (HR) in simulation 3.
6.7 Summary
A closed-loop simulation structure for DOA was developed, linking the patient model, the
FRC and a control system. This structure is an advisor system for the anaesthetist. In fact,
the system should provide information about the adequate infusion rate of propofol and
remifentanil simultaneously.
In a first stage, a SISO fuzzy PI controller was developed. This controller determines the
change in propofol infusion rate according to the DOA error and based on the patient
model. Remifentanil is considered as being manually controlled by the anaesthetist. The
patient model uses the infusion rate of both drugs to determine the effect on the
cardiovascular parameters and on the wavelet extracted AEP features.
The SISO fuzzy PI controller parameters were optimized using a GA. Overall, the
controller had a good performance and was able to respond effectively to changes in the
DOA set point. The fuzzy PI controller also proved to be better than a conventional PI
controller under the same conditions.
The second stage of the study related to the development of a multivariable controller for
the simultaneous administration of propofol and remifentanil. Fuzzy logic was used to
construct the multivariable controller, which was based on the anaesthetist experience
translated to linguistic rules.
The multivariable controller uses three rule-bases to establish the infusion rates of propofol
and remifentanil, according to the DOA level. In the case of remifentanil, the perceived
surgical stimulus intensity is also used to ensure an adequate level of analgesia. The
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controller takes into account the synergistic interaction between the two drugs, and uses
this to rapidly achieve the desired DOA level.
In order to test the reactions of the multivariable controller, several closed-loop simulations
were performed using different induction profiles, and adding set point changes and
disturbances to the system. The controller performed efficiently in all simulations, by
adjusting the infusion rate of both drugs in response to DOA changes. These results can be
used to determine ideal combinations of infusion profiles for future use in the operating
theatre.
203
Chapter 7
Conclusions and Recommendations
7.1 Conclusions
Depth of anaesthesia (DOA) is defined as the degree of lack of response and recall to
noxious stimuli. While clinical signs can be used to establish the lack of response to
stimulus, they are not reliable indicators of possible recall. In addition, balanced
anaesthesia comprises the use of a muscle relaxant, an analgesic and an anaesthetic, and
such use of several different drugs may obscure the clinical signs. Unconsciousness is hard
to define and measure accurately, however one should look for a DOA indicator within the
central nervous system (CNS). Previous researchers investigated the auditory evoked
potentials (AEP) as an indicator of DOA. The AEP are responses on the EEG to auditory
stimuli, and have been proved to show similar graded changes with equipotent
concentrations of different anaesthetics, and distinguish between the different DOA levels.
The introduction of balanced anaesthesia gave rise to another problem: how to determine
the adequate infusion rate of the anaesthetic and analgesic drugs, considering that the two
drugs interact and that there is no direct measure of analgesia (i.e. pain relief). The
possibility of recall with implicit or explicit pain brings serious problems for the physician
and for the patient.
The objective of this research project was to solve part of the problems that concern the
anaesthetist in the operating theatre. The study was based on clinical data gathered during
surgical procedures with the anaesthetic propofol and the analgesic remifentanil.
The first step was the classification of DOA. Multiresolution wavelet analysis was used to
extract meaningful features from the AEP relating to the different DOA levels. A set of ten
wavelet extracted AEP features was found to provide the necessary information to
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distinguish between the DOA levels. A fuzzy relational classifier (FRC) was developed in
order to process the AEP features and classify them into DOA levels. The FRC uses fuzzy
clustering and fuzzy relational composition to establish the link between the natural data
clusters and the DOA levels. An automatic system is required to process the AEP and
translate the relevant information into a reference value, to which the anaesthetist can
relate. Online AEP processing provides the anaesthetist with information about the CNS
depression, hence, the degree of unconsciousness of the patient. The FRC classification was
evaluated against the anaesthetist classification, which was taken as being the correct
classification since there is no precise analysis to evaluate DOA. This is not an easy
classification problem, and the overall trend of anaesthetic depth needs to be considered.
The FRC was able to distinguish between the five different DOA levels, which were
established by the anaesthetist. The results of the FRC were compared with the results of
KSOM and ANFIS classifiers. Overall, the FRC achieved a better performance. Therefore,
the FRC provided a reliable DOA indicator based on features extracted from the AEP,
giving the anaesthetist the possibility of using brain signals as part of day-to-day surgical
procedures. The cardiovascular parameters   SAP and   HR can also be used to reinforce
the overall decision scheme.
Remifentanil is a potent analgesic with a strong interaction with propofol. Its rapid onset
and offset of action make it ideal for general anaesthesia with a fast and efficient response
to the effects of surgical stimuli. Remifentanil has a synergistic interaction with propofol,
hence, the effects of propofol are potentiated by the use of remifentanil. From the family of
synthetic opioids, remifentanil presents the strongest interaction with propofol. In fact, the
optimal concentration of propofol is largely reduced in the presence of remifentanil. In
addition, the use of this opioid can also reduce the recovery time. A patient model was
developed to determine the effects of these two drugs on the cardiovascular parameters (i.e.
SAP and HR) and on the AEP features. The objective was to establish the effects of the
interaction between the two drugs and how this affects the adequate infusion rates to
maintain a stable DOA level. It is worth noting that the two drugs interact only in the
presence of stimuli.
A patient model was developed for the two phases of anaesthesia, i.e. induction and
maintenance. In the induction phase, remifentanil acts by reducing the haemodynamic
response to intubation which is the only strong stimulus during this phase. It was found that
the cardiovascular parameters are largely affected by propofol. Therefore, Hill equation
models were optimized and used to model the cardiovascular parameters, and linear
quadratic models were developed to determine the effect of remifentanil on the response to
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intubation. The AEP are not a reliable signal during the induction phase, due to the drastic
changes in the drugs concentrations and tracheal intubation.
The maintenance phase is the longest and most important phase of general anaesthesia,
since it is the period corresponding to the surgical procedure. In addition, surgical stimulus
is almost a continuous event throughout the maintenance phase and the interaction between
the two drugs is an important aspect. The anaesthetist is confronted with the dilemma of
which drug to change in response to the DOA level. Surgical stimulus causes arousal,
hence, the analgesic properties of remifentanil have to be titrated so as to block the stimulus
effect.
The effect concentration governs the drug effect, since it is in the effect site that the drug
exerts its action. Therefore, a fuzzy structure of models was built to relate the effect
concentrations of both drugs with the patients vital signs. Only the pharmacodynamic
interactions were considered, since they have a higher clinical importance than the
pharmacokinetic interactions, which are obscured by the inter-patient variability.
The Adaptive Network-Based Fuzzy Inference System (ANFIS) was used to adapt
Takagi-Sugeno-Kang (TSK) fuzzy models for  SAP,  HR and the AEP features, based on
clinical data. The fuzzy models led to acceptable errors and reflected the drugs effect and
synergistic interaction. Considering that during the maintenance phase the infusion rates
follow a specific profile to maintain a stable DOA in the presence of stimulus, these fuzzy
models are only valid within specified effect concentrations ranges and safety warnings
have to be built in. Overall, this is a reasonable model that helps to understand the effects of
the combination of propofol and remifentanil. The model has a good performance on the
checking data sets and clearly shows how SAP and HR respond to the drug related
synergism.
The patient model would not be complete if the effect of surgical stimulus was not
included. The anaesthetist experience was used to construct a Mamdani type of fuzzy
model describing the effect of surgical stimuli. The effect concentration of remifentanil was
used to determine the level of analgesia and the level of stimulus perceived by the patient.
This was used to establish the effect of the stimulus on SAP and HR. It was found that: 1.
the DOA level has some influence on the stimulus effect; 2. the cardiovascular variables
include a time-delay in response to surgical stimulus; 3. the stimulus effect is proportional
to its intensity.
The AEP features were also analysed according to the stimulus effect. The brain signals
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respond immediately to stimulus indicating the degree of arousal. The low and high
frequency AEP features respond differently to different stimuli. The effect of stimulus on
the AEP was not modelled due to the lack of information and data. However, it is important
to establish that there is a relation between these two signals and one needs to be aware of
its influence on the state of the patient. In the future, SAP and HR may be considered safety
indicators, while the AEP represent awareness.
Overall, the developed patient model has an adequate performance reflecting the effect of
the drugs and of the surgical stimuli. This model represents a typical patient’s behaviour
during a surgical procedure, and should be recognized as such. A model describing the
drugs effect and interactions is very important for the development of a closed-loop system
in anaesthesia. The objective of a control system for DOA is to determine the infusion rates
of the anaesthetic and analgesic drugs, helping the anaesthetist to decide which drug should
be changed in response to different events.
The developed patient model was used to construct and test two different control structures.
First, a SISO fuzzy PI controller was developed using GA optimization. The controller
determines the change in propofol infusion rate according to the DOA level and its
difference from the desired OK level. The remifentanil infusion rate is considered as
manually controlled by the anaesthetist. This is the most common option for control
systems in anaesthesia. However, the patient model considers the effects of both drugs and
their interaction, hence, the propofol infusion rate will reflect this information. The SISO
fuzzy PI controller performed better than a conventional PI controller, leading to a smaller
amount of drug infused and being able to respond efficiently to set-point changes. This is
one of the advantages of fuzzy logic controllers, which can prove to be robust against
disturbances.
Second, the development of a multivariable controller for simultaneous administration of
remifentanil and propofol during the maintenance phase was reviewed. Considering the
complexity of the two components of anaesthesia (i.e. unconsciousness and analgesia), a
multivariable fuzzy controller was developed with the anaesthetist’s cooperation. The
anaesthetist experience was incorporated into the control structure using linguistic rules.
According to the different possibilities for the DOA level and for the surgical stimuli, the
multivariable controller defines the required change in the infusion rates of the two drugs.
The controller is able to adjust the remifentanil infusion rate according to the stimulus
intensity, and takes advantage of the synergistic interaction to change adequately the
propofol infusion rate. Propofol is titrated to lower infusion rates, decreasing the amount of
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drug infused, and speeding up recovery. In addition, the controller ensures adequate
analgesia by titrating the remifentanil according to stimulus.
The multivariable fuzzy controller was tested under different simulations, and responded
efficiently to different induction profiles, set point changes and disturbances. The infusion
rates of both drugs were adequately changed to achieve and maintain a stable DOA level,
taking advantage of the interaction between the two drugs. It was found that it is possible to
model the interaction between propofol and remifentanil, and to use successfully this model
to develop a closed-loop system in anaesthesia with simultaneous automatic control of both
drugs.
Fuzzy logic techniques proved to be efficient in incorporating human knowledge for a
better solution in biomedicine. The complexity of DOA, and the unavailability of large data
sets, make this latter ideal for the application of fuzzy logic based concepts. The FRC, the
TSK pharmacodynamic models and the multivariable fuzzy controller were combined
successfully in a hybrid structure to provide a closed-loop simulation platform for
anaesthesia. This system can act as an advisor to anaesthetists in the operating theatre.
In conclusion, the closed-loop system:
 decreases the amount of drug infused;
 reduces the anaesthetist workload;
 can be used as an alarm system;
 processes and provides information about the brain signals (i.e. AEP);
 models the interaction between propofol and remifentanil;
 administers both drugs simultaneously taking advantage of the existent synergism and
adjusting to the presence of stimulus;
 leads to an overall increase in the patient’s comfort and safety.
7.2 Further Work
The developed patient model represents a typical patient’s response to a surgical procedure.
Nevertheless, the gathering of more clinical data would be beneficial for improving
generalization properties of the model. A balanced set of data from different patients could
be used to develop Mamdani type of fuzzy models describing the drugs pharmacodynamics.
This would lead to a better understanding of the drugs relations and the way they affect the
patient physiological systems. Additional clinical data could be used in extended tests with
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the developed patient model, and provide off-line testing of the multivariable controller.
Some aspects could improve the patient model and, hence, the closed-loop simulation
system as a whole. Clinical data could be used to study the existence of the time-delay
between the surgical stimulus and the haemodynamic responses, improving the quality of
analgesia. Research on the effect of surgical stimuli in the presence of remifentanil on the
AEP is a real challenge. If a model could be developed, relating the level of analgesia, the
stimulus intensity and the effects on the brain signal, this would open a new area of
biomedical studies.
Genetic programming could be used to decide on the nonlinear function relating the effects
of each drug on the cardiovascular parameters to the final effect of the combination of the
drugs. This could be used to compare the results of the patient model and provide new
information.
A measure of patient sensitivity to the two drugs could be studied and included in the
patient model. A gain could be introduced in the pharmacokinetic and the
pharmacodynamic models. Therefore, the variability between patients could be accounted
for and used in testing and generalization of the simulation system. In practice, the
anaesthetist is faced with patients responding in different ways to the same drugs. If the
patient’s resistivity to the drug could be detected analysing the initial response during the
induction phase, this information could be included in the control system. On-line Adaptive
Fuzzy Controllers could also be used to deal with the interpatient variability. Therefore, the
drugs would be titrated according to the DOA level, the surgical stimulus, the drugs
interaction and also the patient’s individual characteristics.
This is one of the first studies on the modelling of drug interactions and multivariable
control in humans. The combination of propofol and remifentanil is becoming more
popular in anaesthesia, due to specific and unique properties of remifentanil. Nevertheless,
different drugs interact differently and this research could be extended to several
combinations of anaesthetic and analgesic drugs.
A closed-loop simulation system helps to train the anaesthetist in the different aspects of
DOA, and to develop and test different control structures. It also plays and important role in
the study of drug interactions and possible side effects. However, the final objective is the
implementation of the system in the operating theatre. The advantages of such an advisor
system as a source of information and rapidly achieving optimal conditions, would improve
the quality of general anaesthesia.
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Appendix A
Glossary
AEP - Auditory Evoked Potentials
ANFIS - Adaptive Network-Based Fuzzy Inference System
ANN - Artificial Neural Network
BIS - Bispectral Index of the EEG
CNS - Central Nervous System
CWT - Continuous-Time Wavelet Transform
DAP - Diastolic Arterial Pressure
DOA - Depth of Anaesthesia
DSP - Digital Signal Processing
DTWT - Discrete Time Wavelet Transform
ECG - Electrocardiogram
EEG - Electroencephalogram
EP - Evoked Potentials
FIS - Fuzzy Inference System
FRC - Fuzzy Relational Classifier
GA - Genetic Algorithm
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HR - Heart Rate
ICU - Intensive Care Unit
KSOM - Kohonen Self-Organizing Map
MAC - Minimum Alveolar Concentration
MAP - Mean Arterial Pressure
MLAEP - Middle Latency Auditory Evoked Potentials
MEP - Motor Evoked Potentials
MF - Median Frequency of the EEG
MRA - Multiresolution Analysis
NCD - Nonlinear Control Design
OMT - Ocular Microtremor
PC - Personal Computer
PD - Proportional-Derivative
PI - Proportional-Integral
PID - Proportional-Integral-Derivative
SAP - Systolic Arterial Pressure
SEF - Spectral Edge Frequency of the EEG
SEP - Somatosensory Evoked Potentials
SISO - Single Input Single Output
STFT - Short-Time Fourier Transform
TCI - Target Controlled Infusion
TIVA - Total Intravenous Anaesthesia
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TSK - Takagi-Sugeno-Kang
VEP - Visual Evoked Potentials
WT - Wavelet Transform
  SAP - Change in Systolic Arterial Pressure from Baseline
 
HR - Change in Heart Rate from Baseline
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Fuzzy Logic
B.1 Fuzzy Sets and Systems
Classical sets are crisply defined collections of distinct elements (numbers, symbols,
objects), and for this reason are also called crisp sets. The elements of all the sets under
consideration in a given situation belong to an invariable, constant set, called the universe
of discourse. The fact that elements of a set A either belong or do not belong to a crisp set A
can be formally indicated by the characteristic function of A defined as:
 
A  x  
1 if and only if x  A
0 if and only if x  A
B-1
where the symbols  and  denote that x is and is not a member of A, respectively. The pair
of numbers  0,1  is called the valuation set. Another way of writing Equation B-1 is:
	
A 
 x  : X   0,1  B-2
There is a restrict sense of membership to a set in classical set theory, i.e. an element either
belongs or does not belong to the set.
In 1965, Zadeh launched the foundation of fuzzy set theory, where a more flexible sense of
membership is possible. In fuzzy sets many degrees of membership are allowed. The degree
of membership to a set is indicated by a number between 0 and 1, i.e. a number in the
interval  0,1  . Fuzzy sets generalize the valuation set from the pair of numbers  0,1  to all
numbers found in  0,1

. By expanding the valuation set the nature of the characteristic
function is altered, and called membership function and denoted by  A  x  . Therefore, an
infinite number of membership degrees are possible, since there is an infinity of numbers in
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the interval  0,1  . The membership function maps every element of the universe of
discourse X to the interval  0,1  , and this is written as:

A  x ﬀ : X ﬁ  0,1  B-3
Membership functions are a mathematical tool for indicating flexible membership to a set,
and for modelling and quantifying the meaning of symbols. Membership functions may
represent an individual’s subjective notion of a value class.
Definition B.1. A fuzzy set in an universe of discourse X is characterized by a membership
function  A  x ﬀ that takes values in the interval  0,1  .
Fuzzy systems are knowledge-based or rule-based systems. In the centre of a fuzzy system
is a knowledge base consisting of the so-called IF-THEN rules. A fuzzy IF-THEN rule is an
IF-THEN statement in which some words are characterized by continuous membership
functions For example, the following is a fuzzy IF-THEN rule:
IF the speed of a car is low, THEN apply less force to the accelerator B-4
where the words “high” and “less” are characterized by membership functions. A fuzzy set
is constructed from a collection of fuzzy IF-THEN rules. Formally:
IF premise (antecedent), THEN conclusion (consequent) B-5
In the linguistic fuzzy system (also called the Mamdani model), both the antecedent and the
consequent are fuzzy propositions. A general form of the linguistic fuzzy rules is:
R i : If x is A i then y is B i, i ﬂ 1,2, . . . ,K B-6
where x is the antecedent variable, which represents the input to the fuzzy system, and y is
the consequent variable representing the output of the fuzzy system. In most cases,
real-valued vector inputs and outputs are used: x ﬃ X   p and y ! Y "  q. A i and B i are
linguistic terms (fuzzy sets) defined by multivariable membership functions
#
Ai
$
x % : X & ' 0,1 ( and # Bi
$
y % : Y & ' 0,1 ( , respectively. Finally, K denotes the number of
rules in the system.
Instead of considering the fuzzy IF-THEN rules in the form of Equation B-6, in the
Takagi-Sugeno-Kang (TSK) system, the rules consequent are crisp functions of the model
inputs:
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R i : If x is A i then y i ) fi * x + , i ) 1,2, . . . , K B-7
where x , - p is the input (antecedent) variable and y i , - is the output (consequent)
variable. R i denotes the ith rules, and K is the number of rules in the rule base. A i is the
antecedent fuzzy set of the ith rule. As in the linguistic model, the antecedent proposition “x
is A i” is usually expressed as a logical combination of simple propositions with invariant
fuzzy set defined for the individual components of x, often in the conjunctive form:
R i : If x1 is A i1 and x2 is A i2 and ... and xp is A ip then y i ) fi * x + , i ) 1,2, . . . ,K B-8
The consequent functions fi are typically chosen as instances of a suitable parameterised
function, whose structure remains equal in all the rules and only in the parameters vary. A
special case of the TSK fuzzy systems is the system that uses rules in the form of Equation
B-8 but fi * x + is a linear function of x: fi * x + ) c ix . bi where c i and bi are constants.
B.2 Fuzzy Sets Operations and Properties
Assume that A and B are fuzzy sets defined in the same universe of discourse U.
1. A and B are equal if an only if / A
0
x 1 2 / B
0
x 1 for all x 3 U.
2. B contains A, denoted by A 4 B, if and only if / A 0 x 1 5 6 B 7 x 8 for all x 9 U.
3. The complement of A is a fuzzy set A in U whose membership function is defined as:
6 A 7 x 8 : 1 ; < A = x > B-9
4. The union of A and B is a fuzzy set in U, denoted by A ? B, with the membership
function defined as (Figure B-1):
@
A
A B B max C D A E x F , D B E x F G B-10
5. The intersection of A and B is a fuzzy set A H B with membership function (Figure B-2):
I
A
J B K min L M A N x O , M B N x O P B-11
6. Morgan’s Laws are true for fuzzy sets:
A Q B
K
A R B B-12
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A
S
B
T
A
U
B B-13
7. Extension Principle 1: If A is a fuzzy set in the universe U and f is a mapping from U to
the universe of discourse V such that y T f V x W , then the extension principle allows to define
a fuzzy set B in V such that:
B
T
f
V
A
W T
V
y, X B V y W W y T f V x W , x Y U B-14
where,
X B V y W T
sup X A V x W if f Z 1 [ y \ ] 0
0 if f ^ 1 _ y ` a 0 B-15
8. Zadeh’s Principle: Let X be a cartesian product of the universes U1,U2, . . . ,Un such that
X a U1 b U2 b . . . b Un and A1,A2, . . . ,An are fuzzy sets in these universes. f is a mapping
from X to the universe of discourse V, where y c f d x1,x2, . . . ,xn e . The fuzzy set B in V is
defined as:
B
d
y, f B d y
e
e
y c f d x1,x2, . . . , xn e , d x1, x2, . . . ,xn e g X B-16
where
f B d y e c
sup min h f A1 d x1 e , . . . , f An d xn e i if f j 1 d y e k 0, d x1,x2, . . . ,xn e g f j 1 d y e
0 if f j 1 d y
e
c 0
B-17
Figure B-1: Union of fuzzy sets A and B.
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Figure B-2: Intersection of fuzzy sets A and B.
B.3 Properties of a Fuzzy System (Set of Rules)
1. A set of fuzzy IF-THEN rules is complete if for any x l U, there exists at least one
rule-base, say rule R l (in the form of Equations B-6 or B-7), such that
m
Ail n x i o p 0 B-18
for all i q 1,2, . . . ,K.
2. A set of fuzzy IF-THEN rules is consistent if there are no rules with the same IF parts but
different THEN parts.
3. A set of fuzzy IF-THEN rules is continuous if it does not exist such neighbouring rules
whose THEN part fuzzy sets have empty intersection.
B.4 Fuzzy Relations
In a fuzzy inference engine, fuzzy logic principles are used to combine the fuzzy IF-THEN
rules in the fuzzy rule base into a mapping from a fuzzy set A in U to a fuzzy set B in V. A
fuzzy relation of the form:
If A then B or A r B B-19
is denoted as R (relational matrix) and is defined as a relationship of two fuzzy sets A l U,
B
l
V, and it is a subset on the Cartesian product U s V. R is characterized by the
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membership function t R u x,y v , x w U, y w V such that:
R
x
A
y
B
x z { R | x,y } / | x,y } ~
z
min
|
{ A | x } , { B | y } }
z { A | x } { B | y }
B-20
the z represents all possible combinations of all elements of both universes of discourse
and not the mathematical operation sum.
If R is a fuzzy relation in U  V and A is a fuzzy set in U then the fuzzy set B in V is given
by:
B ~ A  R B-21
B is inferred from A using the relational matrix R which defines the mapping between U
and V, and the operation  is defined as the “max-min” operation.
B.5 Fuzzifiers and Defuzzifiers
The fuzzy inference engine combines the rules in the fuzzy rule-base into a mapping from
fuzzy set A in U to fuzzy set B in V. Because in most applications the input and output of
the fuzzy system are real valued numbers, interfaces must be constructed between the fuzzy
inference system and the environments. The interfaces are the fuzzifier and the defuzzifier
(Figure B-3).
Figure B-3: Basic configuration of fuzzy systems with fuzzifier and defuzzifier.
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Fuzzy systems can be used either as open-loop controllers or closed-loop controllers. When
used as an open-loop controller, the fuzzy system usually sets up some controller
parameters and then the system operates according to these parameters. When used as a
closed-loop controller, the fuzzy system measures the outputs of the process and takes
control actions on the process continuously. However, fuzzy systems have been applied to a
wide variety of fields ranging from control, signal processing, communications and expert
systems (modelling).
B.5.1 Fuzzifiers
Fuzzification is the process which allows to convert a numeric input into a fuzzy input.
There are two types of fuzzifiers.
Fuzzification maps a crisp input x i  U into a fuzzy set Axi in U such that:
1. Axi is a fuzzy singleton:

Axi  x  
1 if x  x i
0 otherwise
B-22
2. Axi is a fuzzy set (triangular, trapezoidal, Gaussian):

Axi  x  
1 if x  x i
decreases from 1 as x moves from x i
B-23
B.5.2 Defuzzifiers
Defuzzification is the conversion of a fuzzy quantity into a crisp one. Formally, a
defuzzifier is defined as a mapping from fuzzy set B in V   (which is the output of the
fuzzy inference engine) to a crisp point y   V. The defuzzifier specifies a point in V that
best represents the fuzzy set B. The following three criteria should be considered in
choosing a defuzzification scheme:
Ł Plausibility: the point y  should represent B from an intuitive point of view;
Ł Computational simplicity;
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 Continuity: a small change in B should not result in a large change in y  .
The defuzzifier is only necessary for the Mamdani system type. Three different defuzzifiers
are presented next.
B.5.2.1 Centre of Gravity Defuzzifier
The centre of gravity defuzzifier specifies y  as the centre of the area covered by the
membership function of B, that is:
y
 

V
y  B  y  dy

V 
B  y  dy
B-24
where

V
is the conventional integral.
B.5.2.2 Centre Average Defuzzifier
The fuzzy set B is the union or intersection of M fuzzy sets, a good approximation of
Equation B-24 is the weighted average of the centers of the M fuzzy sets, with the weights
equal to heights of the corresponding fuzzy sets. Let y l be the centre of the l’th fuzzy set
and wl be its height, the centre average defuzzifier determines y  as:
y    l 1
M y lw l

l  1
M
w l
B-25
B.5.2.3 Maximum Defuzzifier
The maximum defuzzifier chooses y  as the point in V at which  B  y  achieves its
maximum value. Define the set:
hgt

B   y   V| B  y  
y ¡ V
sup ¢ B £ y ¤ B-26
hgt
£
B ¤ is the set of all points in V at which ¢ B £ y ¤ achieves its maximum value. The
maximum defuzzifier defines y ¥ as an arbitrary element in hgt
£
B ¤ .
y ¥ ¦ any point in hgt
£
B ¤ B-27
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B.6 Fuzzy Control
A simple fuzzy logic controller can generally be depicted by a block diagram such as that
shown in Figure B-4. A number of assumptions are implicit in a fuzzy control system
design:
1. The plant is observable and controllable: state, input, and output variables are usually
available for observation and measurement or computation;
2. There exists a body of knowledge comprised of a set of expert production linguistic
rules;
3. A solution exists;
4. The control engineer is looking for a “good enough” solution, not necessarily the
optimum one;
5. A controller will be designed to the best of the available knowledge and within an
acceptable range of precision;
6. The problems of stability and optimality are still open problems in fuzzy controller
design.
The knowledge-base module in Figure B-4 contains knowledge about all the input and
output fuzzy partitions. It includes the term set and the corresponding membership
functions defining the input variables to the fuzzy rule-base system and the output
variables, or control actions, to the plant under control.
The steps in designing a simple fuzzy logic control system are as follows:
1. Identify the variables (input, states, and outputs) of the plant;
2. Partition the universe of discourse or the interval spanned by each variable into a number
of fuzzy subsets, assigning each a linguistic label (subsets include all the elements in the
universe);
3. Assign or determine a membership function for each fuzzy subset;
4. Assign the fuzzy relationships between the inputs (or states) fuzzy subsets on the one
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hand and the outputs fuzzy subsets on the other hand, thus forming the rule-base;
5. Choose appropriate scaling factors for the input and output variables in order to
normalize the variables to the § 0,1 ¨ or the § © 1,1 ¨ interval;
6. Fuzzify the inputs to the controller;
7. Use fuzzy appropriate reasoning to infer the output contributed from each rule;
8. Aggregate the fuzzy outputs recommended by each rule;
9. Apply defuzzification to form a crisp output.
The results of the nine steps mentioned above are fixed in a nonadaptive simple fuzzy logic
controller. In an adaptive fuzzy logic controller, they are adaptively modified based on
some adaptation law in order to optimize the controller.
Figure B-4: A simple fuzzy logic control system block diagram.
B.6.1 Fuzzy Linguistic Controllers
The core of a fuzzy controller is a linguistic description prescribing appropriate action for a
given state. Fuzzy linguistic descriptions involve associations of fuzzy variables and
procedures for inferring. In order to design a proportional-integral-derivative (PID) like
fuzzy controller, it is necessary to choose the input and output variables and the rules of the
controller.
B.6.1.1 Input Variables
The most common input variable in fuzzy control is the error, or e. It is defined on the
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universe of discourse of crisp error e, which is the deviation of some measured variable y
from a setpoint or reference r. At anytime time t ª k crisp error is defined as:
e « k ¬
ª
r ­ y « k ¬ B-28
The change in error, ® e, between two successive time steps is also commonly used as an
input variable. It is defined on the universe of discourse of crisp changes in error. At time
t ¯ k the crisp change in error is the difference between the present error and the error in
the previous time step t
¯
k ° 1
® e ¯ e ± k ² ° e ± k ° 1 ² B-29
The sum of errors e
±
k
²
may be used as an input fuzzy variable also. It takes into account
the integrated effect of all past errors and is defined as:
e ± k ² ¯ ³ i
´
1
k
e ± i ² B-30
B.6.1.2 Output Variables
Output variables may be any directly manipulated variable. An output fuzzy variable u can
be defined on the universe of discourse of a crisp manipulated variable. The change in
output
®
u is more often used as the output variable.
®
u indicates the extent of change of the
control variable u at time t ¯ k, i.e. the change in action. Therefore, if the defuzzified
output at time k is
®
u µ
±
k
²
, the overall crisp output of the controller will be:
u ± k ² ¯ u ± k ° 1 ² ¶ ® u µ ± k ² B-31
B.6.1.3 IF-THEN Rules and Inference
For the proportional fuzzy controller, as a SISO fuzzy controller, the rule-base can be
constructed in a symmetric fashion with rules of the following form:
1. If e is NB then u is NB
2. If e is NM then u is NM
3. If e is NS then u is NS
4. If e is ZE then u is ZE
5. If e is PS then u is PS
6. If e is PM then u is PM
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7. If e is PB then u is PB
where NB, NM, NS, ZE, PS, PM, and PB are linguistic values representing “negative big”,
“negative medium”, “negative small”, “zero”, “positive small”, and so on.
A fuzzy controller emulating a conventional proportional-derivative (PD) model of
controller would consist of rules of the form:
If e is A and · e is B then u is C B-32
The complete set of rules is shown in tabulated form in Table B-1.
Table B-1: Rule table for a PD fuzzy controller.
Output change of error ¸ e ¹ k º
u NB NM NS ZE PS PM PB
NB NB NB NB NB NM NS ZE
NM NB NB NB NM NS ZE PS
error NS NB NB NM NS ZE PS PM
e ZE NB NM NS ZE PS PM PB
PS NM NS ZE PS PM PB PB
PM NS ZE PS PM PB PB PB
PB ZE PS PM PB PB PB PB
A proportional-integral (PI) controller would have rules of the form:
If e is A and » e is B then » u is C B-33
The complete set of rules is shown in tabulated form in Table B-2.
Table B-2: Rule table for a PI fuzzy controller.
Output change of error ¼ e ½ k º
¼ u NB NM NS ZE PS PM PB
NB NB NB NB NB NM NS ZE
NM NB NB NB NM NS ZE PS
error NS NB NB NM NS ZE PS PM
e ZE NB NM NS ZE PS PM PB
PS NM NS ZE PS PM PB PB
PM NS ZE PS PM PB PB PB
PB ZE PS PM PB PB PB PB
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Tables B-1 and B-2 are examples of PD and PI configurations, not all controllers have the
same configuration, this depends on the specific problem at hand.
The rule form of a PID like fuzzy controller is:
If e is A and ¾ e is B and e is C then u is D B-34
The previous fuzzy algorithms are presented in terms of rules involving fuzzy values as the
output variable, such rules are the Mamdani rules. However several fuzzy controllers use
rules where the output variable is given in terms of a functional relation of the inputs (TSK
systems, Equation B-7).
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Appendix C
Multiresolution Wavelet Analysis
The objective of signal analysis is to devise a transformation that represents the signal
features simultaneously in time and frequency. Standard Fourier analysis decomposes the
signal into frequency components and determines the relative strength of each component.
It does not tell when a signal exhibited the particular frequency characteristic. In
transforming to the frequency domain, time information is lost. Looking at a Fourier
transform of a signal, it is impossible to tell when a particular event took place. The
short-time Fourier Transform (STFT) analyses a small section of the signal at a time, it
maps a signal into a two-dimensional function of time and frequency. The STFT drawback
is that once a particular size for the time window in chosen, that window is the same for all
frequencies. Wavelet analysis is a windowing technique with variable-sized regions. It
allows the use of long time intervals when more precise low frequency information is
required, and shorter regions for high frequency information. Wavelet analysis has the
ability to perform local analysis.
C.1 Fourier Transform
The Fourier transform rules over linear time-invariant signal processing because sinusoidal
waves e i
  t are eigenvectors of linear time-invariant operators. A linear time-invariant
operator L is entirely specified by the eigenvalues

h
  
:
   
, Lei 	 t 
 h    e i  t C-1
To compute Lf, a signal f is decomposed as a sum of sinusoidal eigenvectors  e i  t     :
f  t   12
 ﬀ ﬁ
ﬂ ﬃ
F   ! e i " td C-2
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If f has a finite energy, the theory of Fourier integrals proves that the amplitude F # $ % of
each sinusoidal wave e i & t is the Fourier transform of f:
F
# $ % ' ( ) *
+
*
f
#
t
%
e
)
i & tdt C-3
Applying the operator L to f in Equation C-2 and inserting the eigenvector expression of
Equation C-1 gives:
Lf
#
t
% '
1
2
,
( ) *
+
*
F
# $ % -
h
# $ %
e i& td
$
C-4
The operator L amplifies or attenuates each sinusoidal component e i & t of f by
-
h
# $ % . It is a
frequency filtering of f.
If the frequency content of a signal were to vary drastically from interval to interval as in a
musical scale, the standard Fourier transform would sweep over the entire time axis and
wash out any local anormalities in the signal. It is not adequate for such nonstationary
signals.
C.1.1 Short-Time Fourier Transform
The windowed short-time Fourier transform (STFT), moves a fixed-duration window over
the time function and extracts the frequency content in that interval. This would be suitable
for signals that are locally stationary, but globally nonstationary.
The STFT positions a window g
#
t
%
at some point . on the time axis, and calculates the
Fourier transform of the signal within the extent or spread of that window:
F / 0 , . 1 2 3 4 5
6
5
f / t 1 g 7 8 t 9 : ; e < i= tdt C-5
The inner product between two functions is denoted by:
> f,g ? @ A B C
D
C
f E t F g G E t F dt C-6
When the window g E t F is Gaussian, the STFT is called a Gabor transform. The basis of this
transform is generated by modulation and translation of the window function g E t F , where H
and I are modulation and translation parameters, respectively. The difficulty with the STFT
is that the fixed-duration window g E t F is accompanied by a fixed frequency resolution and
thus allows only a fixed time-frequency resolution. The STFT maps a function of one
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variable into a function of two variables, corresponding to the time and frequency. These
transforms are highly redundant in the parameters J K , L M .
C.1.1.1 Discrete Short-Time Fourier Transform
An appreciation of the time-frequency properties of the STFT can be developed by
discretising
J K
,
L M
, sampling the continuous STFT, Equation C-5, on a uniform grid to
obtain the discrete STFT. With:
K N
m
K 0 L N nL 0 C-7
F
J
m,n M N O P Q
R
Q
f
J
t
M
g
S J
t
T
n
L 0 M e
P
im U 0tdt
N V
f
J
t
M ,e im U 0tg S J t T nL 0 M W C-8
This is also the inner product between f
J
t
M
and the windowed sinusoid e imU 0t over the spread
of g J t T nL 0 M .
The STFT can be interpreted as the convolution of Xg Y Z [ \ g ] ^ _ ` a with the modulated
signal e b ic tf ^ t a
F ^ d , t a e fg ^ t a g e h i i tf j t k C-9
The discretisation can be carry even further so that the time function itself is sampled, f j n k .
The discrete version of the STFT is then:
F j k,n k l m
m n o p
p g q m r n s f q m s e o i 2tM km, k u 0,1, . . . ,M v 1 C-10
where g w m x is a sampled window function of finite extent (or compact support M).
C.1.1.2 Continuous Short-Time Fourier Transform
The continuous STFT (Equation C-5) is a function of the continuous variables y and z . The
STFT can be conceptualized as the limit of the discrete STFT of Equation C-8 as m y 0 { |
and n } 0
{
} . The discrete function defined on the grid points involves into a continuous
function over the
|
, } plane. The interpretation of constant resolution cells is still
applicable, with m
|
0
~ |
, and n} 0
~
} .
To summarize these properties, for g  t   L2    let
F

|
, }

~
f

t

e  i t  g

}

~ 
 

 f

t

g Ł

t  }

e  i tdt C-11
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That is, the transform is a highly redundant mapping L2     L2   2  . It can be shown that
the reconstruction formula is:
f  t   12    


  


F   ,   g  t    e i td  d C-12
C.2 Wavelet Transform
Certain signals can be modelled suitably by combining translations and dilations of a
simple, oscillatory function of finite duration called a wavelet. A wavelet is a waveform of
effective limited duration that has an average value of zero. Wavelet analysis is the
breaking up of a signal into shifted and scaled versions of the original (or mother) wavelet.
Consider a real or complex-value continuous-time function   t  with the following
properties:
1. The function integrates to zero:
  
 

 
t

dt ¡ 0 C-13
2. It is square integrable or, equivalently, has finite energy:
  
 

|   t  |2dt ¢ £ C-14
The function ¤ ¥ t ¦ is a mother wavelet or wavelet if it satisfies these two properties as well
as the admissibility condition (Equation C-29).
C.2.1 Continuous-Time Wavelet Transform
Let f ¥ t ¦ be any square integrable function. The Continuous-Time Wavelet Transform
(CWT) or continuous-time wavelet transform of f
¥
t
¦
with respect to a wavelet
¤ ¥
t
¦
is
defined as:
W
¥
a,b
¦ § ¨ © ª
«
ª
f
¥
t
¦
1
|a | ¤ ¬ ¥
t
©
b
a ¦ dt C-15
where a and b are real and ­ denotes complex conjugation. Thus, the wavelet transform is a
function of two variables. Both f ¥ t ¦ and ¤ ¥ t ¦ belong to L2 ¥ ® ¦ , the set of square integrable
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functions, also called the set of energy signals. Equation C-15 can be written in a more
compact form by defining ¯ a,b ° t ± as:
¯ a,b
°
t
± ²
1
|a | ¯ °
t³ b
a ± C-16
Then, combining Equations C-15 and C-16,
W
°
a,b ± ² ´
³ µ
¶
µ f
°
t
± ¯ a,b
·
°
t
±
dt C-17
Notice that
¯ 1,0 ° t ± ² ¯ ° t ± C-18
The normalizing factor of 1|a | ensures that the energy stays the same for all a and b:
´
³ µ
¶
µ | ¯ a,b
°
t
± |2dt ² ´
³ µ
¶
µ | ¯
°
t
± |2dt C-19
For any given value of a, the function ¯ a,b ° t ± is a shift of ¯ a,0 ° t ± by an amount b along the
time axis. The variable b represents time shift or translation. From:
¯ a,0 ° t ± ² 1|a | ¯ °
t
a ± C-20
it follows that ¯ a,0 ° t ± is a time-scaled and amplitude-scaled version of ¯ ° t ± . Since a
determines the amount of time scaling or dilation, it is referred to as the scale or dilation
variable. If a ¸ 1, there is a stretching of ¹ º t » along the time axis, whereas if 0 ¼ a ¼ 1,
there is a contraction of
¹ º
t
»
. Negative values of a result in a time reversal in combination
with dilation. As a increases, wavelets are stretched and analyse low frequencies, while for
small a, contracted wavelets analyse high frequencies. Since the CWT is generated using
dilates and translates of the single function ¹ º t » , the wavelet for the transform is referred to
as the mother wavelet.
The CWT is essentially a collection of innerproducts of a signal f º t » and the translated and
dilated wavelet
¹ a,b º t » for all a and b:
W º a,b » ½ ¾ f º t » , ¹ a,b º t » ¿ C-21
C.2.1.1 The Continuous-Time Wavelet Transform as an Operator
The CWT takes a member in the set of square integrable functions of one real variable in
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L2 À Á Â and transforms it into a member of the set of functions of two real variables. It can
be seen as a mapping operator from L2 À Á Â to the latter set.
W Ã Ä f Å t Æ Ç È W É a,b Ê C-22
Then W Ë Ì Ç is to be read “CWT with respect to Í É t Ê of”. The transform depends not only on
the function f É t Ê but also on the mother wavelet. These are some properties of the CWT
using the operator notation:
1. Linearity
W Ë Ì Î f Ï t Ð Ñ Ò g Ó t Ô Õ Ö × W Ø Ù f Ó t Ô Õ Ú Ò W Ø Ù g Ó t Ô Õ C-23
for scalars
×
and
Ò
and functions f
Ó
t
Ô
, g
Ó
t
Ô Û
L2
Ó Ü Ô
.
2. Translation
W
Ø Ù
f
Ó
t Ý Þ
Ô Õ Ö
W
Ó
a,b Ý Þ
Ô
C-24
3. Scaling
W
Ø
1ß f à 1ß á â W à aß , bß á C-25
for ã ä 0.
4. Wavelet shifting: Let å à t á â å à t æ ç á . Then
W è é f à t á ê â W à a,b ë aç á C-26
The CWT obtained by shifting the wavelet is different from the one obtained by shifting the
signal.
5. Wavelet scaling: Let å à t
á
â
è ì t/ í î
|ï | . Then
W ð ñ f ò t ó ô õ W ò a ö ,b ó C-27
CWT is a scaled version of the original in the a variable.
6. Linear combination of wavelets: Given two wavelets ÷ 1 ò t ó and ÷ 2 ò t ó , their linear
combination ö ÷ 1 ò t ó ø ù ÷ 2 ò t ó for scalars ö and ù is also a wavelet.
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W
ú û 1 ü ý þ 2 ß f   t     W þ 1 ß f   t     W þ 2 ß f   t   C-28
C.2.1.2 Inverse Continuous-Time Wavelet Transform
If the mother wavelet satisfies the (sufficient) condition:
C    	


	
|
    |2
|  | d C-29
where     is the Fourier transform of   t  , and is such that 0  C   , then
f  t   1C  a ﬀ ﬁ
ﬂ
ﬁ
 b ﬀ ﬁ
ﬂ
ﬁ 1
|a|2 W  a,b   a,b  t  da db C-30
The condition in Equation C-29 is known as the admissibility condition on   t  .
Equation C-30 expresses W  a,b

as the convolution of f  t

and  a,0  ﬃ b  . In the frequency
domain this becomes
 b
 ﬀ ﬁ
ﬂ
ﬁ W  a,b

e ﬀ jwbdb

|a| F  
  !
 a 

C-31
where F    and     are the Fourier transforms of f  t  and   t  respectively. Multiplying
both sides of Equation C-31 by
 
 a 

/|a|3/2 and integrating with respect to a yields
 a
 ﬀ ﬁ
ﬂ
ﬁ
 b
 ﬀ ﬁ
ﬂ
ﬁ 1
|a|3/2 W  a,b    a   e
ﬀ
j
"
bda db

F  

 a
 ﬀ ﬁ
ﬂ
ﬁ |# $ a " % |2
|a| da C-32
and
 a  ﬀ ﬁ
ﬂ
ﬁ |
#
$ a
"
% |2
|a| da  
"  ﬀ ﬁ
ﬂ
ﬁ |
#
$
"
% |2
|w| d   C C-33
where C is the constant from the admissibility condition. Therefore,
F     1C  a ﬀ ﬁ
ﬂ
ﬁ
 b ﬀ ﬁ
ﬂ
ﬁ 1
|a|3/2 W  a,b    a   e
ﬀ j" bda db C-34
The expression of the inverse CWT in Equation C-30 is obtained by taking the inverse
Fourier transform on both sides of Equation C-34.
C.2.2 Discrete-Time Wavelet Transform
The discrete-time wavelet transform (DTWT) is generated by sampling the wavelet
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parameters & a,b ' on a grid or lattice.
Let the sampling lattice be
a ( a0
m b ( nb0a0m C-35
so that
)
mn & t ' ( a0
* m/2
)
& a0
* mt
+
nb0 ' C-36
where m, n , Z. If this set is complete in L2 & - ' for some choice of ) & t ' , a, b, then the
.
)
mn / are called affine wavelets. Then we can express any f & t ' , L2 & - ' as the
superposition:
f & t ' (
m
0
n
0
dm,n ) mn & t ' C-37
where the wavelet coefficient dm,n is the inner product:
dm,n ( 1 f & t ' , ) mn & t ' 2 ( 1
a0
m/2 3 f & t ' ) & a0* mt + nb0 ' dt C-38
The two-dimensional sequence dm,n is commonly referred to as the DTWT of f & t ' . DTWT is
still the transform of a continuous-time signal. The discretisation is only in the a and b
variables.
The orthonormal wavelets . ) mn
/
satisfy:
3
)
mn & t '
)
m 4 n 4 5 t 6 dt 7
1 m 7 m 8 , n 9 n 8
0 otherwise
C-39
and are orthonormal in both indices. This means, that for the same scale m they are
orthonormal in time, and they are also orthonormal across the scales.
C.2.3 Examples of Wavelets
C.2.3.1 Daubechies Wavelets
Daubechies wavelets have a support of a minimum size for any given number p of
vanishing moments. They are wavelets of compact support and can be computed with finite
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impulse response conjugate mirror filters h. Consider the real causal filters h : n ; , which
implies that <h is a trigonometric polynomial:
<h = > ? @ A
nB 0
NC 1 h : n ; e C inD C-40
To ensure that E has p vanishing moments, <h must have a zero of order p at F @ G . A
minimum size polynomial having p zeros at H I G , is:
J
h K
H L I
2 1M e N iO2
p
R P e Q i R S C-41
The difficulty is to design a polynomial R P e Q i R S of minimum degree m such that Th satisfies:
Th P U S
2 V
Th P U
V W
S
2 X
2 C-42
As a result, h has N
X
m
V
p
V
1 non-zero coefficients. The minimum degree of R is
m
X
p Y 1.
The minimum degree polynomial
R P e Q iR S
X
r0 Z k[ 0
m \ 1 ] ake ^ iw _ C-43
Let z ` e ^ i a :
R \ z _ R \ z ^ 1 _ ` r02 Z k [ 0
m \ 1 ] akz _ \ 1 ] akz ^ 1 _ C-44
To design R \ z _ that satisfies Equation C-44, lets choose each root ak of R among a pair
\
ck, 1/ck _ and include akb as a root to obtain real coefficients. This procedures yields a
polynomial of minimum degree m ` p
]
1, with r02 ` 2p^ 1. The resulting filter h of
minimum size has N ` p c m c 1 ` 2p non zero coefficients.
If d is a wavelet with p vanishing moments that generates an orthonormal basis of L2 \ e _ ,
then it has a support of size larger than or equal to 2p ] 1. A daubechies wavelet has a
minimum size support equal to f
]
p c 1,p g . The support of the corresponding scaling
function h is i 0,2p j 1 k . Figure C-1 displays the graphs of l for p m 2,3, . . . , 10.
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Figure C-1: Daubechies wavelet n with p o 2,3,4,5,6,7,8,9,10 vanishing moments.
C.2.3.2 Coiflet Wavelets
The family of coiflet wavelets p has p vanishing moments and a minimum size support,
and the scaling functions satisfy:
q r s
t t dt u 1 and
q
tk
r s
t t dt u 0 for 1 v k v p C-45
Such scaling functions are useful in establishing precise quadrature formulas. The coiflets
wavelets w are shows in Figure C-2.
Figure C-2: Coiflets wavelets with p x 1,2,3, 4,5.
C.2.3.3. Mexican Hat Wavelets
The mexican hat wavelet is equal to the second derivative of a Gaussian. The normalised
mexican hat wavelet is:
w y t z { 2
| 1/4 3
}
t2
}
2 ~ 1 exp  t
2
2} 2
C-46
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For   1, Figure C-3 plots   .
Figure C-3: Mexican hat wavelet for   1.
C.2.3.4 Meyer Wavelets
A meyer wavelet is a frequency band-limited function whose Fourier transform is smooth.
This smoothness provides a much faster asymptotic decay in time. These wavelets are
constructed with conjugate mirror filters h    that are Cn and satisfy:
h    Ł
2 if      /3,  /3 
0 if 



 ,

2  /3    2  /3,  
C-47
The only degree of freedom is the behaviour of h    in the transition bands
  2

/3, 

/3




/3, 2

/3

. It must satisfy the quadrature condition:
h
  
2

h
 

 
2

2 C-48
and to obtain Cn junctions at | |   /3 and | |  2  /3, then n first derivatives must vanish
at these abscissa. The scaling function
 
  
 
p  1
 
2   1/2 h  2   p   has a compact support
and
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¡ ¢ £ ¤ ¥ ¦ 2 § 1/2
¡
h £ ¤ /2
¥
if |¤ | ¨ 4 © /3
0 if |¤ | ª 4 © /3 C-49
The resulting wavelet is
«
£ ¤ ¥ ¦
0 if |¤ | ¨ 2 © /3
2 § 1/2e § i¬ /2
¡
h ­ ¬2
®
© if 2 © /3
¨ |¤ | ¨ 4 © /3
2 § 1/2e § i¬ /2
¡
h ­ ¬4 if 4 © /3 ¨ |
¤ | ¨ 8 © /3
0 if |¤ |
ª
8 © /3
C-50
Since «
£ ¤ ¥
in the neighbourhood of
¤ ¦
0, all its derivatives are zero at
¤ ¦
0, which
proves that « has an infinite number of vanishing moments. Figure C-4 shows the meyer
wavelet « .
Figure C-4: The meyer wavelet « .
C.3 Multiresolution Signal Decomposition
Multiresolution signal analysis (MRA) provides the links between orthonormal wavelet
families of compact support, and the pyramid-dyadic tree expansions of a signal. In this
representation, a function f ¯ L2 is expressed as a limit of successive approximations, each
of which is a smoothed version of f £ t ¥ . These successive approximations correspond to
different resolutions. This smoothing is accomplished by convolution with a low-pass
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kernel called the scaling function ° ± t ² .
C.3.1 Multiresolution Analysis Spaces
A multiresolution analysis consists of a sequence of closed subspaces ³ Vm|m ´ Z µ of
L2 ± ¶ ² µ which have the following properties:
· Containment:
¸ Coarser Finer ¹
. . .V2
º
V1 º V0 º V » 1 º V » 2. . . C-51
¼ Completeness:
m ½ Z
¾ Vm
¿ À
0 Á
m Â Z
Ã Vm
¿
L2 Ä Å Æ C-52
Ç Scaling property:
f Ä x Æ È Vm É f Ê 2x Ë Ì VmÍ 1 C-53
for any function f Ì L2
Ê Î Ë
.
Ï The Basis/Frame property: There exists a scaling function Ð Ê t Ë Ì V0 such that Ñ m Ì Z,
the set
Ò
Ð mn Ê t Ë Ó 2 Í m/2 Ð Ê 2 Í mt Ô n Ë Õ C-54
is an orthonormal basis for Vm, i.e.
Ö
Ð mn Ê t Ë Ð mn × Ê t Ë dt Ó Ø nÙ n Ú C-55
Let Wm be the orthogonal component of Vm in VmÙ 1, i.e.
VmÙ 1 Û Vm Ü Wm C-56
Vm
Ý
Wm C-57
Furthermore, let the direct sum of the possibly infinite spaces Wm span L2 Þ ß à :
. . . á Wj á Wj
â
1. . . á W0. . . á W
â
j
ã
1 á W
â
j
ã
2. . . ä L2 Þ ß à C-58
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Associate the scaling function å æ t ç with the space V0, and the wavelet function with W0.
The projection operators Pm, Qm from L2 æ è ç onto Vm and Wm respectively. The
completeness property ensures that
mé ê ë
lim Pmf ì f, for any f í L2 æ è ç .The containment
property implies that as m decreases Pmf leads to successively better approximations of f.
Any function f can be approximated by Pmê 1f, its projection onto Vmê 1. From Equation C-56
this can be expressed as a sum of projections onto Vm, and Wm
Pmê 1f ì Pmf î Qmf C-59
Pmf is the low pass part of f in Vm and Qmf is the high frequency detail or difference, i.e.
the increment in information in going from Vm to Vm ê 1.
Equation C-59 can be expressed as Qmf ì Pmê 1f ï Pmf, where Qmf í Wm. Hence, it can be
said that the orthogonal or complementary space Wm is given by the difference Vm ê 1
ð
Vm.
Now ñ ò t ó n ô õ V0 and ñ ò 2t ó n ô õ V ö 1. Since V0 ÷ span ø ñ ò t ó n ô ù and
V
ö 1
÷
span
ø ñ ò
2t ó n
ù
, it is reasonable to expect the existence of a function ú
ò
t
ô
õ W0,
such that W0 ÷ span ø ú ò t ó n ô ù . This function ú ò t ô is the wavelet function associated with
the multiscale analysis.
By the scaling property, Wm ÷ span ø ú ò 2 ö mt ó n ô ù . The term Wm is also generated by the
translates and dilations
ø
ú mn ò t ô ù of a single wavelet ú ò t ô . The containment and
completeness properties together with Wm û Vm, and Vmö 1 ÷ Vm ü Wm imply that the spaces
Wm are mutually orthogonal and that their direct sum is L2 ò ý ô . Since for each m, the set
ø
ú mn ò t ô ; n õ Z ù constitutes an orthonormal basis of Wm, it follows that the whole collection
ø
ú mn ò t ô ; m,n õ Z ù is an orthonormal wavelet basis for L2 ò ý ô . The set
ø
ú mn ò t ô ÷ 2 ö m/2 ú ò 2 ö mt ó n ô ù is the wavelet basis associated with the multiscale analysis,
with property
þ
ú mn ò t ô ú m ß n ß ò t ô dt ÷   mö m ß   nö n ß C-60
Since
V iö 1 ÷ Wi ü V i ÷ Wi ü Wi  1 ü Wi 2 ü . . . C-61
the function Pmö 1f at a given resolution can be represented as a sum of added details at
different scales.
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C.3.2 Multiresolution Pyramid Decomposition
The MRA is used to decompose the signal into successive layers at coarser resolutions plus
detail signals, also at coarser decomposition.
Let f  V0. Then, since    t  n   spans V0, f can be represented as a superposition of
translated scaling functions:
f

t
 	
n


c0,n   t  n  	
n


c0,n  0n  t  C-62
where
c0,n 	  f,  on  	  f  t    t  n  dt C-63
Since, V0 	 V1  W1, f can be expressed as the sum of two functions, one lying entirely in
V1 and the other in the orthogonal complement W1:
f

t
 	
P1f  Q1f 	
fv1  t 
n


c1,n  1n  t  
f 1  t 
n


d1,n  1n  t  C-64
where the scaling coefficients c1,n, and the wavelet coefficients d1,n are given by:
c1,n 	  fv1,  1n  	 12  fv
1

t
 
t
2  n dt C-65
d1,n 	  f 1 ,

1n

	
1
2

f 1

t
 
t
2  n dt C-66
The discrete signal d1,n is just the discrete wavelet transform coefficient at resolution 1/2. It
represents the detail or difference information between the original signal c0,n and its
smoothed down-sampled approximation c1,n. These signals c1,n and d1,n are said to have a
resolution of 1/2, if c0,n has unity resolution. Every down-sampling by 2 reduces the
resolution by that factor.
The next stage of decomposition is now easily obtained. Take fv1  V1 	 V2  W2 and
represent it by a component in V2 and another in W2
fv1  t  	 fv2  t   f 2  t  C-67
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fv2  t    c2,n  2n  t  C-68
f 2  t
  
d2,n ﬀ 2n  t  C-69
The decomposition into coarser, smoother approximation and detail can be continued as far
as necessary.
C.3.3 Finite Resolution Wavelet Decomposition
The function f ﬁ V0 can be represented as Equation C-62, and decomposed into the sum of
a lower-resolution signal (approximation) plus detail (approximation error):
f  t
 
fv1  t  ﬂ f 1  t    c1,n2 ﬃ 1/2   t/2  n  ﬂ  d1,n2 ﬃ 1/2 ﬀ  t/2  n  C-70
The coarse approximation fv1  t  can be decomposed as Equation C-67, so that:
f  t
 
fv2  t  ﬂ f 2  t  ﬂ f 1  t  C-71
Continuing up to fvL  t  , we have
f  t
 
fvL  t  ﬂ f L  t  ﬂ f L ﬃ 1  t  ﬂ . . . ﬂ f 1  t  C-72
or
f  t
  
n  
ﬃ !
! c  L,n

2
ﬃ
L/2

1
2L
 n
ﬂ 
m 1
L

n 
ﬃ !
! d  m,n

2
ﬃ
m/2
ﬀ
t
2m  n C-73
The purely wavelet expansion of Equation C-37 requires infinite number of resolutions for
the complete representation of the signal. Equation C-73 shows that f  t

can be represented
as a low-pass approximation at scale L plus the sum of L detail (wavelet) components at
different resolutions.
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Appendix D
Wavelet Extracted AEP Features Fuzzy Models
In this appendix, the fuzzy TSK models for the six wavelet extracted AEP features, not
presented in Chapter 5, are detailed (i.e. D2, D31, D32, D33, D4 and D52). The inputs of the
fuzzy TSK models are the propofol effect concentration (PCe) and the remifentanil effect
concentration (RCe). The TSK models were obtained using the ANFIS MATLAB Toolbox
for each of the AEP features, considering the training and checking data sets. For each of
the AEP features, the models are presented in the following order:
  Input membership functions;
  Rule-base table;
  Output membership functions;
  Output surface;
  Results on the training and checking data sets.
D.1 AEP Feature D2
a) b)
Figure D-1: Input membership functions describing the propofol effect concentration ( a) ) and the
remifentanil effect concentration ( b) ), for the AEP feature D2 TSK fuzzy model.
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Table D-1: Rule-base table for the fuzzy TSK model of the AEP feature D2. RCe is the remifentanil
effect concentration, PCe is the propofol effect concentration. fi is the i output membership function,
i  1, . . . , 4.
PCe RCe
mf1 mf2 mf3
mf1 f1
mf2 f2
mf3 f3
mf4 f4
The D2 membership functions (output membership functions) are the following:
f1  0.0007PCe  0.0190RCe  1.3494
f2   0.0229PCe  1.9570RCe  25. 6094
f3   0.0002PCe  0.1049RCe  0.6819
f4   0.0309PCe  0.5019RCe  162.1829
Figure D-2: Output surface of the AEP feature D2 TSK fuzzy model.
The results of the TSK model on the training and checking data sets are presented in Figure
D-3. The training and checking data sets are the same for all the wavelet extracted AEP
features, they consist of 2/3 and 1/3 of the whole data, respectively. One out of three
samples was selected for the checking data set.
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Figure D-3: Results of the AEP feature D2 TSK fuzzy model on the training and checking data sets
(dashed line) versus the AEP feature D2 from patient Pat1 (solid line), considering the maintenance
phase.
D.2 AEP Feature D31
a) b)
Figure D-4: Input membership functions describing the propofol effect concentration ( a) ) and the
remifentanil effect concentration ( b) ), for the AEP feature D31 TSK fuzzy model.
Table D-2: Rule-base table for the fuzzy TSK model of the AEP feature D31. RCe is the remifentanil
effect concentration, PCe is the propofol effect concentration. fi is the i output membership function,
i  1, . . . , 4.
PCe RCe
mf1 mf2 mf3
mf1 f1
mf2 f2
mf3 f3
mf4 f4
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The D31 membership functions (output membership functions) are the following:
f1   0.0032PCe  0.6908RCe  11. 1178
f2


0.0022PCe  0.1321RCe

9.6112
f3  0.0157PCe  0.1656RCe  34.5303
f4

0.0021PCe  1.8165RCe

1.0153
Figure D-5: Output surface of the AEP feature D31 TSK fuzzy model.
Figure D-6: Results of the AEP feature D31 TSK fuzzy model on the training and checking data sets
(dashed line) versus the AEP feature D31 from patient Pat1 (solid line), considering the maintenance
phase.
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D.3 AEP Feature D32
a) b)
Figure D-7: Input membership functions describing the propofol effect concentration ( a) ) and the
remifentanil effect concentration ( b) ), for the AEP feature D32 TSK fuzzy model.
Table D-3: Rule-base table for the fuzzy TSK model of the AEP feature D32. RCe is the remifentanil
effect concentration, PCe is the propofol effect concentration. fi is the i output membership function,
i
 1, . . . , 4.
PCe RCe
mf1 mf2 mf3
mf1 f1
mf2 f2
mf3 f3
mf4 f4
The D32 membership functions (output membership functions) are the following:
f1  	 0.007PCe 
 1.566RCe 
 8.5694
f2  	 0.0043PCe 	 0.3294RCe


19. 2396
f3  0.0217PCe 
 1.8704RCe 	 61.8629
f4  	 0.0008PCe


0.0378RCe


1.7855
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Figure D-8: Output surface of the AEP feature D32 TSK fuzzy model.
Figure D-9: Results of the AEP feature D32 TSK fuzzy model on the training and checking data sets
(dashed line) versus the AEP feature D32 from patient Pat1 (solid line), considering the maintenance
phase.
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D.4 AEP Feature D33
a) b)
Figure D-10: Input membership functions describing the propofol effect concentration ( a) ) and the
remifentanil effect concentration ( b) ), for the AEP feature D33 TSK fuzzy model.
Table D-4: Rule-base table for the fuzzy TSK model of the AEP feature D33. RCe is the remifentanil
effect concentration, PCe is the propofol effect concentration. fi is the i output membership function,
i
 1, . . . , 4.
PCe RCe
mf1 mf2 mf3
mf1 f1
mf2 f2
mf3 f3
mf4 f4
The D33 membership functions (output membership functions) are the following:
f1   0.0024PCe  0.4232RCe  4.3817
f2   0.0033PCe  0.0888RCe

13. 6081
f3   0.0007PCe  1.0139RCe  6.6304
f4  0.0021PCe  1.2998RCe  0.1886
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Figure D-11: Output surface of the AEP feature D33 TSK fuzzy model.
Figure D-12: Results of the AEP feature D33 TSK fuzzy model on the training and checking data sets
(dashed line) versus the AEP feature D33 from patient Pat1 (solid line), considering the maintenance
phase.
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D.5 AEP Feature D4
a) b)
Figure D-13: Input membership functions describing the propofol effect concentration ( a) ) and the
remifentanil effect concentration ( b) ), for the AEP feature D4 TSK fuzzy model.
Table D-5: Rule-base table for the fuzzy TSK model of the AEP feature D4. RCe is the remifentanil
effect concentration, PCe is the propofol effect concentration. fi is the i output membership function,
i
 1, . . . , 4.
PCe RCe
mf1 mf2 mf3
mf1 f1
mf2 f2
mf3 f3
mf4 f4
The D4 membership functions (output membership functions) are the following:
f1  0.0134PCe  2.2962RCe  13.6722
f2  0.2PCe  103.4RCe  1098. 8
f3   0.0416PCe  0.128RCe  94.7275
f4  0.3PCe  55.1RCe  1644.8
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Figure D-14: Output surface of the AEP feature D4 TSK fuzzy model.
Figure D-15: Results of the AEP feature D4 TSK fuzzy model on the training and checking data sets
(dashed line) versus the AEP feature D4 from patient Pat1 (solid line), considering the maintenance
phase.
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D.6 AEP Feature D52
a) b)
Figure D-16: Input membership functions describing the propofol effect concentration ( a) ) and the
remifentanil effect concentration ( b) ), for the AEP feature D52 TSK fuzzy model.
Table D-6: Rule-base table for the fuzzy TSK model of the AEP feature D52. RCe is the remifentanil
effect concentration, PCe is the propofol effect concentration. fi is the i output membership function,
i
 1, . . . , 4.
PCe RCe
mf1 mf2 mf3
mf1 f1
mf2 f2
mf3 f3
mf4 f4
The D52 membership functions (output membership functions) are the following:
f1   0.0006PCe  72.2264RCe  338.7697
f2  0.0199PCe

9.5601RCe  123. 3977
f3   0.3571PCe  39.6468RCe  427.9056
f4  0.016PCe

30.4844RCe  73.4977
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Figure D-17: Output surface of the AEP feature D52 TSK fuzzy model.
Figure D-18: Results of the AEP feature D52 TSK fuzzy model on the training and checking data sets
(dashed line) versus the AEP feature D52 from patient Pat1 (solid line), considering the maintenance
phase.
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